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ABSTRACT 
 
IMMUNOTHERAPEUTIC APPLICATIONS OF NUCLEIC ACID 
BASED TLR AGONISTS AND ANTAGONISTS 
 
Fuat Cem Yagci 
Ph.D. in Molecular Biology and Genetics 
Supervisor: Assoc. Prof. Dr. İhsan Gürsel 
January, 2014 
 
Recent evidence suggests that genetic material is not just the blueprint of life. 
Depending on the type of the source that genomic material is extracted or the type of 
motif that DNA harbors DNA could be immunostimulatory or immunosuppressive to 
innate immune system cells. Unmethylated CpG motifs, from bacterial genome is 
recognized by TLR9 expressing cells as “non-self” and initiates an orchestrated 
immune activation characteristics of Th1-biased immunity. Conversely, mammalian 
genome rich in G-runs motifs, such as telomeric ends expressing TTAGGG repeats 
downregulate Th1-biased immune responses and contributes to restore over 
exuberant immune response. Several TLR agonists/antagonists candidates are 
currently under preclinical/clinical trials to prevent or treat cancer, infectious disease, 
allergic disorders and autoimmune or autoinflammatory diseases. In this thesis, we 
attempted to broaden the application of nucleic acid based TLR therapy by 
investigating their beneficial effects either as vaccine adjuvants against Foot and 
Mouse Disease or to test as immunosuppressive agents that may control autoimmune 
uveitis. We showed that an immunosuppressive ODN namely A151 downregulated 
severity of an established animal  model of uveitis, endotoxin induced uveitis (EIU), 
up to more than 60% histologically, or more than 80% based on cytokine production 
such as MIP3α, IL6, IFNγ from uveitic animals. In order to compare effects of this 
biological immunosuppressive agent, next we studied effects of a broad-spectrum 
immunosuppressive drug, namely cyclosporine A in an emulsion form, commercially 
known as Restasis™. Our results indicated that Restasis™ had significantly lower 
capacity to reduce disease severity and downregulate in vivo chemokine or cytokine 
levels compared to A151. The second theme of this thesis was to demonstrate 
effective utilization of CpG ODN as an immunostimulatory agent. The adjuvant 
effect of CpG ODN 1555-PS in Foot and Mouth Disease (FMD) vaccine 
formulations were tested. In this study, CpG ODNs were formulated either with 
commercially used monovalent vaccine or mixed with free Serotype-O Ag. Data 
suggested that, in mice, inclusion of CpG ODN as an adjuvant, spared the Ag by 6 
fold and the vaccine dependent virus neutralization titers were not only higher but 
also long lasting compared to commercial monovalent vaccine. CpG inclusion in the 
FMD vaccine helped to generate 1.5-2 fold more cell mediated immunity 24 h after 
booster injection. Implicating that virus infection could be more effectively 
controlled by the novel approach. In the last part of this thesis, effects of CpG ODNs 
as prophylactic agents for newborn broiler chicken were tested in vivo. Our results 
suggested that CpG ODN pretreatment not only significantly reduced mortality rates 
(> 2.0 %) but also contributed to growth performance of these industrially important 
animals. We demonstrated that nucleic acid based agonists and antagonists might be 
 iii 
of great potential to be developed as therapeutic agents either in the clinic or for 
controlling health of industrially important animals.  
 
Keywords: Innate immunity, TLR, suppressive ODN A151, Cyclosporine A EIU, 
FMD, vaccine, adjuvant, chicken, prophylactic agent.
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ÖZET 
 
NÜKLEİK ASİT TEMELLİ TLR AGONİST VE 
ANTAGONİSTLERİNİN İMMÜNÖTERAPÖTİK UYGULAMALARI  
 
Fuat Cem Yağcı 
Moleküler Biyoloji ve Genetik, Doktora Tezi 
Tez Yöneticisi: Doç. Dr. İhsan Gürsel 
Ocak, 2014 
 
Yapılan son çalışmalar genetik materyalin yaşamın sadece mavi baskısı olmadığını 
göstermektedir. Genetik materyal, elde edildiği kaynağa ve barındırdığı DNA 
örgesine göre immün-stimülan ya da immün baskılayıcı özellik göstermektedir. 
Bakteri genomu kökenli metillenmemiş CpG örgeleri, TLR9 eksprese eden hücreler 
tarafından yabancı madde olarak algılanıp Th1 tipte bağışıklık yanıtına neden 
olmaktadır. Memeli genomu kökenli G-zengini sekanslar, telomerik TTAGGG 
örgesi gibi,  ise aksine Th1 tip immün yanıtı baskılamakta ve immün homeostazın 
sağlanmasını desteklemektedir. Çeşitli TLR ulağı agonist/antagonistleri 
preklinik/klinik test fazlarında kanserin, bulaşıcı hastalıkların, alerjik hastalıkların ve 
otoimmün ya da otoenflammatuvar hastalıkların tedavisi için aday ajanlar olarak 
denenmektedir. Bu tezde, nükleik asit bazlı TLR terapisinin kullanım alanları ŞAP 
hastalığına karşın aşı formülasyonlarında adjuvant olarak kullanımları ve otoimmün 
üveit hastalığının kontrolünde immün baskılayıcı ajan olarak kullanımları test 
edilerek genişletilmeye çalışılmıştır. Yaptığımız çalışmalarda A151 isimli immün 
baskılayıcı özellikteki nükleik asidin endotoksin kaynaklı üveiti histolojik olarak 
%60 gerilettiğini, aynı zamanda üveitli hayvanlardaki MIP3α, IL6 ve IFNγ gibi pro-
enflammatuvar sitokinleri de %80 oranında baskıladığını gösterdik. Bu immün 
baskılayıcı ajanın biyolojik etkilerini geniş spektrumlu immün baskılayıcı ilaç olan 
Restasis™ (emülsiyon formda siklosporin A) ile karşılaştırdık. Yaptığımız bu 
çalışmada A151’e göre Restasis™ hem hastalık şiddetini gidermede hem de in vivo 
sitokin ve kemokin düzeylerini dengelemekte daha düşük etkinlik göstermiştir. Tezin 
ikinci bölümünde ise metillenmemiş CpG DNA örgülerinin (CpG ODN) immün 
stimülan ajan olarak kullanılması yer almaktadır. Yapılan çalışmada 1555-PS tipi 
CpG ODN ŞAP aşısı formülasyonlarında adjuvant olarak kullanılmıştır. Bu 
çalışmada CpG ODN’ler ticari monovalent ŞAP aşısına katılarak ya da serbest 
Serotip-O antijeni ile formüle edilerek test edilmiştir. CpG ODN katılımının aşı 
formülasyonlarında kullanılan antijen ihtiyacını 6 kat azalttığı ve virüs nötralizasyon 
sonuçlarına göre hem daha güçlü hem de daha uzun süreli koruma sağladığı fare 
çalışmalarında görülmüştür. ŞAP aşı formülasyonlarına CpG ODN katılımı 
güçlendirici (ikincil) enjeksiyondan 24 saat sonra hücresel bağışık yanıtı 1,5-2 kat 
arttırmıştır. Sonuçlarımız, bu özgün yaklaşımın virüs enfeksiyonunun çok daha 
efektif bir şekilde kontrol altına alınabileceğini göstermektedir. Bu tezin son 
bölümünde CpG ODN’lerin yeni doğan besi piliçlerinde profilaktik ajan olarak 
kullanımları in vivo etkileri test edilmiştir. Sonuçlarımız CpG ODN kullanımının 
sadece mortalite oranlarını düşürmekle kalmadığını (> 2.0 %)  aynı zamanda 
endüstriyel açıdan önemli bu hayvanların büyüme performanslarını da olumlu yönde 
etkilediğini göstermiştir. Bu tezde sunulan çalışmalar, nükleik asit bazlı TLR ulağı 
agonist/antagonistlerinin gerek klinik açıdan önemli hastalıkların kontrolünde 
 v 
gerekse endüstriyel açıdan önemli hayvanların korunmasında terapötik amaçlı ajan 
olarak geliştirilmesi için yüksek potansiyele sahip olduğunu göstermektedir. 
 
Anahtar kelimeler: Doğal bağışıklık, polisakkarit, nanokompleks, ilaç salım sistemi, 
TLR, CpG ODN, kanser immünöterapi, aşı, adjuvan. 
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Chapter 1 
1. Introduction 
1.1 Immune System  
 
All living organisms from bacteria to human have evolved several strategies to 
combat invading pathogens. In higher organisms the mechanisms involved in 
providing protection collectively constitute the immune system [1]  
 
In mammals, the epithelial surfaces of the body establish the first lines of defense 
against invading pathogens. Epithelial cells of the skin, gastrointestinal, respiratory 
and urogenital tracts are joined by tight junctions and provide a physical barrier 
between the internal milieu and the external world. Moreover, movement of mucus 
by cilia and longitudinal flow of air and fluids through internal body surfaces 
prevents adhesion of pathogens to the epithelium. Other then these physical 
protection mechanisms, several chemical and enzymatic factors such as antimicrobial 
peptides, salivary enzymes and low pH of the stomach also contribute to protection 
from infections. In addition to these defenses, most epithelial surfaces are in contact 
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with microbial flora which consists of non-pathogenic bacteria, fungi and viruses that 
compete with the pathogenic ones.[2, 3]  
 
Mammalian immune system consists of two interrelated arms: the evolutionarily 
conserved, immediate, but non-specific innate immunity and the highly specific but 
comparably late-acting adaptive immune system. These two systems are interlinked 
and work together to enable the recognition and elimination of invading pathogens. 
The innate and the adaptive immune system use different strategies to recognize and 
eliminate infection. While the innate immune system uses several germ-line encoded 
receptors to detect invading pathogens, the adaptive immune system uses randomly 
generated and highly specific receptors for detection of infection. [1] 
 
One unifying feature of both the innate and the adaptive immune system is their 
ability to discriminate self from non-self. In immunology, “self-molecules” are 
defined as the host’s own molecules that can be distinguished from other foreign 
substances. In contrast, “non-self molecules” are those that are recognized as 
“foreign” by the immune system. By means of this ability to discriminate “self” from 
“non-self”, the  immune system can detect various pathogens such as viruses, 
bacteria and parasitic worms and distinguish them from normal cells and tissues of 
the host [4]. 
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Table 1.1. Components of the Immune System (Adapted from[5]) 
Attribute Innate Immunity Adaptive Immunity 
Response time Minutes/hours Highly specific; 
discriminates even minor 
differences in molecular 
structure; details of 
microbial or nonmicrobial 
structure recognized with 
high specificity 
Diversity A limited number of germ 
line-encoded receptors 
Highly diverse; a very 
large number of receptors 
arising from genetic 
recombination of receptor 
genes 
Memory responses None Persistent memory, with 
faster response of greater 
magnitude on subsequent 
infection 
Self/nonself 
discrimination 
Perfect; no microbe-
specific pattern in host 
Very good; occasional 
failures of self/nonself 
discrimination result in 
autoimmune disease 
Soluble components of 
blood or tissue fluids 
Many antimicrobial 
peptides and proteins 
Antibodies 
Major cell types Phagocytes (monocytes, 
macrophages, 
neutrophils), natural killer 
(NK) cells, dendritic cells 
T cells, B cells, antigen-
presenting cells 
 
 4 
Recognition of microbial pathogens by innate immune cells is mediated by germline-
encoded pattern recognition receptors (PRRs). PRRs recognize molecular structures 
that are expressed by a diverse group of pathogens, collectively known as pathogen 
associated molecular patterns (PAMPs). Following PAMP recognition, PRRs initiate 
a series of signaling cascades that generate an initial response against the pathogen 
[6]. PAMP recognition leads to the maturation and activation of antigen presenting 
cells (APCs) and allows effective presentation of microbial antigens to cells of the 
adaptive immune system..[7] 
 
Adaptive Immunity can be divided into two subsections: humoral immunity and cell 
mediated immunity. Humoral immunity involves the production of antibodies by B 
cells that can opsonize or neutralize pathogens in blood or other body fluids. On the 
other hand, cell mediated immunity is responsible for eradication of cancer cells or 
cells that are infected with intracellular pathogens via cytotoxic T cells. Another 
class of T cells called T helper cells do not have cytotoxic or phagocytic activity 
rather they activate other immune cells such as B cells, cytotoxic T cells, 
macrophages and decide the type of immune response either Th1 or Th2, Th17 or 
Th9 biased [8, 9] B cells and T cells express B cell receptors (BCR) and T cell 
receptors (TCR), respectively. These receptors are generated via DNA recombination 
during the development of these cells and are able to recognize huge numbers of 
pathogens. Each TCR and BCR consist of a constant and a variable region. Variable 
region of these receptors are encoded via different gene segments. By random 
assembly of these gene segments during creation of each receptor, a huge receptor 
repertoire can be produced. If a pathogen invades the body, T and B cells with 
corresponding receptors become activated and induce humoral and cellular immune 
responses. In contrast to the innate immune system, the adaptive immune system has 
memory When the same pathogen re-invades the body, memory B and T cells 
expand monoclonally and induce a more rapid and robust immune response [10]. 
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1.2 Innate Immune System 
 
Our bodies are constantly exposed to infectious microorganisms present in our 
environment. In spite of this frequent exposure, disease occurance is quite low. Most 
of the microorganisms that can cross the protective epithelial surfaces are detected 
and eliminated within minutes or hours by defence mechanisms that do not require a 
prolonged period of induction since they do not rely on the clonal expansion of 
antigen specific lymphocytes. [2, 11] 
 
Innate immune system is an evolutionarily ancient part of the immune system. Since 
plants and animals share the same modules, it seems that it arose before the split of 
these two kingdoms. Defects in innate immunity are almost always lethal, further 
supporting the evidence that this system is evolutionarily conserved [2, 12]. 
 
Innate immune system is composed of many types of cells such as Mast cells, natural 
killer cells, eosinophils, basophils; and the phagocytic cells including macrophages, 
neutrophils and dendritic cells (DCs) [13, 14]. 
 
If a pathogen can breach the epithelial layer and start to replicate in tissues, it would 
be recognized by the phagocytes such as DCs, In the classical view of the immune 
system, DCs engulf invading pathogens, digest their proteins into small peptides and 
then present these digested peptides on their surface in association with major 
histocompatibility complex (MHC) proteins. DCs then migrate to the regional lymph 
nodes and present the antigens to naïve T cells. Once a T cells with a corresponding 
T-cell receptor recognizes the MHC:peptide complex displayed on the surface of the 
DC, it becomes activated and starts proliferating (Figure 1.1) 
 
This view is an incomplete one as recent evidence suggests that a DC can only prime 
a T cell if the DC itself is activated in the first place. Such a prerequisite for DC 
activation explains why DCs that capture self-antigens from dead or dying cells do 
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not activate T cells under steady-state conditions (i.e, when there is no infection). For 
efficient T cell activation to occur, the DCs must first be activated following 
recognition of PAMPS via the PRRs they express. This recognition leads to a series 
of signaling events that culminates in induction of co-stimulatory molecule 
expression on the surface of the DC and provides the “second signal” necessary to 
fully activate the naive T cell [10]. 
 
Figure 1.1. Interactions of Innate and Adaptive Immunity (Adapted from:[10]) 
 
1.3 Pattern Recognition Receptors 
 
Innate immune cells express various PRRs that enable them to recognize PAMPs 
from different origins. Several classes of PRRs such as Toll-like Receptors (TLRs), 
Retinoic acid-inducible gene (RIG)-I-like receptors (RLRs) and Nucleotide-binding 
oligomerization domain (NOD)-like receptor (NLRs) have been identified in 
mammals, each specialized to sense the presence of pathogen at a unique subcellular 
compartment such as  the plasma membrane, endolysosomes or the cytoplasm [15]. 
PAMP recognition triggers the activation and proliferation of B cells, natural killer 
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(NK) cells and professional antigen presenting cells (APCs) and induces release of 
several inflammatory and proinflammatory cytokines and chemokines such as TNF, 
IL1IP10, MIP1, MIP3, MCP Regulated upon activation, normal T-cell 
expressed, (RANTES), IL6, IL12, IL15, IL18, IFNγ and type I interferons (IFN and 
IFN; important for anti-viral response) that are pivotal for host defense. [2, 11, 14-
17]  
 
Toll-like Receptors (TLRs) are the first identified and most well characterized class 
of PRRs that can recognize a wide range of PAMPs [6, 13, 14, 18]. TLRs are type I 
transmembrane proteins containing 3 domains. Ectodomains of TLRs consists of 
leucine-rich repeats (LRRs) which mediates the recognition of PAMPs. 
Transmembrane and intracellular Toll interleukin 1 (IL-1) receptor (TIR) domains 
are required for downstream signal transduction. To date 12 different functional 
TLRs in mice and 10 different functional TLRs in human are identified [19]. Each 
TLR detects distinct PAPMs originating from viruses, mycoplasma, bacteria, fungi 
and parasites such as lipoproteins (TLR1,TLR2,TLR6), double stranded (ds) RNA 
(TLR3), lipopolysaccaride (LPS) (TLR4), flagellin (TLR5), single stranded (ss) 
RNA (TLR7, TLR8) and DNA (TLR9) [6, 13, 19].  
 
TLRs are expressed on various cell types including immune and non-immune cells 
such as B cells, macrophages, NK cells, DCs, epithelial cells, endothelial cells and 
fibroblasts. However, cellular localization of TLRs differs according to the specific 
ligands they recognize. While TLR1, TLR2, TLR4, TLR5, TLR6 are localized on the 
plasma membrane, nucleic acid sensing TLRs such as TLR3, TLR7, TLR8 and 
TLR9 are localized in endosomes [6, 10, 13, 14]. 
 
PAMP recognition with corresponding TLRs initiates several downstream signaling 
pathways that lead to the production of inflammatory cytokines, type I IFNs, 
chemokines and antimicrobial peptides. These modulators cause recruitment of 
neutrophils, induction of IFN stimulated genes and direct killing of the pathogen. 
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Furthermore, activation of TLR signaling leads to the activation of DCs, thereby 
contributing to the induction of adaptive immune responses [6, 19] 
Although TLRs can recognize several PAMPs that are extracellular or present in 
endosomes, other non-TLR PRRs such as membrane-bound C-type lectin receptors 
(CLRs)[20], cytosolic proteins such as NOD-like receptors (NLRs) [21] and RIG-I-
like receptors (RLRs) [22], also contribute to the recognition of PAMPs. CLRs are 
membrane bound proteins that can induce inflammatory responses upon recognition 
of PAMPs from different origins such as bacteria and fungus. NLRs are a large group 
of cytosolic proteins that contains more than 20 members. NLRs respond to various 
types of PAMPs to trigger an innate immune response. NLRs such as NALP1 and 
NALP3 form inflammasomes with the contribution of ASC and Caspase-1 and 
mediate the processing of pro- IL1β to mature  IL1β [21, 23]. RLRs are RNA 
helicases that can recognize RNA species in various types of cells. RLRs such as 
RIG-1, MDA5 and LGP2 recognize RNA in the cytoplasm and coordinate antiviral 
responses via type I IFN induction [24] 
 
In case of an infection with an intact pathogen, several classes of PRRs recognize 
several molecular structures expressed on that pathogen which leads to multiple 
activation of PRRs due to multiple PAMP exposure. Moreover, different PRRs can 
recognize the same PAMP. The nature and the strength of the generated innate 
immune response depends on the coordination between TLRs and other non-TLR 
PRRs. In conclusion, TLRs in concert with other PRRs orchestrates innate immune 
responses against various pathogens such as bacteria, fungi, viruses and other 
protozoan parasites [6]. Table 1.2 shows PAMPs originating from different 
pathogens and their relevant PRRs expressed by immune cells. 
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Table 1.2. PAMP Detection by TLRs and other PRRs (Adapted from [6]) 
Species PAMPs TLR Usage 
PRRs Involved 
in Recognition 
Bacteria, 
mycobacteria 
LPS TLR4  
Lipoproteins, LTA PGN TLR2/1, TLR2/6 
NOD1, NOD2, 
NALP3, NALP1 
flagellin TLR5 IPAF, NAIP5 
DNA TLR9 AIM2 
RNA TLR7 NALP3 
Viruses 
DNA TLR9 AIM2, DAI, IFI16 
RNA 
TLR3, TLR7, 
TLR8 
RIG-1, MDA5, 
NALP3 
structural protein TLR2, TLR4  
Fungus 
zymosan, β glucan TLR2, TLR6 Dectin-1, NALP3 
Mannan TLR2, TLR4  
DNA TLR9  
RNA TLR7  
Parasites 
tGTPI-mutin 
(Trypanosoma) 
TLR2  
glycoinositolphospholipids, 
(Trypanosoma)  
TLR4  
DNA TLR9  
hemozoin (Plasmodium) TLR9 NALP3 
Profiling-like molecule 
(Toxoplasma gondii) 
TLR11  
 
1.4 Toll-Like Receptors 
 
Toll protein was first identified in fruitflies (Drosophila) as a protein that is involved 
in defining dorsoventral polarity during embryogenic development.[25] Following 
this, its role in mounting an effective immune response against the fungus 
Aspergillus fumigatus was also described, causing researches to focus on the 
identification of its homologues in mammals. In 1997, Janeway and his colleagues 
reported that “A human homologue of the Drosophila Toll protein signals activation 
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of adaptive immunity.” and named the homologue as Toll-like Receptors [26]. As 
mentioned in the previous section, to date several TLRs have been identified in 
mouse and human and each recognize a distinct PAMP. Table 1.3 shows the 
chromosomal locations of the genes encoding TLRs [6, 13, 19] (Table 1.2 and Table 
1.3). 
 
Table 1.3.Chromosomal localizations of TLRs.  
 Chromosome 
TLR Mouse Human 
TLR1 5 37.0 cM 4p14 
TLR2 3 E3 4q32 
TLR3 8 B2 4q35 
TLR4 4 33.0 cM 9q32-q33 
TLR5 1 98.0 cM 1q41-q42 
TLR6 5 37.0 cM 4 4p14 
TLR7 X F5 Xp22.3 
TLR8 X F5 Xp22 
TLR9 9 F1 3p21.3 
TLR10 N/A 4p14 
TLR11 14 C1 N/A 
TLR12 4 D2.2 N/A 
TLR 13 X D N/A 
 
TLRs can be devided into two groups with regard to their cellular localizations: One 
group is expressed on the cell surface and include TLR1, TLR2, TLR4, TLR5, 
TLR6, TLR11 responsible for recognition of mainly microbial membrane 
components such as proteins, lipids and lipoproteins [19] (Figure 1.3). The other 
group consists of TLR3, TLR7, TLR8 and TLR9 which are expressed in the 
intracellular compartments and recognize nucleic acid ligands [19] (Figure 1.3). 
 
1.4.1 Cell Surface Toll-Like Receptors 
 
1.4.1.1 TLR1, TLR2 and TLR6 
 
TLR2 recognizes a wide range of PAMPs form different origins such as bacteria, 
fungi, parasites and viruses. This promiscuous ligand recognition property of TLR2 
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can be explained by its ability to form heterodimers with TLR1, TLR6 or with non-
TLR molecules such as CD36, CD14 and dectin-1. TLR2-TLR1 heterodimers and 
TLR2-TLR6 heterodimers recognize triacyl-lipopeptide from Gram negative bacteria 
and diacyl-lipopeptide from mycoplasma, respectively. [13, 27, 28] Thus, TLR1 and 
TLR6 functionally associate with TLR2 and discriminate between diacyl or triacyl 
lipopeptides [29]. TLR2 also recognizes zymosan with association with dectin-1, a 
C-type Lectin Receptor. Furthermore, a type of class II scavenger receptor called 
CD36 functions as a co-receptor in sensing LTA and MALP-2 molecules of Staph. 
Aureus by the TLR2-TLR6 heterodimer [30]. 
 
1.4.1.2 TLR4 
 
TLR4 is the receptor that recognizes lipopolysaccharide (LPS), a component of the 
outer membrane of Gram-negative bacteria. LPS is a potent immunostimulatory 
molecule and causes septic shock [31]. The recognition of LPS by TLR4 is 
dependent on the complex formation of TLR4 with a recognition subunit, MD2 
(myeloid differentiation protein-2) and the membrane bound GPI 
(glycosylphosphatidylinositol) anchored CD14 [32].Additionaly, LPS binding 
protein (LBP) is another important protein that plays a role in LPS recognition [33]. 
LBP acts as a soluble or plasma membrane protein that binds LPS. CD14 binds LBP 
and delivers LPS-LBP complex to the TLR4-MD2 complex. MD2 binds to lipid A 
(active component of LPS) and this binding activates the dimerization of two TLR4 
receptors and TLR4 signalling pathway [24]. In addition to LPS, TLR4 also 
recognizes glycoinositolphospholipids from Trypanosoma [34] and the fusion protein 
from RSV (respiratory syncytial virus) [13, 35]. 
 
1.4.1.3 TLR5 
 
TLR5 recognizes flagellin, which is the monomer of an important structural protein 
of pathogenic and non-pathogenic bacteria called the flagella [36]. Flagellin induces 
mucosal immune responses by acting on TLR5 expressed on epithelial cells or 
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macrophages. The amino acid sequence of flagellin is highly conserved and hence is 
a target of innate immunity. TLR 5 is expressed in the digestive tract, the urinary 
tract and the respiratory tract, all constituting surfaces that are prone to infection by 
flagellated bacteria. In intestinal eptihelia, TLR 5 is expressed only in the basolateral 
surface and not on the apical surface of the cells. This polarized expression pattern, 
enables TLR5 to recognize only invading bacteria that have breached the epithelial 
barrier but not the non-invading commensals. TLR5 activation induces chemokine 
expression from epithelial cells and thereby contributes to inflammatory responses 
and leukocyte accumulation at the site of infection [10].  
1.4.1.5 TLR11 
 
TLR11 recognizes profilin-like molecules of Toxoplasma Gondii, an intracellular 
protozoan parasite [37]. The active component of this profilin-like molecule has a 
role in parasite motility and invasion [38]. In addition to its role in recognition of 
profilin-like molecules originating from Toxoplasma Gondii, TLR11 also contributes 
to protection from uropathogenic bacteria as mice deficient for TLR11 were shown 
to be highly susceptible to infection with such bacteria [39]. Moreover, TLR11 
expression in the kidney and bladder is higher than that of TLR5, suggesting that this 
receptor is likely to sense uropathogenic bacteria-derived products, although no such 
“specific ligand” has been identified thus far [24, 39]. Interestingly, TLR11 is 
expressed only in mice but not in humans which is attributed to the presence of at 
least one premature stop codon [24]. 
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Figure 1.2. PAMP recognition by cell-surface TLRs (Adapted from [19]) 
1.4.2 Intracellular Toll-Like Receptors 
 
TLR3, TLR7, TLR8, TLR9 are the receptors specialized for sensing foreign nucleic 
acids. These receptors are expressed within the intracellular compartments such as 
endosomes, lysosomes and the endoplasmic reticulum (ER) [40, 41]. Upon ligand 
recognition, these receptors initiate an anti-viral innate immune response 
characterized by production of type I IFNs and inflammatory cytokines [24] (Figure 
1.2). 
 
1.4.2.1 TLR3 
 
TLR3 recognizes viral ds RNA from etiher ds RNA viruses or ssRNA viruses that 
are producing dsRNA during their replication [42-44]. TLR3 also recognizes a 
synthetic analogue of ds RNA known as polyI:C. TLR3 is expressed both in immune 
cells such as conventional DCs, macrophages, B cells, NK cells and non-immune 
cells such as uterine, airway, vaginal, cervical, corneal, biliary, and intestinal 
epithelial cells, which function as efficient barriers to infection [13]. Interestingly, 
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TLR3 is not expressed in plasmocytoid DCs (pDCs) which are potent type I IFN 
producers. In addition, TLR3 is highly expressed in the brain [13, 45]. Viral RNA 
recognition via TLR3 triggers production of type I IFNs and inflammatory cytokines. 
Nevertheless, despite such a response, TLR3’s role in protection against viral 
infections is controversial. Some reports indicate that TLR3 deficient mice are more 
susceptible to infections with mouse cytomegalovirus (MCMV) and West Nile 
Viruses (WNV) [46, 47]. In contrast, other reports indicate that TLR3 plays a role in 
pathogenesis rather that protection. For example, TLR3 deficient mice were shown to 
have increased survival rates following infection with WNV or influenza A virus 
(IVA) [43, 48]. Moreover, it has been shown that TLR3 deficiency does not affect 
anti-viral responses of CD4+ and CD8+ T cells following infection with MCMV, 
reoviruses and lymphocytic choriomeningitis virus [49]. 
 
1.4.2.2 TLR7 and TLR8 
 
TLR7 and TLR8 recognizes ssRNA, synthetic antiviral imidazoquinoline compounds 
(R848, Imiquimod, etc.) and some guanine nucleotide analogs (loxoribine etc. ) [6, 
50]. TLR7 and TLR 8 genes show high homology to each other and both are 
expressed on X chromosome. Although both genes are expressed in mouse, mouse 
TLR8 seems to be non-functional [13]. TLR7 and TLR8 are located in endosomal 
compartments .In general, viruses gain entry into cells via receptor mediated 
endocytosis and reach the phagolysosomes. Phagolysosomes have a highly acidic 
environment and contain degradative enzymes that hydrolyse virus coat proteins, 
leading to the exposure of viral RNA to TLRs. In contrast, host’s ssRNA cannot 
enter into these compartments due to the activity of RNases in plasma [51]. TLR 7 is 
highly expressed in pDCs and triggers the secretion of huge amounts of type I IFNs 
from these cells in response to viral infection [24, 52]. 
1.4.2.3 TLR9 
 
TLR9 recognizes bacterial and viral genomic DNA [53, 54] such as those originating 
from MCMV, and herpes simplex viruses 1 and 2 [55, 56]. This recognition induces 
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production of several inflammatory cytokines and type I IFNs from DCs, B cells and 
macrophages [19]. Synthetic CpG dinucleotide motif containing ssDNAs can mimic 
the immune stimulatory activity of bacterial or viral dsDNA [51]. Several different 
factors seem to contribute to the recognition of DNA by TLR9: Most reports indicate 
that recognition is due to the presence of unmethylated CpG motifs expressed 20 
times more abundantly in bacterial and viral genomes than the mammalian genome. 
Furthermore, in mammals, CpG motifs are highly methylated and do not activate the 
mammalian immune cells [13, 51, 57-59]. This theory is supported by publications 
indicating that bacterial DNA must be delivered to endosomal compartments with 
acidic environments and degraded into multiple CpG containing ssDNAs that can 
interact with TLR9 [40, 60]. In contrast, some reports correlate the recognition of 
DNA by TLR9 to the presence of 2’ deoxyribose-phosphate backbone [61, 62] 
specifically in endosomes. It has been shown that a chimeric form of TLR9 localized 
on the cell surface has been shown that can respond to self DNA [63]. It is speculated 
that CpG motifs may play a role in the stability, aggregation and uptake of the DNA 
by cells but is not necessary for TLR9 recognition [50] A more recent publication 
challenged the role of CpG motifs claiming that the 2’ deoxyribose-phosphate 
backbone is important in recognition of phosphodiester backbone DNA irrespective 
of its CpG content while CpG motif is indispensible in recognition of 
phosphorothioate backbone modified DNA [61] Whether TLR9 recognition of DNA 
depends strictly on CpG recognition or on the presence of 2’ deoxyribose-phosphate 
backbone in endosomes, it seems that endosomal co-localization is essential for this 
recognition [50]. For instance, even though malarial DNA itself is not highly 
stimulatory, when it is delivered into the endosomal compartments via transfection or 
bound to malarial hemozoin, it induces a strong immune responses [64]. In another 
study it has been shown that LL37, a human antimicrobial peptide released from 
keratinocytes during skin injury binds to self-DNA and creates aggregates that can 
enter endosomes, contributing to immune activation in an autoimmune disease called 
psoriasis [65]. 
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1.4.2.4 Trafficking of intracellular TLRs 
 
As mentioned above, nucleic acid sensing TLRs such as TLR3, TLR7, TLR8 and 
TLR9 are expressed in various intracellular compartments such as endosomes, 
lysosomes and the endoplasmic reticulum (ER) [19, 50]. This intracellular 
localization is important in terms of two situations. Firstly, viral nucleic acids are 
delivered via receptor mediated endocytosis and they are recognized in these 
endosomes that express TLRs. Secondly, this localization is also important in terms 
of discriminating self from non-self [24]. It has been shown that macrophages 
express TLR9 on the cell surface responds DNA originating from self [63]. These 
intracellular TLRs are expressed in the ER in resting cells and upon PAMP 
stimulation they traffic to the endosomal compartments [24]. It has been shown that 
activation occurs only in the acidified endosomes since usage of agents that prevents 
endosomal acidification abrogated TLR3, TLR7, TLR8 and TLR9 responses [66].  
 
Trafficking of intracellular TLR3, TLR7 and TLR9 are mainly regulated by a12 
membrane spanning ER protein called UNC93B1. UNC93B1 interacts with 
transmembrane domains of these receptors and assists in delivery from ER to the 
endolysosome [67, 68] (Figure 1.2). It has been shown that only a single missense 
mutation on UNC93B1 causes defects in cytokine production and co-stimulatory 
molecule up-regulation in response to TLR3, TLR7, TLR9 ligands [69]. In addition, 
it has been also reported that UNC93B1 deficiency is responsible for HSV-1 
encephalitis in human [70]. 
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Figure 1.3. PAMP recognition by intracellular TLRs and the role of UNC93B1 on their 
trafficking from ER to endolysosome (Adapted from: [19]) 
 
Two other ER proteins are also involved in TLR trafficking PRAT4A and gp96. 
PRAT4A plays role in the trafficking of TLR1, TLR2, TLR4, TLR7 and TLR9 from 
ER to plasma membrane or endolysosome [71]. However it does not affect TLR3 
trafficking indicating that TLR3 trafficking is regulated in a different way than TLR7 
and TLR9 [72]. On the other hand, gp96, another ER protein, functions as a general 
chaperone for most of the TLRs including cell surface expressed ones such as TLR1, 
TLR2, TLR4,TLR5 and intracellular ones such as TLR7 and TLR9 [73]. 
1.4.2.5 Endosomal Cleavage of Intracellular TLRs 
 
As mentioned in previous sections endosomal acidification is required for the 
activation of intracellular TLRs. This acidification is important from two aspects. 
Firstly, acidic environment and enzymes in endosomes facilitates the disassembly of 
microbes in order to release their contents such as CpG DNA [40, 60]. Secondly, 
endosome maturation is involved in essential processing of TLRs themselves. For 
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instance, ectodomain of TLR9 is proteolytically cleaved by proteases upon its arrival 
to the endosomal compartment which generates a functional receptor that can 
recognize ligand and initiate signal transduction [74, 75]. Proteases involved in the 
cleavage of TLR9 involves cathepsin B, cathepsin S, cathepsin L, cathepsin H and 
cathepsin K, and asparaginyl endopeptidase [74-78]. Similar cleavage process was 
also shown for TLR7 but not TLR3 [74] indicating that cleaved forms of TLR7 and 
TLR9 may display a similar ligand binding structure to full-length TLR3 [50] 
 
In conclusion, in addition to other pre and post translational regulatory mechanisms, 
cleavage appears to be an additional step in the maturation of TLRs [50]. 
 
1.5 TLR Signalling 
 
Upon PAMP recognition, TLRs trigger specific immune responses. For instance, 
while TLR3 and TLR4 initiates both type I IFNs and inflammatory cytokine 
responses, cell surface TLRs such as TLR1-TLR2, TLR2-TLR6 and TLR5 induces 
mainly inflammatory cytokines. This specificity depends on the recruitment of a 
single or a specific combination of The Toll/Interleukin-1 receptor (TIR) domain 
containing adaptor protein such as Myeloid differentiation primary response gene 88 
(MyD88), TIR domain containing adaptor protein (TIRAP), TIR-domain-containing 
adapter-inducing interferon-β (TRIF) and TRIF related adaptor molecule (TRAM) 
[6]. TLR1, TLR2, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 and TLR11 recruit 
MyD88 to their TIR domains upon ligand recognition whereas TLR3 and TLR4 
recruits TRIF. TLR1, TLR2, TLR4 and TLR6 use TIRAP, which serves as a linker 
between TIR domain of these TLRs and MyD88 whereas TLR5 and TLR11 binds 
directly to MyD88. Similarly, TLR4 uses TRAM in order to bind TRIF. These 
recruitments of adaptor molecules to specific TLRs initiates the signaling cascade 
and activation of transcription factors such as nuclear factor kappa B (NFκB) and 
interferon regulatory factor (IRFs) [15] (Figure 1.4) 
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Figure 1.4.  TIR domain containing adaptors in TLR signaling (Adapted from [10]) 
 
TLR signaling can be divided into two categories, MyD88-dependent and TRIF- 
dependent pathways. TLR4 is the only TLR that uses all four adaptors and induces 
both pathways [19]. 
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1.5.1 MyD88-dependent pathway 
 
All TLRs (except TLR3) use MyD88-dependent pathway. Upon ligand recognition 
TLRs recruit MyD88 molecules to their TIR domains and MyD88 recruits IL1 
receptor associated kinase (IRAK) family of proteins and TNF receptor associated 
factor (TRAF) 6. TRAF6 activates TAK1 and TAK1 activates the IκB kinase 
(IKK)complex in order to activate NFκB and also activates the mitogen-activated 
protein kinase (MAPK) pathway [15] (Figure 1.5) 
 
 
Figure 1.5.  MyD88 and TRIF dependent pathways (Adapted from [15]) 
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1.5.2 TRIF-dependent pathway 
 
TLR3 and TLR4 use TRIF-dependent pathway upon ligand recognition and initiate 
the production of type I IFNs and inflammatory cytokines from DCs and 
macrophages. TRIF activates the transcription factor IRF3 via activating the kinase 
protein that phosphorylates IRF3 called TBK1. After phosphorylation IRF3 
translocates from cytoplasm to nucleus and triggers the production of type I IFNs. 
Since inducing type I IFNs, TRIF-dependent pathway is involved in anti-viral 
responses. TLR7 and TLR9 recognizes viral nucleic acids however molecular 
mechanism underlying the production of type I IFNs upon TLR7 and TLR9 
activation is different. In pDCs MyD88 directly interacts with IRF7 and induces type 
I IFN production [10] (Figure 1.5)  
 
1.6 Effects of DNA on Immune System 
 
DNA and RNA are the essential components of all living organisms. Accumulated 
evidence strongly suggests that these nucleic acids have multiple and complex effects 
on the immune system and are more than a blueprint of life [79-81]. DNA is 
normally isolated from the extracellular world via nuclear or mitochondrial 
membrane in eukaryotes, the cell wall in bacteria, or the envelope in viruses. 
Following microbial infection or tissue damage DNA can be released from microbes 
or damaged host cells. Such DNA is detected by the immune system [13, 82] On one 
hand, due to their high unmethylated CpG motif frequency, bacterial DNAs are 
recognized as “non-self” via TLR9 and trigger an innate immune response 
characterized by the proliferation and maturation of B cells, natural killer cells, and 
pDCs and the secretion of Th1 type cytokines, chemokines, and/or multivalent 
immunoglobulins [83-88]  
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On the other hand, telomeric regions of mammalian chromosomes contain 
suppressive TTAGGG motifs that can inhibit several TLR-dependent and TLR-
independent Th1-mediated immune responses. Of note, these motifs are 
underrepresented in the prokaryotic genome [31, 89, 90]. Novel therapeutics 
including nucleic acid based agonists/antagonists are currently under 
preclinical/clinical trials to prevent or treat cancer, infectious disease, allergic 
disorders and autoimmunity [91-93]. 
 
1.6.1 Immunostimulatory CpG ODN  
 
CpG ODN story started with the observation that synthetic nucleic acid fractions 
originally found in bacteria has antitumor effects. It was first hypothesed palindromic 
sequences within these sequences were the cause of this immune stimulation [94] but 
it was shown by Krieg and Klinmann in 1995 that specific sequence motifs 
consisting of unmethylated CpG dinucleotide flanked by two 5’ purines and two 3’ 
pyrimidines were responsible for the innate immune response triggered by such 
DNAs [84, 95]. Mammalian DNA has approximately 20 times less frequent CpG 
motifs and due to methylation status they are not immune stimulatory like microbial 
DNA (Table 1.4)  
 
Table 1.4.  Immunostimulatory effect of CpG ODN (Adapted from [96]) 
 Fold Increase in Cytokine secreting cell number 
IL6 IL12 IFNγ IgM 
Bacterial DNA 3.2±0.2 3.8±0.4 4.7±2.3 3.9±1.1 
Mammalian DNA 0.8±0.2 1.1±0.2 0.8±0.3 0.7±0.2 
CpG ODN 5.5±1.1 8.3±1.7 4.7±1.1 4.2±1.6 
CpG ODN (methylated) 0.9±0.2 1.2±0.3 0.8±0.2 1.1±0.2 
CpG ODN (DNase Rx’d) 1.3±0.2 0.8±0.2 1.1±0.2 0.9±0.2 
GpC ODN 1.2±0.3 1.3±0.3 1.2±0.3 1.3±0.3 
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Bacterial DNA or synthetic ODNs expressing these CpG motifs induce 
immunostimulation characterized by a proinflammatory (IL1, IL6, IL18, TNFα) and 
T helper 1 (Th1) biased (IFNγ and IL12) immune milieu [96] 
 
Five years after the discovery of CpG motifs, in 2000 Akira et al., indicated that the 
receptor responsible for CpG ODN recognition is TLR9 [53] As mentioned in 
previous section CpG ODNs are internalized into endosomal compartments where 
they are recognized by TLR9 and induce a robust innate immune response [51]. 
 
There are three known types of CpG ODN: D-type (also known as A-class), K-type 
(also known as B-class) and the recently described C-class, all of which possess 
unmethylated CpG dinucleotides and require TLR9 to activate the immune system 
[92, 97]. These 3 types of ODN possess CpG dinucleotides, but their flanking 
sequences and compositions are different. For example, K-type ODN contain 
multiple CpG motifs, whereas D-type ODN have one CpG with palindromic flanking 
sequences. D-, but not K- nor C-type ODN have a poly-G (5-6 bases) tail at the 3’-
end, which may account for their distinct activity. K- and C- but not D type ODN 
have phosphorothioate linkage between all nucleotides. D-type ODN stimulate 
plasmacytoid DC (pDC) to secrete large amounts of IFNα, whereas K-type ODN 
strongly stimulate B cells to proliferate and to secrete IL6 and IgM. C-type ODN 
show a combined activity of K- and D-type ODN, but to a lesser extent [16, 80].  
 
Several reports indicated that the IFNα induction from pDCs by D type ODNs were 
due to the ability to spontaneously form higher order structures because of their 
palindromic sequences and poly (G) since such higher order structures are not 
observed in K types [98, 99]  
 
In 2006, Gursel et al., discovered the co-receptor CXCL16 expressed on pDC which 
can contribute to discribe the dichotomy of response between D and K types. In this 
work, her group demonstrated for the first time that a type of surface expressed 
scavenger receptor is required for the D-ODN activation of pDC to secrete robust 
IFNα [17]. 
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1.6.2 CpG DNA as adjuvants for vaccines 
 
CpG ODN which acts as ligand for innate immune receptors also supports the 
development of adaptive immune responses via improving the functional activity of 
professional APCs and triggering the production of cytokine and chemokines that are 
critical in the development of adaptive immune responses [84, 88, 100, 101]. 
 
CpG ODNs activate innate immunity by binding their receptor TLR9 located in 
endosomal compartments of pDCs, B-cells, and multiple cells of myeloid lineage in 
mice [102]. CpG ODNs have been shown to activate B cells via upregulating the 
secretion of IgM, IL6 and IL10, inducing the expressions of Fc receptor (FcR) and 
costimulatory molecules such as CD40, CD80, CD86 and major histocompatibility 
complex II (MHCII), inhibiting the apoptosis and enhancing the antigen presentation 
function [95, 102-104]. Effects of CpG ODNs are not limited on B cells. CpG ODNs 
have also been shown to induce the maturation and differentiation of other antigen-
presenting cells such as plasmacytoid dendritic cells (pDCs) and macrophages. pDCs 
and macrophages show increased expression MHCII and costimulatory molecules 
(CD40, CD80, CD86) and cytokines such as IL6, IL12, IL1β upon CpG stimulation 
[102, 105]. 
 
Several studies indicated that use of CpG ODN as an adjuvant increased protein 
immunogenicity, cytokine production and IgG2a:IgG1 ratio [102, 103, 106, 107]. 
Table 1.5 summarizes the type and magnitude of immune response induced with the 
use of CpG ODN with the conventional protein or vaccine based antigens 
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Table 1.5. Use of CpG ODN as an adjuvant with various peptides and vaccines (Adapted 
from [88].) 
Antigen Fold Ab Titer Ig Profile Cytokine 
Profile 
References 
Ovalbumin >7fold (3wk) IgG2a>IgG1 IFNγ [106] 
Hen eggwhite 
lysozyme 
>10fold (3wk) IgG2a>IgG1 IFNγ, IL5 [108] 
Hepatitis B 
Surface 
Antigen 
>104fold 
(4wk) 
  [109] 
Influenza virus >10 fold 
(4wk) 
Intranasal IgA IFNγ [110] 
Measles virus >20 fold 
(4wk) 
IgG2a>IgG1 IFNγ, IL5 [111] 
Tetanus 
Toxoid 
> 3fold (6wk)   [112] 
Brucella >100 fold 
(3wk) 
IgG2a>IgG1 IFNγ [113] 
rPA (anthrax) >8 fold (3wk) IgG2a>IgG1 IFNγ [114, 115] 
L1 and A33 
proteins 
(smallpox) 
>10 fold 
(3wk) 
IgG2a>IgG1  [116] 
 
 
1.6.3 Immunosuppressive ODN  
 
During infection or tissue damage, inflammation must be waned and terminated with 
tissue remodeling and healing [80]. CpG-driven immune activation can exacerbate 
inflammatory tissue damage, or increasing sensitivity to autoimmune diseases or 
toxic shock. Similarly, other immune responses designed to protect the host can have 
deleterious consequences if not adequately regulated [117]. Recent evidence 
suggested that host DNA contained some antagonistic elements to the 
immunostimulatory effect in their DNA or against pathogen derived CpG rich DNA, 
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possibly suppressing DNA-driven immunostimulation [118]. Neutralizing or 
suppressive motifs can selectively block CpG-mediated immune stimulation [119]. 
Suppressive motifs are rich in poly-G or GC sequences, and optimal motifs are 
surprisingly identical to telomere sequences (with a repeat of TTAGGG), which are 
present in DNA of mammals, but not in bacteria [79]. Gursel and his colleagues 
demonstrated for the first time that telomeric DNA consisting of TTAGGG repeats 
can significantly suppress immune activation while non-telomeric mammalian DNA 
cannot. Furthermore they also showed that DNA isolated from telomerase deficient 
KO mice was not capable to suppress immune responses compared to normal DNA 
[79]. 
 
In vitro, it has been shown by many groups that mammalian telomeric suppressive 
ODN (A151) inhibits the production of several proinflammatory cytokines and 
chemokines induced by bacteria such as IL6, IL12, IFNγ, TNFα and MIP2α [79, 
120-122]. As summarized in Table 1.6and Table 1.7, Suppressive ODN can 
significantly reduce cytokine/chemokine production and immune cell proliferation 
induced by CpG ODN or several other different immune activators [122] 
 
Table 1.6. Effect of Suppressive ODN in CpG induced immune activation (Adapted from 
[122]). 
Treatment % Activation 
CpG ODN alone 100±2 
+Mammalian DNA 27±4 
+Telomeric DNA 13±3 
+Non-telomeric DNA 87±5 
+Control ODN 97±3 
+Suppressive ODN (A151) 8±2 
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Table 1.7. Effect of Suppressive ODN on IFNγ production induced by several immune 
activators (Adapted from [122]). 
Stimulus None Control ODN Suppressive 
ODN (A151) 
CpG DNA 27±5 24±6 6±2 
ds RNA 8±2 10±1 2±1 
Peptidoglycan 28±5 31±4 5±2 
LPS 24±7 21±3 6±2 
 
Effects of Suppressive ODN (A151) in the treatment of different autoimmune and 
inflammatory diseases in several animal models have been studied by us and others. 
In 2005, Shirota and Gursel showed that suppressive ODN treatment immediately 
prior to LPS challenge significantly improved survival rates in BALB/c mice injected 
with lethal dose of LPS [31]. 
 
In another study, effect of Suppressive ODN (A151) on the onset of systemic lupus 
erythematosus in NBZ/W mice has been studied. In this study, investigators injected 
mice twice per month starting at age 6 weeks with Suppressive ODN or Control 
ODN and several characteristics of the disease such as proteinuria, kidney 
inflammation and also survival has been followed. According to their results 
Suppressive ODN significantly delayed the onset of proteinuria and inflammation. 
Most importantly survival rates of the animals have been prolonged [123].  
 
Rheumatoid Arthritis (RA) is the most common rheumatic disease which is 
characterized by destruction, disability and deformity of the joints. Effect of 
Suppressive ODN (A151) on RA is studied in an animal model called collagen-
induced arthritis (CIA). In this study arthritis was induced by collagen 
administration. Authors indicated that Suppressive ODN (A151) treatment 
significantly reduced the incidence and severity of the arthritis and also decreased 
serum titers of pathogenic IgG autoantibody titers and IFNγ production by collagen 
reactive T cells [124] 
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Furthermore, effects of Suppressive ODN (A151) in Silica induced Pulmonary 
Inflammation have been studied. Silicosis was induced via instilling silica into the 
lungs of normal BALB/c mice. Silica instilling increased bronchoalveolar lavage 
(BAL) cellularity and production of IL12 and kerationcyte chemoattractant (KC) 
proteins. These effects were significantly reduced in Suppressive ODN treated 
groups [125]. 
 
Uveitis is an ophthalmic disorder that causes vision loss in developed countries [126, 
127] and is characterized by acute, recurrent, or persistent ocular inflammation, the 
breakdown of the blood-ocular barrier, and infiltration of leukocytes [128]. Fujimoto 
et al. [129] reported that suppressive A151 ODN can inhibit ocular inflammation in 
two murine models, IRBP (interphotoreceptor retinoid-binding protein)-induced 
experimental autoimmune uveitis and adoptively transferred ocular inflammation. In 
2010, we published that Suppressive ODN can reduce the symptoms associated with 
a very aggressive form of experimental uveitis initiated via endotoxin administration 
[81]. Compared to previous studies our animal model was a much more aggressive 
form of the disease and Suppressive ODN was still able to alleviate several disease 
induced parameters as described in Results section of this thesis.  
 
Over the last few years, remarkable improvements have been achieved by 
researchers in Suppressive ODN field. In 2011, Klinman and colleagues showed the 
effects of Suppressive ODN (A151) on a type of cancer that inflammation plays a 
critical role called papilloma. In this study, authors used 7,12-
dimethylbenz(a)anthracene (DMBA)/12-O-tetradecanoylphorbol-l3-acetate (TPA) in 
order to induce skin carcinogenesis. Their results indicated for the first time that 
Suppressive ODN blocked TPA-dependent skin hyperplasia, edema, and leukocytic 
infiltration. Most importantly, their results suggested that Suppressive ODN reduced 
papilloma formation in a dose and sequence dependent manner. Up to date, this was 
the first and only study suggesting that Suppressive ODN can be used in 
inflammation associated oncogenesis [130]  
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Their observations were supported by other researchers indicating that Suppressive 
ODNs can improve the antiproliferative effects of anticancer drugs [131]. Most 
recently, again Klinman and colleagues demonstrated that Suppressive ODN A151 is 
capable of reducing lung cancer susceptibility of mice with silicosis [132]. As 
mentioned before in this section of this thesis, Klinman and colleagues have already 
established the inhibitory role of Suppressive ODN on silicosis. In addition to their 
previous observations, in this study researchers investigated the role of potent 
carcinogens present in cigarette smoke (NNK) in development of lung cancer in mice 
with silicosis and protective effects on Suppressive ODNs in pathologic 
inflammation and cancer. In conclusion, authors reported that Suppressive ODN can 
inhibit pulmonary fibrosis and other inflammatory manifestations of chronic silicosis 
and so as lung cancer [132]. 
 
As mentioned in the beginning of this section, Suppressive ODN A151 is a sequence 
that contains poly G runs. Guanosines are tend to make interchain and intrachain 
Hoogstein Bonds and these interactions led the sequence to form higher order 
structures called G-tetrads. It has been shown by Gursel et al., that the suppressive 
activity of ODN A151 is correlated with its ability to form G-tetrads. They showed 
that nucleotide substitutions that inhibit G-tetrad formation abrogated the suppressive 
activity of these sequences [79]. 
 
Suppressive ODN (A151) is not the only sequence motif with suppressive properties. 
Several reports indicate that sequences other than A151 can also reduce immune 
responses. Sequences showing suppressive activity, used disease models, potential 
modes of actions and TLR dependence are given in Table 1.8 
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Table 1.8. Different types of immunosuppressive ODNs used for several immunotherapeutic 
applications  
ODN 
Name 
Sequence Disease Potential Mode of 
Action 
TLR 
dependence 
Reference 
A151 ODN 
(TTAGGG)4 
Endotoxic 
Shock 
Prevent 
phosphprylation of 
STAT1 and STAT4 
TLR4 [31] 
Collagen 
induced 
Arthritis 
N/A TLR-
independent 
[124] 
Systemic Lupus 
Erythematosus 
(SLE) 
N/A TLR-
independent 
[123] 
Silicosis N/A TLR-
independent 
[125] 
CpG induced 
Lung 
Inflammation 
N/A TLR9 [133] 
Endotoxin 
induced Uveitis 
(EIU) 
N/A TLR4 [81] 
Experimental 
Autoimmune 
Uveitis (EAU) 
N/A TLR-
independent 
[129]. 
Inflammation 
induced 
Papillomas 
N/A TLR-
independent 
[130] 
Herpes Simplex 
Virus Infection 
N/A TLR9 [134] 
Candida 
Albicans 
Infection 
Inhibits SOCS3 and 
promotes STAT3 
TLR 
independent 
[102] 
Mouse CMV 
infection 
Inhibits AIM2 
inflammasome 
activation 
TLR 
independent 
[135] 
Small cell lung 
cancer 
Modifying Akt and 
the extracellular 
signal-regulated 
kinase 1/2 pathway 
TLR 
independent 
[131] 
Lung Cancer 
Susceptibility in 
Mice with 
Silicosis 
N/A TLR 
independent 
[132] 
H154 ODN 
CCTCAAGCTTGAGG
GG 
CpG-induced 
Arthritis 
N/A TLR9 [136, 137] 
Experimental 
Autoimmune 
Neuritis 
N/A TLR9 [138] 
CpG-induced 
myocardial 
dysfunction 
N/A TLR9 [139] 
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GpG ODN TGACT
GTGAA
GGTTA
GAGAT
GA 
 
Experimental 
autoimmune 
encephalomyelit
is (EAE) 
Inhibits 
phosphorylation of 
IκB-α at Ser32 
TLR9 [140, 141] 
Lupus Nephritis N/A TLR3, TLR7, 
TLR8, TLR9 
[142] 
Class-R 
INH 
ODN1 and 
ODN2008  
CCTGG
ATGGG
AATTC
CCATC
CAGG 
Systemic lupus 
erythematosus 
(SLE) 
N/A TLR7 and 
TLR9 
[143, 144] 
Multiple 
IRS ODNs 
Various Systemic lupus 
erythematosus 
(SLE) 
N/A TLR7 and 
TLR9 
[145] 
IRS 869 TCCTG
G 
AGGGG
T TGT 
Systemic 
Inflammation 
N/A TLR9 [146] 
IRS 954 TGCTC
CTGGA
GGGGT
TGT 
Skin 
Inflammation 
N/A TLR7 and 
TLR9 
[147] 
SLE N/A TLR7 and 
TLR9 
[148, 149] 
G-Rich 
ODN 
CCTGG
AGG 
GGAAG
T 
(SLE) N/A TLR9 [150].??? 
SAT05f (CCT)8 GVHD N/A TLR7 and 
TLR9 
[151-153] 
MS19 (AAAG)6 Acute lung 
inflammation 
N/A TLR9 [154]  
 
As seen on the Table 1.8 most of the sequences given in the table are G rich 
sequences and their suppressive activity seems to be their ability to form G-tetrad 
structures. 
 
ODN H154 is another G-rich suppressive sequence that has beeen shown to alleviate 
symptoms associated with reactive arthritis and experimental autoimmune neuritis 
(EAN). Reactive arthritis is an inflammatory condition that develops several weeks 
after infection of gastrointestinal or genitourinary tracts with bacteria. Zeuner and 
colleagues injected CpG ODNs directly into the knee joints of BALB/c mice and 
induced a similar form of arthritis in their study. They showed that co-administration 
of equal amount of ODN H154 with CpG ODN significantly reduced both 
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inflammation and swelling on the injected joint. Since arthritis can affect multiple 
joints, systemic effect of the ODN has also been studied. Their results suggested that 
administration of ODN H154 3 days before CpG challenge significantly reduced the 
development of inflammatory arthritis [136, 137].  
 
Guillain-Barre Syndrome is a Th1 type autoimmune disease characterized by 
demyelination and inflammation in peripheral nervous system. In 2012, Wang et al., 
reported beneficial effects of ODN H154 on EAN which serves as an established 
animal model of GBS in humans. In this study authors induced EAN by injecting P2 
peptide and complete Freund’s adjuvant into both hindpads of Lewis rats. Following 
immunization at days 3 and 6 authors injected different types of ODNs (such as CpG 
ODN, control ODN and ODN H154) in shoulders of rats. Their results indicated that 
EAN rats inoculated with ODN H154 had significantly better clinical scores and 
reduced TLR9 activation [138] 
 
Most recently, Boehm et al., indicated that ODN H154 can inhibit CpG induced 
myocardial dysfunction. In this study, researchers induced sepsis via i.p. application 
of the TLR9 agonist 1668-thioate in C57BL/6 wild type (WT) and TLR9-deficient 
(TLR9-D) mice. Their results indicated that inhibition of TLR9 by the suppressive 
ODN H154-thioate significantly ameliorated cardiac inflammation, preserved cardiac 
function, and improved survival [139] 
 
Effects of another G-rich immunosuppressive sequence called GpG ODN have been 
studied. Ho and colleagues showed that GpG ODN can effectively enhance the 
efficacy of myelin cocktail/IL4 tolerizing DNA vaccination in experimental 
autoimmune encephalomyelitis (EAE) which is a prototypical animal model of 
multiple sclerosis in humans. They showed that combining GpG ODN with myelin 
cocktail/IL4 tolerizing DNA can reduce mean disease severity via inducing a shift in 
the autoreactive B and T-cell responses into a protective IgG1 isotype and Th2 type 
cytokine pattern respectively [140, 141]. 
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Like Suppressive ODN (A151), effects of GpG ODN on an animal model of lupus 
nephritis have also been studied. Authors indicated that GpG ODN treatment 
promoted Th2 type T and B cell responses and delayed the onset of proteinuria in 
NZB/W mice [142]. 
 
Another type of G-rich suppressive sequences called class R inhibitory 
oligonucleotides (INH-ODNs) were developed by Lenert and colleagues. They 
indicated that INH-ODNs have high potency in suppressing autoreactive B cell and 
DC responses in vitro and are effective in reducing autoantibody production in lupus 
prone MRL-Faslpr/lpr mice in vivo [143] 
 
Immunoregulatory sequences (IRS) developed by Dynavax Technologies Company 
should be also considered as other types of immunosuppressive sequences. 
Publications of Barrat and colleagues indicated that some of these IRS can 
selectively block TLR7 and TLR9 activation therefore play beneficial roles in the 
treatment of animal models of SLE and skin inflammation[145-149]. 
 
In addition to the G-rich sequences displaying immunosuppressive properties 
mentioned above, microsatellite DNA mimicking ODNs (MS ODNs and Sat05f) 
have been shown to have similar effects on the immune system while their sequences 
lack G residues. Wang and colleagues reported that MS ODNs and Sat05f can inhibit 
TLR7 and TLR9 mediated innate immune responses, protect mice from D-
GalN/CpG ODN induced lethal shock, alleviate symptoms associated with influenza 
virus induced acute lung injury, and reduce anti-ssDNA antibody level in the lupus-
prone mice induced by chronic graft versus host disease (cGVHD) [151-153]. 
 
Studies indicated that Suppressive ODN (A151) did not interfere with binding or 
uptake of CpG ODN [87]. Rather, they blocked either TLR9 binding or assembling 
of CpG DNA or the signaling cascade initiated by CpG DNA upstream of NF-κB 
translocation to the nucleus [79, 87]. 
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The effect of Suppressive ODN (A151) on other inflammatory events that are TLR9 
independent has been explored. Suppressive ODN were shown to bind STAT1 and 
STAT4, thereby inhibiting their downstream signaling cascade that is independent of 
TLR9 signaling, resulting in reduced incidence of LPS-induced endotoxic shock and 
Th2 biased adaptive immune responses [31, 121].Most recently, studies conducted 
by Klinman and colleagues  revealed new insights on the mechanism of action of 
suppressive ODNs. In their study published in Plos One journal in 2013, authors 
indicated for the first time that Suppressive ODNs promote development of  naïve 
CD4+Tcells into Th17 effector cells. It was quite interesting because reports 
published until that study were indicating that Th17cells play role in the development 
of autoimmune and autoinflammatory diseases and  reduction on the severity of these 
diseases via Suppressive ODN administration were thought to be the result of 
inhibitory effects on Th17 cells. Contrary to expectations, their results indicated that 
Suppressive ODN administration significantly promoted the maturation of naïve 
CD4T cells into Th17 cells via inhibiting the expression of suppressor of cytokine 
signaling 3 (SOCS3) and promoting activation of STAT3. These observations were 
also supported with the protection of mice injected with Suppressive ODN against 
Candida albicans infection where Th17 cells play critical roles [102] 
 
In another study of the same group, it was demonstrated for the first time that 
Suppressive ODNs can inhibit AIM2 inflammasome activation. In this study, authors 
revealed that in addition to blocking TLR9 dependent inflammatory pathways, 
Suppressive ODN A151 can also abrogate activation of cytosolic nucleic acid 
sensing pathways via competing with immunostimulatory ODN to bind cytosolic 
nucleic acid sensors, AIM2 and IFI16 [135] 
 
It is quite interesting that suppressive sequences in self-DNA may play a role in 
neutralizing exacerbating inflammation or modulating both innate and adaptive 
immune responses in a TLR9 independent manner, thereby providing potential 
therapeutic uses as natural anti-inflammatory agents or Th2 inducing adjuvants. 
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1.7 Endotoxin Induced Uveitis 
 
The eye is an immune privileged organ that allows its protection from the potentially 
damaging effects of an inflammatory immune response. Several complex 
mechanisms contribute to the persistence of immune privilege in the eye [155]. The 
presence of a physical barrier between the blood circulation and the retina (the blood-
retinal barrier (BRB)), constitutes one such mechanism where the non-fenestrated 
capillaries of the retinal circulation and tight-junctions between retinal epithelial cells 
prevent entry and exit of large molecules such as proteins into or from the eye [156].  
 
Furthermore, certain soluble and cell-bound ocular immunosuppressive factors 
inhibit the activity of immune cells that may have gained entry, while other proteins 
that are released from ocular cells following a damage, elicit a deviant systemic 
immunity via limiting the generation of proinflammatory effector cells [157, 158] . 
All of these elements collectively create an environment that protects the visual axis 
from damage by inflammatory processes.  However, in spite of the presence of such 
protective mechanisms, the integrity of the BRB can be breached under certain 
circumstances such as the case with uveitis or retinopathy [156]. 
 
Uveitis is an ophthalmic disorder that causes vision loss in developed countries [126, 
127] and is characterized by acute, recurrent, or persistent ocular inflammation, the 
breakdown of the blood-ocular barrier, and infiltration of leukocytes [128]. The 
underlying causes of uveitis can vary. For example, acute anterior uveitis is often 
associated with (i) Behcet disease, (ii) Reiter syndrome, and (iii) ankylosing 
spondylitis, as well as other systemic inflammatory diseases [159]. 
 
Endotoxin-induced uveitis (EIU) is an established animal model of acute ocular 
inflammation. It is triggered by the administration of LPS, which is a component of 
the Gram-negative bacterial outer membrane [160]. A ligand for TLR4, LPS 
enhances the expression of various proinflammatory cytokines and chemokines such 
as IL6 [161, 162], TNFα [163], and MCP1 (monocyte chemoattractant protein 1) 
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[164] and the production of nitric oxide. All of these mediators contribute to the 
breakdown of the blood-ocular barrier and infiltration of leukocytes, resulting in the 
development of EIU [160]. 
 
It has been shown that suppressing proinflammatory cytokines, including IL6, TNFα, 
MCP1, and inducible nitric-oxide synthase (iNOS), retards if not prevents the 
development of EIU [165]. Conventional drugs used to control these concerted 
inflammatory activation are mainly immunosuppressive in character and are 
associated with undesirable systemic side effects [128]. It is of the utmost importance 
to develop effective, less toxic agents that selec tively block proinflammatory 
immune activation while eliminating the unwanted systemic side effects. 
 
1.8 Cyclosporin A 
 
Cyclosporin A is a fungal antimetabolite that has been widely used for solid organ 
transplantation. Although full mechanism of action is currently unknown, it has been 
shown that CsA can reversibly inhibit T-cell mediated autoimmune responses [166, 
167]. It is speculated that CsA binds and inhibits calcineurin and prevents the nuclear 
translocation of nuclear factor of activated T-cells (NFAT). This inhibition blocks 
the signaling cascade starting from T cell receptor to genes encoding multiple 
cytokines and chemokines such as IL2 which are necessary for the activation of 
resting T-cells [168]. 
 
Clinical use of CsA in ophthalmology has been studied by many groups. Palestine et 
al., were the first group demonstrated that use of CsA in patients with intractable 
uveitis in Behcet disease, Vogt-Koyanagi-Harada syndrome (VKH), sarcoidosis, and 
sympathetic ophthalmia has beneficial effects [169]. Furthermore, the same group 
also indicated that CsA monotheraphy was able to decrease inflammation in 15 out 
of 16 patients showing resistance to steroid theraphy [170]. In another study efficacy 
of colchicine and CsA treatment in Behcet disease has been compared and 
superiority of CsA treatment was reported [171]. Along with those studies data 
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demonstrated that CsA reduced the production of the proinflammatory cytokines 
IL1β, TNFα, IL6 and IL8 from U937 human monocyte-like cells in vitro [172]. 
Recently, Chi et al., reported that CsA suppressed IL17 production  from Behcet`s 
patients` PBMC [173]. Moreover, several other studies report that systemic 
cyclosporine treatment can reduce the severity of uveitis and can downregulate the 
expression of proinflammatory cytokines such as IL12, IL18 and TNFα [174-176].  
 
Topical use of CsA has been shown to be effective in many disease conditions such 
as vernal conjunctivitis, ligneous conjunctivitis, Sjogren syndrome, and atopic 
keratoconjunctivitis[177]. Of interest, a recent study showed that topical treatment 
with 1% cyclosporine A reduced the severity of subepithelial corneal infiltrates 
[178].  
 
1.9 Foot and Mouth Disease 
 
Foot and Mouth Disease (FMD) is one of the major contagious and devastating viral 
disease of the cloven hoofed animals [179]. FMD outbreaks all around the world 
caused serious economic losses during the last century. The last FMD outbreak in 
United Kingdom (UK) in 2001 resulted with the loss of 11.7-18.4 billion US dollars 
due to slaughter of nearly 7 million animals. Although USA has been FMD-free 
since 1929, it is predicted that, if there were an FMD epidemic in USA (similar to the 
2001 UK FMD outbreak) the cost would be around 7-21 billion US dollars due to 
reduced farm incomes [180]. In the past decade FMD arouse global concerns by not 
only reducing animals and their products commercial value but also its potential use 
as a bio-terrorist threat in the context of several new outbreaks in previously FMD-
free countries [181]. 
 
The causative agent of the disease FMD virus (FMDV) belongs to the Picornaviridae 
family and is a member of the genus Aphthovirus. Infection with FMDV occurs 
commonly with the respiratory tract following contact or inhalation of airborne virus 
[182]. The disease is characterized by fever, lameness and vesicular lesions on the 
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feet, tongue, snout and teats, with high morbidity but low mortality [183]. To date 
seven serotypes (A, O, C, Asia1, Southern African Territories [SAT] 1, SAT2 and 
SAT3) of the virus have been identified which differ in distribution across the world. 
The widest distributed one of them is serotype O including Middle East, Asia and 
Southern America [184]. 
 
Vaccines against FMD have been available since the early 1900s. The current 
vaccines against FMD are produced by infecting BHK-21 cells with growing live 
velogenic foot and mouth disease virus (FMDV) under bio-secure conditions and 
inactivating it by using a chemical such as binary ethyleneimine. Inactivated FMD 
vaccines have proven to be an important component of control and eradication of the 
disease so far. However due to difficulties to grow certain serotypes and subtypes in 
cell culture to get sufficient amount of Ag for vaccine production and the lack of 
longevity and rapidity features of currently used vaccines, more rapid and potent 
vaccination strategies are urgently needed [179, 185-188]. 
 
1.10 Immunostimulatory Effects of CpG ODNs in Chicken 
 
CpG ODN stimulates innate immune responses of human and a variety of species 
including mice, sheep, cats, dogs, fish, horses and chicken [189]. These responses 
can vary from species to species. It has been shown that mice can respond differently 
and generally stronger than human to CpG ODN [190]. This phenomenon can be 
associated with the differences in TLR9 expression in different cell types between 
these two species. In human TLR9 is expressed only in pDCs and B cells however in 
mice TLR9 is expressed in all DC subsets (conventional and plasmacytoid), 
macrophages and B cells [191, 192]. Although cellular TLR9 expression is one of the 
criteria in responding to CpG ODN, sequences of CpG ODN also differs the level of 
immune responses in different animal species [16, 193]. 
 
Following in vivo administration immune effects of CpG ODN has been studied in 
different species. For example it has been shown that CpG ODN administration leads 
 39 
to the protection against many pathogens including viruses, bacteria and protozoa in 
mice [194-196]. When used with an antigen CpG ODNs can be used as an effective 
adjuvant in many species including human, mice, cattle, turkey and horses [197-200] 
 
CpG ODN can protect chicken against different bacterial infections such as S. 
typhimurium, S. enteritidis and E. coli. [201-204]. Surprisingly, chicken do not 
express TLR9 which leaded to the questions to identify the receptor that recognizes 
CpG ODN and mediates immune responses against CpG ODN in chicken[192]. In 
2009, Brownlie et al., showed that TLR21 is the functional homologue of 
mammalian TLR9 that is responsible for CpG recognition [205]. 
 
High mortality rates of newborn broiler chickens cause serious economic losses for 
the industry in Turkey and abroad. Administration of antibiotics in ovo or drinking 
water in the first week of age in order to protect chicken from bacterial infections is 
becoming unacceptable. Therefore, developing prophylactic agents that can decrease 
newborn mortality rates of broiler chicken is extremely important [192, 202]. 
 
1.11 Aim and Strategy 
 
This thesis is designed to broaden the spectrum of ODNs with known 
immunosuppressive and immunostimulatory properties.  
 
The first part of the thesis is devoted to demonstrate the beneficial role of 
suppressive ODN A151 on endotoxin induced uveitis. For this, we have selected to 
work with two different animal models. Upon parenteral or local LPS administration, 
EIU was established either in rabbit or in murine models respectively, as a local 
autoimmune disease. To date, the inhibitory effect of suppressive ODN on LPS 
mediated EIU at both the local and systemic levels has not been studied by others. In 
this study, a very aggressive form of experimental uveitis was initiated via endotoxin 
administration. We investigated whether the suppressive ODN “A151” can inhibit 
the induction and development of ocular inflammation (before or at the time of LPS 
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insult or even 2 h after LPS treatment) and help to reduce the symptoms of EIU in 
rabbits and mice. Our results revealed, for the first time, that A151 is capable of 
downregulating the mRNA expression and protein levels of several potentially 
pathologic chemokines and cytokines at both the local and systemic levels. 
Consequently, suppressive ODN mimicking telomeric DNA offers a novel nucleic 
acid-based immunotherapeutic agent to control overexuberant undesirable immune 
responses such as seen in autoimmune and autoinflammatory diseases. 
 
In the second part of this thesis the immunosuppressive potential of ocularly 
administered Restasis (an ophthalmic emulsion consisting of 0.05% cyclosporine A) 
was tested in rabbits and mice following local or intraperitoneal LPS injection, 
respectively, to induce EIU. To our knowledge, the present study demonstrates for 
the first time that Restasis suppresses the expression and protein levels of several 
Th1- biased proinflammatory cytokines and chemokines that were upregulated as a 
result of EIU. 
 
In the third part of this thesis adjuvant effect of CpG ODNs were tested either by 
formulating them in a lipidic nanoemulsion together with Serotype -O Ag containing 
Monovalent vaccine or with their Ag alone mixture. Data suggested that, in mice, 
inclusion of CpG ODN as an adjuvant, significantly improved FMD vaccine 
formulation that conferred rapid, long lasting humoral and cell mediated immunity as 
well as persisting virus neutralization titers. These new vaccine candidates may 
prove to be more protective against FMD epidemics in the field trials. 
 
Finally, in an auxiliary project the effects of immunostimulatory CpG ODNs as 
prophylactic agents for newborn chickens were tested in vivo. Several studies in the 
literature were strongly indicating the potential of these sequences as prophylactic 
agents for different species. High mortality rates of newborn broiler chickens cause 
serious economic losses for the industry in Turkey and abroad. Therefore we aimed 
to exhibit the prophylactic effects of these sequences in chickens. 3 doses of two 
different CpG ODNs were injected to 1 day old broiler chickens and percent of 
mortality, (Feed Conversion Ratio) FCR ratios, live body weights and (European 
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Efficiency of Productivity Factor) EPEF values of animals were investigated Our 
results suggested that CpG ODN pretreatment not only significantly reduced 
mortality rates and FCR ratios but also increased live body weights and EPEF values 
for a duration of 41 days.  
 42 
 
Chapter 2 
2. Materials and Methods 
2.1. Materials and Methods Used in EIU Experiments 
 
2.1.1. The Maintenance of the Animals 
 
Adult female BALB/C mice and New Zealand rabbits were used for the experiments. 
The animals were kept in the animal holding facility of the Department of Molecular 
Biology and Genetics at Bilkent University under controlled conditions at 22o C with 
12 hour light and 12 hour dark cycles. They were provided with unlimited access of 
food and water. Our experimental procedures have been approved by the animal 
ethical committee of Bilkent University (Bil-AEC No: 06/027). 
 
2.1.2. Induction of Endotoxin Induced Uveitis  
 
Specific pathogen-free ten weeks old female BALB/c mice were obtained from the 
animal holding facility of the Department of Molecular Biology and Genetics at 
Bilkent University. In A151 experiments mice grouped as 1) Untreated, 2) LPS Only, 
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3) A151 Only, 4) Cont. ODN Only, 5) LPS+Cont.ODN, 6) LPS+A151, 7) Cont. 
ODN then LPS, 8) A151 then LPS, 9) LPS then Cont. ODN, 10) LPS then A151. (5 
mice/group) In Table 2.1 injection and treatment protocols for these experiments are 
presented. The mice were injected i.p with 25, 50, 100 or 200 µg LPS in 200µl of 
PBS and/or 100-250 µg suppressive ODN (2h before and at the time of LPS injection 
and 2h after LPS treatment. In Restasis experiments mice grouped as ; 1: Untreated, 
2: LPS only, 3: Restasis only, 4: Restasis then LPS, and 5: LPS then Restasis (4 
mice/group). In order to induce EIU some groups were injected i.p with 20 or 50 μg 
LPS in 200 μl of PBS. Restasis was topically administered ocularly either before or 
after the establishment of EIU with 1 h intervals for 6 times (1.0 μg CsA 
emulsion/administration). Mice were killed 24 hrs following the LPS injection. In 
Table 2.2, injection and treatment protocols for mouse studies are presented. Clinical 
assessment of EIU explained in detail in Clinical Evaluation and Histopathological 
Investigation Section. Mice were sacrificed at the end of clinical evaluation. Both 
eyes were enucleated and used for cytokine expression assays. Spleens were 
removed and split into two, and splenocytes were incubated on tissue culture plates 
for 6, 12 and 24 h and supernatants were collected for cytokine determination by 
ELISA.  IL6 was measured as an indicator of EIU response. The other half of the 
spleen was used to extract total RNA for further cytokine/chemokine gene transcript 
expression analysis by RT-PCR. In rabbit experiments for A151 treatment (3-4 
animal/groups, 1500 g each housed in Ankara Hospital animal facility, Cebeci, 
Ankara) animals were separated into six different treatment groups (1-Untreated, 2-
LPS Only, 3-LPS+A151, 4-A151 then LPS, 5-LPS then Cont. ODN, 6-LPS then 
A151) and EIU was initiated via intraocular LPS injection (100 µg) with or without 
suppressive ODN treatment. In Table 2.3 injection and treatment protocols for rabbit 
A151 studies are presented. In rabbit experiments for Restasis treatment (3-4 
animal/groups, 1500 g each housed in Ankara Hospital animal facility, Cebeci, 
Ankara) animals were separated into three different treatment groups (1-Untreated, 
2-LPS Only, 3-LPS then Restasis) and EIU was initiated via intraocular LPS 
injection (100 µg) with or without Restasis treatment. In Table 2.4 injection and 
treatment protocols for rabbit Restasis studies are presented. Rabbit eyes were 
removed and gene expression analyses that were described for mice were conducted. 
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Table 2.1. EIU induction and A151 treatment schedule of mouse experiments  
Group 
ID 
Time (h) 
0 1 2 3 4 5 6 7 8 20 21 22 23 24 
Untreated       P       X 
LPS Only       L       X 
A151 Only       A       X 
Cont. ODN Only       C       X 
LPS+Cont. ODN       L+C       X 
LPS+A151       L+A       X 
Cont.ODN then 
LPS 
    C  L       X 
A151 then LPS     A  L       X 
LPS then 
Cont.ODN 
      L  C     X 
LPS then A151       L  A     X 
P: PBS Injection, L: LPS Injection, A: A151 Treatment, C: Cont. ODN Treatment, X: 
Sacrifice Animals 
 
Table 2.2: EIU induction and Restasis treatment schedule of mouse experiments  
Group 
ID 
Time (h) 
0 1 2 3 4 5 6 18 19 20 21 22 23 24 
Untreated P             X 
LPS Only       L       X 
Restasis Only R R R R R R        X 
Rest. then LPS R R R R R R L       X 
LPS then Rest.       L R R R R R R X 
P: PBS Injection, L: LPS Injection, R: Restasis Treatment, X: Sacrifice Animals 
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Table 2.3. EIU induction and A151 treatment schedule of rabbit experiments 
Group 
ID 
Time (h) 
0 1 2 3 4 5 6 7 8 20 21 22 23 24 
Untreated       P       X 
LPS Only       L       X 
LPS+A151       L+A       X 
A151 then LPS     A  L       X 
LPS then Cont.ODN       L  C     X 
LPS then A151       L  A     X 
P: PBS Injection, L: LPS Injection, A: A151 Treatment, C: Cont. ODN Treatment,  X: 
Sacrifice Animals 
 
Table 2.4. EIU induction and Restasis treatment schedule of rabbit experiments 
Group 
ID 
Time (h) 
0 1 2 3 4 5 6 18 19 20 21 22 23 24 
Untreated P             X 
LPS Only L             X 
LPS then 
Rest. 
L       R R R R R R X 
P: PBS Injection, L: LPS Injection, R: Restasis Treatment, X: Sacrifice Animals 
 
2.1.3. Clinical Evaluation and Histopathological Investigation 
 
Animals were subjected to blind investigation by an ophthalmologist under a 
dissection microscope 18–24 h after injection, corresponding to the time of maximal 
severity of EIU. Clinical ocular inflammation was graded on a scale from 0 to 4 for 
each animal described previously: no sign of inflammation = 0; discrete 
inflammation in iris and conjunctiva = 1; dilatation of iris and conjunctiva vessels = 
2; hyperemia in iris associated with Tyndall effect in anterior chamber = 3; in 
addition to the signs in scale 3, synechia or fibrin is formed = 4 ([206]). For 
histopathological investigations, enucleated eyes were fixed in 10% formalin for 24 
h, washed with running tap water for 1 h, and placed in 60% ethyl alcohol for an 
extra 3 h. Eyes were embedded in paraffin, which was sectioned and stained with 
hematoxylin and eosin. Sections were examined blindly by a histopathologist, using 
score systems of severity ranging from 0 to 4. Focal non-granulomatous monocytic 
infiltration in the choroid, the ciliary body and retina were scored as 0.5. Retinal 
perivascular infiltration and monocytic infiltration in the vitreous were scored as 1. 
 46 
Granuloma formation in the uvea and retina and the presence of occluded retinal 
vasculitis along with photoreceptor folds, serous detachment, and loss of 
photoreceptor were scored as 2. In addition, the formation of Dalen-Fuchs nodules 
(granuloma at the level of the retinal pigmented epithelium) and the development of 
subretinal neovascularization were scored as 3 and 4 according to the number and 
size of the lesions ([207]). 
 
2.1.4. Spleen and Ocular Cell Preperation 
 
Spleens and eyes were removed from the BALB/C female mice after cervical 
dislocation. Single cell suspensions were obtained by smashing of spleens and eyes 
with the back of the sterile syringes by circular movements in the 2% FBS 
supplemented regular RPMI. The cells were washed 2-3 times at 1500 rpm for 10 
mins. The cell pellet was gently dislodged with fresh media, the tissue debris was 
removed and finally the cell suspensions were counted and adjusted to 2-4x106/ml 
unless otherwise stated. 
 
2.1.5. Cell Number Detection with Cell Count 
 
After the spleen cells were smashed, washed and precipitated, they were suspended 
in 10 ml of 5% Regular RPMI-1640 media. Cells were diluted 10 fold and 
micropipetted into a hemocytometer. 
 
The number of cells in the chamber was determined by counting under the light 
microscope from these gridlines as indicated with red areas: 
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The cell number was calculated according to the following formula: 
    __Cell number__       106    = Total cell number in 10 ml media 
    4 
 
2.1.6. Cytokine and IgM ELISAs and NO Assays 
 
Immulon 2 HB microtiter plates (Thermo Scientific) were coated with anti-cytokine 
or anti-IgM antibodies (BD Pharmingen) and then blocked with PBS and 1% BSA 
([79],[107]). Serially diluted standards and culture supernatants or mouse sera were 
added to these plates for 2 h. Cytokine was detected using biotinylated anti-cytokine 
antibody followed by phosphatase-streptavidin (Perbio), whereas bound IgM was 
detected using phosphatase-conjugated anti-IgM antibodies (Southern Biotechnology 
Associates, Birmingham, AL) as described ([79]). Nitric oxide detection by the 
Griess method was conducted on murine peritoneal exudate cells (106/ml) after 12–
36 h of ex vivo incubation as described by the supplier (Promega). 
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2.1.7. Analysis of Cell-surface Molecule Expression by FACS 
 
2 × 106spleen cells/ml were isolated from 24-h post-treated mice. Cells were washed, 
fixed, and co-stained with one of the phycoerythrin-labeled anti-CD40, anti-CD86, 
and anti-ICAM-1 and FITC-labeled cell-specific antibodies (i.e.CD11c for dendritic 
cells, CD11b for macrophages, and B220 for B cells (BD Pharmingen) for 30 min at 
room temperature. Following washing, they were studied using a FACSCalibur (BD 
Biosciences) and analyzed with CellQuest Pro software. 
 
2.1.8. Determination of the Gene Expression 
 
2.1.8.1. Total RNA Isolation from the Cells 
 
Cells extensively mixed and homogenated by a mono-phasic solution of phenol and 
guanidinium thiocyanate: TRItidy G. 200 µl of chloroform for every 1ml of TRItidy 
G was used and tubes were vigorously shaken for 15 seconds and incubated at room 
temperature for 2-3 mins followed by a centrifugation for 15 mins at 13.900 rpm at 
4°C. The aqueous phase was transferred to a fresh tube. Total RNA was precipitated 
by adding 500 µl of 2-propanol for every 1ml of TRItidy G, incubated at room 
temperature for 10 min. and centrifuged for 10 min. at 13.900 rpm. Next the 
supernatant was removed and the pellet was washed with 1 ml, 75% EtOH for every 
1 ml of TRItidy G used. Tubes were vortexed and centrifuged at 8000 rpm for 7 mins 
in order to remove 2-propanol from the pellet. Supernatant was discharged and pellet 
was washed with 99.9% EtOH, vortexed and centrifuged as previously discussed. 
After centrifugation, the alcohol was removed and pellet was air-dried under laminar 
flow hood, and dissolved with 20-30 µl RNase/DNase free ddH2O. The OD 
measurements were taken at 260/280 nm wavelengths using a spectrophotometer 
(NanoDrop® ND-1000). The expected value of the A260/A280 ratio in order to 
determine if there is a phenol, protein or DNA contamination in the RNA samples is 
between 1.8-2.0 OD. The isolated RNA was stored at -80°C. 
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2.1.8.2. cDNA Synthesis 
 
The cDNAs were synthesized from the total RNA samples with the cDNA synthesis 
kit according to the manufacturers’ protocol. 2µg RNA was mixed with 1µl of 
Oligo(dT) primer and completed to a total volume of 12 µl with RNase/DNase free 
ddH2O (Hyclone). They were pre-denatured at 65°C for 5 min. then chilled on ice for 
3-5 min. 15µl RT Buffer (includes dNTP mix and 10 mM MgCl2) and 3µl M-MuLV 
RNase H+ reverse transcriptase (includes RNase inhibitor) were added to the mixture 
and incubated at 25°C for 10 min., 40°C for 45 min., 85°C for 5 min. and on ice 
(+4°C) for 10 min. respectively. cDNA’s were runned on %2 Agarose gel for 45-50 
min, at 80V and visualized under transilluminator (Gel-Doc BIO-RAD, USA and 
Vilber Lourmat, France) for 1 sec exposure time. The cDNA’s were stored at -20°C. 
 
2.1.8.3 Primers 
 
Primers such as; il-18, cxcl-16, mip 3-α were designed using Primer3 Input 0.4.0 
program (http://frodo.wi.mit.edu/primer3/input.htm) and Primer Designer 3.0 
program with the cDNA sequences of the mouse homologues of these genes which 
are available at the Ensembl database. Each primer pair was blasted 
(http://www.ncbi.nlm.nih.gov/BLAST/) against mouse genome. Other primer 
sequences were obtained from different articles and sources (Table 2.5). 
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Table 2.5. Oligonucleotide PCR primers used in mouse  and rabbit experiments 
Primer  Sequence Product Size  
m β-actin** 
Forward 
Reverse 
5’-GTATGCCTCGGTCGTACCA-3’ 
5-‘CTTCTGCATCCTGTCAGCAA-3’ 
450bp 
m GAPDH* 
Forward 
Reverse 
5’-TCCTGCACCACCAACTGCTTAGCC-3’ 
5’-GTTCAGCTCTGGGATGACCTTGCC-3’ 
510bp 
m TLR2* 
Forward 
Reverse 
5’-TCTCTGGGCAGTCTTGAACATTTG-3’ 
5’-CGCGCATCGACTTTAGACTTTG-3’ 
320bp 
m TLR4* 
Forward 
Reverse 
5’-TGCCGTTTCTTGTTCTTCCTCT-3’ 
5’-CTGGCATCATCTTCATTGTCCTT-3’ 
240bp 
m TLR5* 
Forward 
Reverse 
5’-TGGGGCAGCAGGAAGACG-3’ 
5’-AGCGGCTGTGCGGATAAA-3’ 
380bp 
m TLR6* 
Forward 
Reverse 
5’-GCCCGCAGCTTGTGGTATC-3’ 
5’-GGGCTGGCCTGACTCTTA-3’ 
650bp 
m TLR7* 
Forward 
Reverse 
5’-TTAACCCACCAGACAAACCACAC-3’ 
5’-TAACAGCCACTATTTTCAAGCAGA-3’ 
700bp 
m TLR9* 
Forward 
Reverse 
5’-GATGCCCACCGCTCCCGCTATGT-3’ 
5’-TGGGGTGGAGGGGCAGAGAATGAA-3’ 
430bp 
m IP10** 
Forward 
Reverse 
5’-GCCGTCATTTTCTGCCTCAT-3’ 
5’-GCTTCCCTATGGCCCTCATT-3’ 
127bp 
m iNOS** 
Forward 
Reverse 
5’-CAGCTGGGCTGTACAAACCTT-3’ 
5’-CATTGGAAGTGAAGCGTTTCG-3’ 
95bp 
mMIP1α* 
Forward 
Reverse 
5’-ACCATGACACTCTGCAACCA-3’ 
5’-AGGCATTCAGTTCCAGGTCA-3’ 
238bp 
mIL5** 
Forward 
Reverse 
5’-AGCACAGTGGTGAAAGAGACCTT-3’ 
5’-TCCAATGCATAGCTGGTGATTT-3’ 
117bp 
mIL15** 
Forward 
Reverse 
5’-CATCCATCTCGTGCTACTTGTGTT-3’ 
5’-CATCTATCCAGTTGGCCTCTGT-3’ 
126bp 
mIL18* 
Forward 
Reverse 
5’-GATCAAAGTGCCAGTGAACC-3’ 
5’-ACAAACCCTCCCCACCTAAC-3’ 
384bp 
mMCP1* 
Forward 
Reverse 
5’-AGGTCCCTGTCATGCTTCTG-3’ 
5’-TCTGGACCCATTCCTTCTTG-3’ 
249bp 
mMIP3α* 
Forward 
Reverse 
5’-CGTCTGCTCTTCCTTGCTTT-3’ 
5’-CCTTTTCACCCAGTTCTGCT-3’ 
250bp 
mCXCL16* 
Forward 
Reverse 
5’-CCTTGTCTCTTGCGTTCTTC-3’ 
5’-GGTTGGGTGTGCTCTTTGTT-3’ 
384bp 
mMIP1β* 
Forward 
Reverse 
5’-CCAGCTCTGTGCAAACCTAA-3’ 
5’-CTGTCTGCCTCTTTTGGTCA-3’ 
250bp 
Rb GAPDHω 
Forward 
Reverse 
5’-TCACCATCTTCCAGGAGCGA-3’ 
5’-CACAATGCCGAAGTGGTCGT-3’ 
319bp 
Rb IL6ω 
Forward 
Reverse 
5’-GCTCCTGGTGGTGGCTAC-3’ 
5’-GGGTGGCTTCTTCATTCAAA-3’ 
450bp 
Rb IL1βω 
Forward 
Reverse 
5’-GCCGATGGTCCAATTACAT-3’ 
5’-ACAAGACCTGCCGGAAGCT-3’ 
121bp 
m: mouse, rb: rabbit,   * in house designed primers, **taken from Ref. [208], ωtaken from Ref 
[209] 
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2.1.8.4. Semi-Quantitative RT-PCR 
 
For the comparison of the mRNA expression levels of the samples, semiquantitative 
reverse-transcriptase PCR (MJ Mini, BIO-RAD, USA) was performed. 
Quantification of the band intensities was performed using MultiAnalyst and Bio1D 
softwares. The quantitated values for the samples were normalized by the division 
with the quantitated values for the β- actin for each sample separately. 
 
2.1.8.5. Agarose Gel Electrophoresis 
 
2% agarose gel was prepared with 1X TAE Buffer and 1 mg/ml ethidium bromide 
solution. Samples were prepared by mixing of 5μl Agarose Gel Loading Dye to 10μl 
of cDNA sample and loaded to the agarose gel. The gel was run at 80V for 60 
minutes and visualized under transilluminator (Gel-Doc BIO-RAD, USA and Vilber 
Lourmat, France) softwares were used to take photographs of the gels and compare 
the cDNA band intensities for the analysis. The, Low Range DNA Ladder (Jena 
Biosciences) and 100 bp DNA ladder (Jena Biosciences) were used as a marker and 
3µl was loaded to every gel. 
 
2.1.6. Statistical Analysis 
 
Assays were performed in triplicate on at least three to five different cell 
preparations. Statistical significance between untreated (or control) and treated 
groups was evaluated using Student's t-test. 
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2.2. Materials and Methods Used in Foot and Mouth Disease 
Experiments 
 
2.2.1. Mice 
 
Adult female BALB/c mice were used for the experiments. The animals were kept in 
the animal holding facilities of the Department of Molecular Biology and Genetics at 
Bilkent University under controlled conditions at 22°C with 12 h light and 12 h dark 
cycles. They were provided with unlimited access to food and water. Animal 
procedures were approved by the animal ethical committee of Bilkent University. 
 
2.2.2. CpG Oligodeoxynucleotiedes 
 
The ODNs were either synthesized by (Alpha DNA, Canada) or synthesized in house 
on a Mermade 6 automated ODN synthesizer (BioAutomation, USA). Sequences and 
properties of the sequences were provided in Table 2.6. All ODNs were tested for 
endotoxin by LAL assay, or TLR4-stably transfected HEK293 cell based promoter 
assay and was found to contain no detectable LPS. 
 53 
Table 2.6. List of CpG ODNs used in FMD study 
ODN Name Sequence Length Size Backbone 
1466_Acore_PO TCAACGTTGATTCAAA 16 4864 PO 
1466_Acore_PS tcaacgttgattcaaa 16 4864 PS 
1466_Acore_MB tcAACGTTGATTCAaa 16 4864 MB 
1555_PO GCTAGACGTTAGCGT 15 4608 PO 
1555_PS gctagacgttagcgt 15 4608 PS 
1555_MB gcTAGACGTTAGCgt 15 4608 MB 
D35_3CG_PO GGTCGATCGATCGAGGGGGG 20 6279 PO 
D35_3CG_PS ggtcgatcgatcgagggggg 20 6279 PS 
D35_3CG_MB ggTCGATCGATCGAGGGGgg 20 6279 MB 
1466_pG6_PO TCAACGTTGAGGGGGG 16 5002 PO 
1466_pG6_PS tcaacgttgagggggg 16 5002 PS 
1466_pG6_MB tcAACGTTGAGGGGgg 16 5002 MB 
ODN5547_PO TCGACGTTCGACGTTGGG 18 5547 PO 
ODN5547_PS tcgacgttcgacgttggg 18 6782 PS 
ODN5547_MB TcGACGTTCGACGTTGGg 18 5547 MB 
ODN7440_PO GTCGATCGATTTTCGATCGAGGGG 24 7440 PO 
ODN7440_PS gtcgatcgattttcgatcgagggg 24 7440 PS 
ODN7440_MB gtCGATCGATTTTCGATCGAGGgg 24 7440 MB 
1466_PS tcaacgttga 10 3027 PS 
K3_PS atcgactctcgagcgttctc 20 6044 PS 
K23_PS tcgagcgttctc 12 3612 PS 
1826_PS tccatgacgttcctgacgtt 20 6059 PS 
2006_PS tcgtcgttttgtcgttttgtcgtt 24 7329 PS 
2007_PS tcgtcgttgtcgttttgtcgtt 22 6720 PS 
Upper case: phosphodiester (PO), Lower case: phosphorothioate (PS), Mixed Backbone 
(MB) 
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2.2.3 Preparation of vaccines 
 
FMDV strain O/TUR/07 was grown in BHK-21(Baby Hamster Kidney) suspension 
cultures. The virus was harvested after propagation and clarified by centrifugation at 
3000 x g for 30 minutes. After inactivation with binary ethyleneimine (BEI), 10% 
(w/v) polyethyleneglycol 6000 was added to the supernatant and the mixture was 
stirred overnight at 4°C. The antigens were precipitated by centrifugation at 600g and 
resuspended in 1/10 volume of PBS. Aliquots were frozen at liquid nitrogen and 
stored until use. 146S antigen amount was measured by Sucrose Density Gradient 
method. In order to get the required final concentration, the concentrated antigen was 
diluted in PBS (pH 7.6) to yield 22ug Ag/ml.  
 
Monovalent vaccine containing FMDV O/TUR/07 inactivated antigen in double oil 
emulsion with montanide ISA 206 (Seppic, France) were prepared. Equal ratios of 
antigen and oil volumes were used and antigen and oil slowly blended to ensure 
water-in-oil-in-water emulsion. 
 
2.2.4. Immunization  
 
4-6 weeks old female BALB/c mice (8/group) were injected twice (ip, at day=0 and 
15) either monovalent vaccine (labeled as "Mono") or free FMDV serotype-O 
antigen (labeled as "Ag") or their combinations with CpG ODN mixture 
(10µg/animal). Optimum Dose antigen (ODAg) indicates a 3µg serotype O antigen 
per mouse, Low Dose antigen (LDAg) indicates 0.5µg serotype O antigen per 
mouse. Either serotype-O antigen(Ag) or monovalent vaccine containing 
formulations then mixed with the CpG ODN to yield 3µg or 0.5ug Ag or Monovalent 
Vaccine + 10µg CpG ODN /300µl injections. 
Treatment Groups and formulation ingredients used throughout immunization study 
was given in Table 2.7. 
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Table 2.7. Injection groups and formulation ingredients used throughout immunization 
studies 
Treatment Groups Formulation Ingredients 
Untreated PBS  
OD Ag 3µg Ser-O Ag 
LD Ag 0.5µg Ser-O Ag 
OD Ag+CpG 3µg Ser-O Ag+10µg CpG ODN 
LD Ag+ CpG ODN 0.5µg Ser-O Ag+10µg CpG ODN 
OD Mono 3µg Monovalent Vaccine 
LD Mono 0.5µg Monovalent Vaccine 
OD Mono+CpG 3µg Monovalent Vaccine+10µg CpG ODN 
LD Mono+CpG 0.5µg Monovalent Vaccine+10µg CpG ODN 
 
Mouse was bled via tail vein and sera were collected with 2-4 weeks intervals for a 
duration of 5 months from the time of post-booster injection. Detailed information 
about injection/bleeding schedule is given in Figure 2.1. Sera were prepared by 
centrifugation at 8000 rpm for 5 min followed by incubation of blood at 37ºC for one 
hour and were stored at −20ºC until for further use. 
 
Figure 2.1. Injection and bleeding schedule of mice used in immunization studies. 
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2.2.5. Ig ELISA 
 
Serum Total IgG, IgG1 and IgG2a antibody in mice was determined by ELISA. 
Briefly, wells (96 wells, Immulon 1B, Thermo Scientific, USA) were coated with 
appropriately diluted of  Rb-α mouse SerO Ab in PBS (pH 7.2) and incubated 
overnight at 4ºC and blocked by using 200µl of PBS- BSA (5%) for 3h at RT. After 
5X wash with PBST, 1/20 diluted supernatants of the cell lysates of FMDV-infected 
BHK added to the plates in PBS and incubated overnight at 4ºC. After 5X wash with 
PBST, 80X diluted mouse sera added to the first wells and subjected to 2X serial 
dilutions with PBS and incubated overnight at 4ºC. After 5X wash with PBST, 
appropriately diluted alkaline phosphatase conjugated goat anti- mouse IgG-AP, 
IgG1-AP and IgG2a-AP (Southern Biotech) were added to the plates and incubated at 
RT for 2h. After removal of unbound conjugated antibody, positive binding was 
detected by adding PNPP substrate (Perbio, Pierce, USA) and the absorbance was 
read at 405nm.  
 
2.2.6. IFNγ ELISA 
 
Serum IFNγ levels in mice was determined by ELISA. Briefly microtiter plates 
(Immulon 2 HB, Thermo Scientific, USA) were coated with mouse anti-IFNγ 
antibodies (MABTECH, Sweden) in PBS (pH 7.2) and incubated overnight at 4ºC 
and then blocked using 200µl of PBS- BSA (5%) at RT for 3 h [79, 81] After 5X 
wash with PBST, serially diluted standards and mouse sera were added to these 
plates and incubated overnight at 4ºC. After 5X wash with PBST, appropriately 
diluted biotinylated mouse anti IFNγ Ab (MABTECH, Sweden) were added to the 
plates and incubated at RT for 2 h. After removal of unbound conjugated antibody, 
positive binding was detected by adding substrate PNPP and the absorbance was read 
at 405 nm. 
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2.2.7. Virus Neutralization Assay  
 
Neutralizing antibody titers to FMDV from mice sera were measured by micro-
neutralization assay described by OIE Terrestial Manual for Foot and Mouth Disease 
(2009). Briefly, all sera samples and positive and negative controls were heat 
inactivated (56°C, 30 min) and used for microneutralization assay on BHK-21 cells. 
Serial two fold dilutions of serum were made in 5% FCS supplemented Glasgow 
MEM and incubated with a virus doses of 100 TCID50 of FMDV O/TUR/07 for 1h 
at 37°C. The BHK-21 cells (6x105 cells/ml) were added to the wells and incubated 
further for 48–72 h at 37°C. The cells were monitored every day for 
Cytopathological Effects (CPE) under cell culture microscope. Wells then were 
stained with crystal violet-formalin.  End-point titers were calculated as the 
reciprocal of the last serum dilution to neutralize 100 TCID50 of homolog virus CPE 
in 50% of the wells. 
 
2.2.8. Statistical Analysis 
 
Statistical significance between CpG formulations vs non-CpG formulations were 
evaluated using Student`s T- test. p<0.05 was considered as significant over control 
group. 
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2.3. Materials and Methods Used in Chicken Experiments 
 
2.3.1 Chicken Housing 
 
Chickens were kept in 60 separate sections (200 chickens/section) randomly 
distributed within Research and Development coop facility of the Beypilic. They 
were provided with unlimited access of food and water. Survival rates, live body 
weights, water and food consumption rates were routinely monitored by a 
computerized system within the integrated facility. 
 
2.3.2 Immunization 
 
All procedures involving chicken were done with one day old animals provided by 
Beypilic hatchery in Bolu, Turkey.  
Groups of chickens (1000/group) were subcutaneously injected once either with 3 
different doses (0.8μg, 4μg, 20μg) of 1466 Acore PO or D35 3CG MB CpG ODNs in 
200 µl Hanks Buffer or Hanks Buffer alone (6000 chicken) as control.  
 
2.3.3 FCR and EPEF Calculation 
 
FCR (Feed conversion ratio) and EPEF (European Poultry Efficiency Factor) were 
calculated with following formulations. 
 
FCR= Total Feed (kg)/Total Weight (kg) 
EPEF= [(Live weight, kg X Viability %) / (FCR X Age, days)]X100 
 59 
 
Chapter 3 
3. Results 
3.1 Immunotherapeutic Use of Suppressive ODN in Endotoxin 
Induced Uveitis 
 
EIU is an established animal model of acute ocular inflammation. It is induced by 
either systemic or intravitreal administration of LPS, the major component of Gram-
negative bacteria. LPS acts through the TLR4-triggering proinflammatory signaling 
cascade. The expression of Th1 cytokines and chemokines, including IL6, IL1β, and 
MIP3α (macrophage inflammatory protein 3α), contributes to the development of 
EIU. 
 
Initial experiments were conducted to optimize the induction of EIU (Figure 3.1). 
For the mouse experiments, systemic administration of LPS doses between 20 and 
100 µg/mouse were sufficient to induce uveitic eyes within 24 h as judged by clinical 
and histopathological investigations (Figure 3.1 and Figure 3.3). For the rabbit 
experiments, intraocular 100 µg LPS injection was found to be optimal to induce 
EIU. Following local or intraperitoneal LPS and/or suppressive ODN administration, 
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rabbit and mouse eyes were removed, and RNAs from the irises, vitreous, and 
corneas of the rabbit eyes were obtained. PCR was run with the cDNA from each 
sample, and then RNA levels of IL6, IL15, IP10 (interferon-γ-inducible protein 10), 
iNOS, MIP1α, IL-18, MIP3α, CXCL16 (CXC chemokine ligand 16), MIP1β, and 
IL1β were monitored. In addition, 24 h post-LPS and/or A151 treatment, splenocyte 
suspensions were incubated ex vivo for 6 –24 h, and IgM, IL6, IL10, IL12, and IFN γ 
levels from the supernatants were determined by ELISA. FACS analyses were 
conducted on spleen cells to monitor co-stimulatory/surface marker molecule 
expressions. 
 
 
Figure 3.1. Effect of A151 treatment on clinical EIU. Following ip LPS injection animals 
were treated with A151. Before animals were sacrificed clinical EIU evaluation was 
performed on both eyes and scored as described in methods section 2.1.3. * p<0.05, ** 
p<0.01 between LPS treated and LPS+A151 ODN co-administered groups.  
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Figure 3.2. Histopathological changes showing retinal perivascular infiltration in eyes of 
mice following LPS and/or suppressive ODN treatment. A) retinal vessels of untreated eye. 
B) retinal perivascular infiltration of mononuclear cells (MNC) and neutrophils in LPS and 
Cont.ODN injected eye. C) decreased MNCs post-A151 treatment before and D) 
simultaneous with LPS challenge. E-H) represent inlets of A-D respectively (Mag:40X) 
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Figure 3.3. A151 mediated changes in histopathological scoring following EIU (for details 
see Figure 3.2). * p<0.05, ** p<0.01 between LPS vs LPS & A151 treated groups.  
 
Our results revealed that suppressive ODN administration significantly diminished 
disease severity proven by reduction on clinical (Figure 3.1) and histopathological 
(Figure 3.2 and Figure 3.3) scores of groups injected with A151 ODN. 
 
The results indicated that in rabbits, suppressive ODN administered before or after 
100 µg LPS treatment or co-injected with LPS significantly down-regulated the 
expression of IL1β message from the iris (Figure 3.4). In cornea, IL6 was 
downregulated when suppressive ODN was given before or simultaneously with LPS 
administration (Figure 3.5). There was no significant inhibitory effect when A151 
was given post-LPS treatment. In all these experiments, the mRNA message 
reduction was suppressive ODN-dependent because control ODN administration did 
not show any benefit for alleviation of LPS reactogenicity. 
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IL1β 
 
Figure 3.4 Suppressive ODN A151 administration after LPS challenge downregulated IL1β 
expressions in iris. Rabbits were injected intraocularly with 100 µg LPS and 250 µg 
suppressive ODN. Average of four animals’ densitometric measurements for IL1β mRNA 
from iris is shown. Inlets are the representative gel image of each group ** p<0.01 between 
LPS vs LPS & A151 ODN treated groups. 
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IL6 
 
Figure 3.5. Suppressive ODN A151 administration after LPS challenge downregulated IL6 
expressions in cornea. Rabbits were injected intraocularly with 100 µg LPS and 250 µg 
suppressive ODN. Average of four animals’ densitometric measurements for IL6 mRNA 
from cornea is shown. Inlets are the representative gel image of each group * p<0.05, ** 
p<0.01 between LPS vs LPS & A151 ODN treated groups. 
 
On the murine EIU model, mouse tolerated up to 100 µg LPS i.p. treatment. Doses 
over 150 µg caused animals to succumb to endotoxin treatment. The mice 
experiments were conducted with three doses of LPS; 25, 50, and 100 µg. 
Suppressive A151 ODN and Control ODN (2h before, at the time of LPS injection 
and 2 h after LPS treatment) were used in the range of 100-250 µg. While in rabbits 
the injection of ODNs and endotoxin was intraocular, in mice injections were via 
intraperitoneal route in 200 µl PBS. 
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(A) 
 
(B) 
 
Figure 3.6. A) Suppressive ODN A151 treatment after 100 µg LPS challenge significantly 
downregulates MIP3α, IP10, iNOS, MIP1β and CXCL16 mRNA expression levels on the 
eyes of mice. Mice were injected intraperitoneally with 100 µg LPS and 250 µg suppressive 
ODN and were killed at 18 h after injection. * p<0.05, ** p<0.01 between LPS treated and 
LPS+A151 ODN co-administered groups. B) Representative agarose gel picture (M1 
indicates mouse #1, M2 indicates mouse #2). 
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Results showed that when 250 µg suppressive ODN was administered before LPS 
injection (2h) it significantly downregulated the expression of MIP3α, IP10, iNOS, 
MIP1β and CXCL16 in 100 µg LPS injected mEIU model (Figure 3.6). The other 
cytokines like MIP1α and IL18 also showed substantial but insignificant down 
regulation at these doses (please see Appendix Bi). 
 
In order to understand the systemic effect of suppressive ODN A151, IL6 secreted 
from murine splenocytes after ex-vivo incubation for up to 24h in culture were 
monitored by ELISA (Figure 3.7). Our results revealed that suppressive ODN was 
able to reduce more than 65 % of the secreted IL6 (43070 vs 13555 ng/mL, for 
LPS and A151+LPS groups, respectively). When suppressive ODN were co-
administered with LPS, cytokine mRNA levels failed to rise in vivo, and in ex-vivo 
spleen cells failed to increase their cytokine production (*p<0.05, and **p<0.01 
Figure 3.6 & Figure 3.7). These effects were attributable to the activity of 
suppressive motifs, since control ODN did not reduce the cytokine production 
elicited by co-administered LPS (Figure 3.3, Figure 3.4, Figure 3.5, Figure 3.6, 
Figure 3.7). 
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Figure 3.7. Suppressive ODN A151 administration significantly suppressed IL6 release from 
murine splenocytes. Mice were injected ip with 100 µg LPS and 250 µg suppressive or 
control ODN as indicated. Spleen cells were removed (post 24h Rx) and incubated for 
further 6-24 h and supernatants were collected for cytokine ELISA.  IL6 was measured as an 
indicator of EIU response (* p<0.05, LPS treated vs LPS & A151 groups) 
 
The (TTAGGG)4 multimers inhibited LPS-dependent up-regulation of co-stimulatory 
and surface marker molecules on antigen presenting cells (CD40, CD86 and ICAM-
1), IgM production by B cells, and NO release from peritoneal macrophages (p< 
0.01, Figure 3.8). Furthermore co-administration of LPS (50 µg) with A151 ODN 
(250 µg) inhibited >65% of several immunoregulatory and inflammatory cytokines 
(i.e. IL6, IL10, and IL12, p<0.001, Figure 3.8). This reduction reached over 85% for 
IFN (17629 vs 2615 ng/mL, for LPS and A151+LPS groups, respectively). 
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Figure 3.8. Inhibitory effect of suppressive ODN on LPS mediated immune activation. 
Levels of CD40, CD86, and ICAM-1 expression (MFI) were determined by FACS after 24 
hr of in vivo LPS or LPS plus A151 (50 µg LPS and 250 µg ODN, respectively) injection.  
IL6, IL10, IL12, IFNγ and IgM levels in culture supernatants were determined by ELISA 
following 36h of ex vivo incubation.  The Griess method was used to detect nitric oxide from 
isolated PEC cell supernatants after 24 hr post Rx.* p<0.01, **p<0.001 
 
3.2 Immunosuppressive Effects of Restasis in EIU 
 
Cyclosporin A (CsA) is an effective orally-administered immune suppressor, widely 
used during organ transplantation or for the control of several systemic and ocular 
autoimmune diseases [210, 211]. A CsA formulation suitable for topical application 
is the ophthalmic emulsion under the trade name of “Restasis”, consisting of 0.05% 
cyclosporine. This drug was shown to increase the production of tear in patients 
where this process was presumed to be suppressed due to ocular inflammation 
associated with keratoconjunctivitis sicca (Product data sheet, Allergan, USA). In 
order to compare immunosuppressive effects of ODN A151 originated from 
mammalian telomeric DNA with a commercially used immunosuppressive drug 
with a non-biological origin Restasis™ was used in further experiments. Of note, 
initial optimization experiments with Restasis revealed that when EIU was 
established with 100μg LPS, there was no effect of topical Restasis administration 
(please see Appendix Bii). These studies, therefore, was conducted with 50μg or 
20μg of LPS administration. 
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Administration of Restasis (detailed in Methods Section 2.2.2) prior to or following 
LPS injection reduced the severity of disease since the clinical scores of these 
animals ranged between 1.7 and 2.2 (Figure 3.9) 
 
 
Figure 3.9. Effect of Restasis treatment on clinical EIU. Following ip LPS injection animals 
were treated with Restasis. Before animals were sacrificed clinical EIU evaluation was 
performed on both eyes and scored as described in methods section 2.1.3. * p<0.05 between 
LPS treated vs LPS & Restasis treated groups. 
 
In order to evaluate the levels of expression of inflammatory mediators in LPS 
treated animals, rabbit and mouse eyes were removed 18 h post treatment and RNA 
was isolated from iris, vitreous and cornea for the rabbits and from the whole eye for 
mice. Following PCR amplification, changes in transcript levels were monitored 
from gel pictures. 
 
EIU experiments in mice revealed that LPS treatment alone led to a significant 
upregulation of TLR2, 4,5,6,7 and 9 gene products (Figure 3.10) when compared to 
expression levels in untreated animals, suggesting the presence of an inflammatory 
response. 
 
Although Restasis alone had no effect on TLR expression in the absence of LPS 
challenge, administration of Restasis prior to or post LPS treatment inhibited the 
LPS-induced TLR gene upregulation (Figure 3.10).  
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(A) 
 
 
(B) 
 
Figure 3.10. Restasis treatment pre- or post 20 µg LPS challenge (4 mouse/group) 
significantly downregulated several TLR mRNA expression levels from mice eyes 18 h after 
LPS challange (* =p<0.05, ** =p<0.01 between LPS Only and LPS & Restasis treated 
groups). A) Representative gel image of the TLR panel (2 mouse/group). B) Densitometric 
analyses of several TLR gene transcripts. 
 
This suppression encouraged us to analyze the expression levels of other key 
proinflammatory chemokines. Similarly, administration of Restasis prior to or 
following LPS injection suppressed the LPS-induced MCP1 and IP10 production in 
mice (Figure 3.11).  
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A)MCP1 
   
(B) IP10 
 
Figure 3.11. Restasis treatment pre- or post 20 µg LPS challenge (4 mouse/group) 
significantly downregulated A) MCP1, B) IP10 expression levels of mice eyes 18 h after 
LPS injection (* =p<0.05, ** =p<0.01 between LPS Only and Restasis treated groups) 
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Of note, treatment with Restasis was more effective when administered prior to LPS 
(85% and 75% inhibition for MCP1 and IP10, respectively) in contrast to post-
treatment (70% and 65% inhibition for MCP1 and IP10, respectively). 
 
Next, in order to investigate whether locally administered Restasis induced a 
systemic effect, IL6 secretion from murine spleen cells was studied following a 24 h 
ex-vivo incubation of splenocytes (Figure 3.12). As expected, LPS injection resulted 
in secretion of high levels of IL6 from mouse splenocytes. Restasis suppressed the 
LPS-induced IL6 production by 50% when administered prior to the endotoxin. 
Surprisingly, Restasis had a strong systemic effect and inhibited the IL6 production 
in the spleen (>90%) when administered after LPS (Figure 3.12). It is possible that 
the concentration of the drug in the circulation is still high in the post-treatment 
group whereas in the pre-treated animals some of it is cleared from the circulation as 
more time has elapsed since exposure. 
 
Figure 3.12. Restasis treatment pre- or post-20 µg LPS challenge (4 mouse/group) 
significantly diminished IL6 levels from murine splenocytes 24 h after LPS challenge (* 
=p<0.05 between LPS Only and Restasis treated groups). 
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In an attempt to simulate the clinical scenario and assess the suppressive potential of 
Restasis, another set of animals were treated with higher doses of LPS (50 and 100 
μg/mouse). Similar responses were checked to assess the inhibitory effect of the 
drug. Since patients are admitted to hospital with uveitis application of Restasis 
before LPS challenge was abandoned at this stage. Induction of EIU by 100 µg LPS 
and subsequent treatment of animal eyes with 6x Restasis demonstrated no beneficial 
therapeutic value (please see Appendix Bii). However, when a 50 µg LPS dose was 
used to initiate EIU Restasis suppressed the MCP1 (Figure 3.13A, 55%) and IP10 
(Figure 3.13B; 40%) expressions in the eyes. 
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(A) MCP1 
 
 
(B) IP10 
 
Figure 3.13. Restasis treatment post 50 µg (high dose) LPS challenge (4 mouse/group) 
significantly downregulated A) MCP1, B) IP10 expression levels of mice eyes (* =p<0.05) 
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Restasis showed no inhibitory effect on LPS-induced upregulation of IL-15, 
CXCL16, MIP1α, IL18, MIP3α, and MIP1β in murine eyes (please see Appendix 
Biii). 
 
The EIU experiments in mice were limited with gene expression analyses from the 
whole eyes owing to the difficulty in sub-sectioning of the organ from this species. 
Therefore, in order to analyze whether Restasis was effective in controlling the 
inflammation occurring at separate anatomical locations in the eye, a rabbit EIU 
model was used where the uveitis was induced following intravitreal injection of 100 
µg LPS. At the end of Restasis treatment rabbit eyes were removed and iris, cornea 
and vitreous sections were recovered for further analyses. The rabbit model of EIU 
revealed that Restasis administration downregulated IL1β and IL6 expressions in 
cornea and vitreous, respectively (Figure 3.14). PCR analyses of the iris section did 
not provide any significant downregulation of these genes (please see Appendix 
Biv). 
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(A) IL1β 
 
(B) IL6 
              
  
Figure 3.14. Restasis administration after LPS treatment downregulated IL1β and IL6 
expressions of rabbit (5 rabbit/group) cornea and vitreous respectively. A) IL1β and B) IL6 
mRNA levels. Representative agarose gel images. (* =p<0.05) 
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As mentioned in the beginning of this part, along with exploring immunosuppressive 
effects of Restasis in EIU, another aim of this study was to compare 
immunosuppressive properties of ODN A151 originated from mammalian 
telomeric DNA with a commercially used immunosuppressive drug from a non-
biological origin. As summarized in Table 3.1, although Restasis showed some 
immunosuppressive properties, its effect in EIU was limited compared to A151 
ODN. 
 
Table 3.1. Comparative effects of biological and non-biological immunosuppressive 
agents to control established LPS induced EIU. 
Name of 
Immunosuppressive 
Agent 
Origin Administration 
Route 
Clinical 
Score 
Reduction 
Suppressed 
Immunemediators 
A151 ODN Biological Intraperitoneal inj. 
Intraocular inj. 
~%80 IL1β, IL6, 
MIP3α,MIP1β, IP10, 
iNOS, CXCL16, 
CD40, CD86, 
ICAM1, IL10, IL12, 
IFNγ, IgM, NO 
Restasis™ Non-biological Dropped into eye ~%47 TLR2, TLR4, TLR5, 
TLR6, TLR7, TLR9, 
MCP1, IP10, IL6, 
IL1 β 
A151 ODN Study: LPS 100μg/mouse 
Restasis Study: LPS 20 μg/mouse 
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3.3 Use of CpG ODN as a Vaccine Adjuvant Against Foot And 
Mouth Disease 
 
To determine the most potent CpG ODN sequence(s) as a potential adjuvant for the 
intended vaccine formulation, we synthesized more than 50 different CpG/Non CpG 
ODN sequences (i.e with their proper CpG flip controls) and tested them in vitro on 
spleen cells for their ability to induce pro-inflammatory and inflammatory cytokine 
secretions. Of note, three different backbone of these sequences were synthesized 
(PO/PS/MB) and tested on spleen cells Part of these CpG ODN sequences were 
either newly synthesized or they were previously reported as an effective adjuvant 
against various infections [16, 17, 87, 212-218] Table 2.6, summarizes these 
sequences and their general properties. Next, splenocytes from BALB/C mice were 
incubated with different concentrations (0.1-3.0 µM) of CpG ODNs and supernatants 
from 12-72 hours culture were collected to assess IL6, IL12p40, and IFNγ 
productions by ELISA. In Figure 3.15, data obtained only from 1µM ODN were 
presented (@ t=42h stimulation). When secretion profiles of the three cytokines were 
considered, ODN Seq 1555-PS ODN were determined to be the most potent 
inducers. Corresponding control ODNs did not result any significant cytokine 
production (please see Appendix Bv) indicating that activation of spleen cells were 
strictly CpG motif dependent. Immunization studies were conducted by using 1555-
PS ODN. 
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Figure 3.15. Immunostimulatory effects of different CpG ODNs. Balb/C splenocytes 
(4X106) were stimulated with phosphorothioate (PS), phosphodiester (PO), and mixed 
backbone (MB) modified K and D type CpG ODNs for 42hrs. IL6, IL12p40 and IFNγ 
production were assessed by ELISA. Data represents average ±SEM of three independent 
experiments carried out in triplicate repeats for each treatment groups (** =p<0.01 between 
CpG treated groups vs UnRx for all cytokines). 
 
Here, in order to document the benefit of CpG ODN involvement in the 
formulations, 2 different doses of either antigen or monovalent vaccine was selected. 
As explained in detail in Materials and Methods section 2.3.4 animals injected with 
Optimum Dose (OD-3µg/animal) or Low Dose (LD-0.5 µg/animal) with Serotype-O 
Ag/Monovalent Vaccine or their CpG ODN including counterparts. After booster 
injection, mice were bled regularly for the next 5 months and anti Serotype-O Ag 
responses were studied. Formulations containing CpG ODN induced significantly 
higher levels of anti Serotype-O total IgG (Figure 3.16) 
 80 
A) 
 
B) 
 
Figure 3.16. Anti Serotype-O total IgG responses of mice immunized twice either with A) 
Ser-O Ag or B) Monovalent Vaccine or their CpG ODN containing groups and followed for 
a period of 20 weeks. Anti serotype-O total IgG responses significantly enhanced with 
inclusion of CpG ODN within formulations. Serum total IgG levels were determined by 
ELISA. Plots are the OD readings of anti-FMDV total IgG responses at 900 titer (8 
mice/group) 
 
In order to evaluate the type of Th response, different IgG isotypes (IgG1 and IgG2a) 
were investigated. In BALB/c mice predominance of IgG1 or IgG2a indicates the 
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character of immune response either Th2 or Th1 biased respectively. Our results 
suggested that CpG ODN including formulations induced significantly higher levels 
of IgG2a (Figure 3.18) but not IgG1 (Figure 3.17). 
A) 
 
B) 
 
Figure 3.17. Anti Serotype-O IgG1 responses of immunized mice (for details please 
see Figure 3.16 legend). LD: Low Dose, OD: Optimum Dose. 
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Figure 3.18. Anti Serotype-O IgG2a responses of immunized mice (for details please see 
Figure 3.16 legend). LD: Low Dose, OD: Optimum Dose. 
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When IgG2a/IgG1 ratios were compared among treatment groups, our results 
revealed that anti Serotype-O immunity induced via CpG ODN adjuvanted groups 
showed more Th1 biased immunity compared to non-CpG formulations (please see 
Appendix Bvi). 
 
ELISA experiments indicated that anti Serotype-O antibody levels are higher in CpG 
including formulations, however it does not give any information that whether these 
antibodies are capable to neutralize viruses or not. For this reason, virus 
neutralization tests were conducted and neutralization capabilities of immune sera 
collected from different treatment groups studied.  
 
As seen in Figure 3.19A, neither ODAg nor LDAg injected mice gave any detectable 
neutralization titers at 2 weeks. CpG ODN addition brought these neutralization titers 
to very high levels (480±450, 150±124, p<0.05). Similar responses were observed in 
monovalent vaccine treated groups. As seen in Figure 3.19A, while ODMono and 
LDMono injected mice gave average neutralization titers of 80±113 and 15±30 
respectively these titers enhanced to 1040±872 and 210±234 with CpG ODN 
inclusion within formulations at 2 weeks post booster injection. . Similar trend were 
observed over the course of 5 months (Figure 3.19, Figure 3.20, Figure 3.21 and please 
see Appendix Bvii).  
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@ 2 weeks  
 
Figure 3.19. FMDV neutralizing Ab Titers of mice injected either with Optimum Dose (OD) 
and Low Dose (LD) Serotype O Ag/Monovalent Vaccine or their CpG ODN containing 
counterparts at 2 weeks post booster injection was assesed by Virus Neutralization Assay. 
Each dot represents the neutralizing Ab levels of one mouse (p<0.01, p<0.05) 
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@ 8 weeks  
 
Figure 3.20. FMDV neutralizing Ab titers of immunized mice at post booster 8 weeks (for 
details please see Figure 3.19 legend). LD: Low Dose, OD: Optimum Dose. 
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@ 20 weeks  
 
Figure 3.21. FMDV neutralizing Ab titers of immunized mice at post booster 20 weeks (for 
details please see Figure 3.19 legend). LD: Low Dose, OD: Optimum Dose. 
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The most fascinating outcome of virus neutralization assay can be observed when 
number of non-responsive and responsive animals were compared. As seen in Table 
3.2 number of responsive mice according to the virus neutralization titers are 
superior in CpG ODN including formulations compared to Ag alone or Monovalent 
vaccine formulations. 
 
Table 3.2. Number of immunized mice developed detectable virus neutralization titers for a 
duration of 20 weeks. 
Weeks Untreated ODAg ODAg+CpG LDAg LDAg+CpG ODMono ODMono+CpG LDMono LDMono+CpG
2 weeks 0/8 0/8 7/8 0/8 7/8 4/8 8/8 2/8 6/8
4 weeks 0/8 3/8 8/8 0/8 8/8 8/8 8/8 4/8 8/8
6 weeks 0/8 5/8 8/8 0/8 8/8 8/8 8/8 4/8 8/8
8 weeks 0/8 6/8 8/8 0/8 8/8 7/8 8/8 6/8 7/8
12 weeks 0/8 6/8 8/8 0/8 7/8 6/8 8/8 4/8 7/8
16 weeks 0/8 2/8 8/8 0/8 7/8 5/8 8/8 3/8 6/8
20 weeks 0/8 2/8 7/8 0/8 6/8 5/8 8/8 2/8 5/8
Serotype-O Antigen Monovalent Vaccine
 
 
In conclusion, CpG ODN addition brought neutralization titers and percent of 
responder animals to a higher extent even in 6 fold less Serotype-o Ag or 
Monovalent vaccine injected animals. 
 
Rapidity of the immune response generated by vaccine is another important 
parameter in vaccine development. In addition to the long lasting humoral immune 
responses, a good vaccine formulation should also confer rapid immune responses as 
well. It has been shown that IFNγ induced in vaccinated cattle is correlated with the 
animal`s ability to control the replication of FMD virus before humoral immune 
responses established [219]. In order to understand whether our vaccine formulation 
can induce a rapid cell mediated immunity sera collected from immunized animals 
only 24h after booster injection and IFNγ levels determined by ELISA. Our results 
revealed that mice injected with CpG ODN including formulations induced much 
more IFNγ (p<0.05) responses compared to non-CpG formulations either formulated 
with Serotype-O Ag or Monovalent vaccine (Figure 3.22). 
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Figure 3.22. Rapid serum IFNγ response of mice immunized with indicated formulations 
mice 24h after booster injection IFNγ levels were determined by ELISA (Untreated mice 
gave 423±38 pg/ml). 
 
3.4 Prophylactic Use of CpG ODNs in Broiler Chickens 
 
As mentioned in Introduction section high mortality rates of newborn chickens cause 
serious economic losses for the industry in Turkey and abroad. In this part of this 
thesis, different classes of CpG ODNs were tested in order to develop effective 
prophylactic agents that can decrease newborn mortality rates of broiler chicken. For 
this purpose, effects of different classes and types of CpG ODNs were tested both in 
mice (Figure 3.15) and chicken[220]. As indicated by Tincer et al., especially D35 
3CG MB and 1466 Acore PO sequences induce stronger immune stimulation and 
could mediate Th-1 biased immune response on both B cells (DT40 cell line) and 
chicken splenocytes. 
 
After determination of most potent CpG ODN types and sequences these ODNs were 
tested in broiler chickens in-vivo. Briefly, 1 day old broiler chickens (1000 
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chicken/group) were subcutaneously injected with 3 doses of D35 3CG MB and 
1466 Acore PO in 200µl Hanks Buffer or Hanks Buffer alone (detailed in Methods 
Section) and mortality rates, live body weights, feed conversion ratios (FCR) and 
European Efficiency of Productivity Factor (EPEF) values were controlled.  
 
Our results indicated that chicken injected with both 1466 Acore PO ODN or D35 
3CG MB ODN exhibited lower mortality percentages at the end of 41 days (Figure 
3.23). As seen on Figure 3.23, while all 3 doses of 1466 Acore PO ODN were able to 
reduce mortality, only 4 μg dose of D35 3CG MB was able to reduce mortality 
significantly.  
 
Figure 3.23. Mortality percentages of chickens at the end of 41 days. 1 day old chicken 
injected s.c with 3 doses (0.8μg, 4μg, 20μg) of 1466 Acore PO ODN or D35 3CG MB ODN 
in 200 μl Hanks buffer or Hanks buffer alone (Untreated). (p<0.05) (N=1000 chicken/group, 
Untreated: 6000/group). 
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In broiler chicken industry, animals are sent to slaughter house at the end of 41 days. 
During this period, mass gained by animals and ability of the animal to convert feed 
mass to body mass are important economical parameters. For this reason, effect of 
CpG ODN injection on live body weights, FCR and EPEF values were studied. 
 
Our results revealed that chickens injected with D35 3CG MB ODN (4 μg and 20 μg 
doses) significantly gained more mass in 41 days compared to untreated chickens 
(Figure 3.24). 
 
 
Figure 3.24 Body weights of chickens at the end of 41 days (for details please see Figure 
3.23). 
 
Since gained live body weight within a specific time period is directly related to the 
amount of feed mass, FCR values were also calculated in order to understand the 
effect of CpG ODNs in nutrition. Briefly, FCR is a measure of animals efficiency to 
convert feed mass to body mass. Animals that have lower FCR are considered as 
efficient users of the feed. 
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As seen in Figure 3.25, chicken injected with 0.8μg and 20μg 1466 Acore PO ODN 
exhibited significantly lower FCR values.  
 
Figure 3.25. FCRs (Feed conversion ratio) of chickens at the end of 41 days. (for details 
please see Figure 3.23). 
 
Another parameter that indicates growth performance is European Efficiency of 
Productivity Factor (EPEF) value. As seen in Figure 3.26, 20μg 1466 Acore PO 
ODN and 4 μg and 20 μg D35 3CG MB ODN injection significantly enhanced EPEF 
values. 
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Figure 3.26. EPEF (European Efficiency of Productivity Factor) of chickens at the end of 41 
days. (for details please see Figure 3.23). 
 
Although mortality, body weight, FCR and EPEF values are not perfectly correlated 
our results collectively representing the benefits of CpG ODNs on growth 
performance.  
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Chapter 4 
4. Discussion 
4.1 Immunotherapeutic Use of Suppressive ODN in Endotoxin 
Induced Uveitis  
 
In this study, we examined the effect of synthetic telomeric repeat units (suppressive 
A151 ODN) localized at the end of mammalian chromosomes on EIU, which is an 
established animal model of acute ocular inflammation in both mouse and rabbit 
models. The results indicated that suppressive ODN was able to down-regulate the 
expression and protein levels of several proinflammatory and immunoregulatory 
cytokines/chemokines at local and systemic levels when administrated (i) prior to, 
(ii) simultaneously with, or (iii) even after LPS challenge (Figure 3.4, Figure 3.5, 
Figure 3.6, Figure 3.7, Figure 3.8). 
 
Compared with local injection of (intraocular) LPS and/or LPS- and control ODN-
treated rabbits, suppressive ODN-administrated animals exhibited reduced levels of 
IL1β and IL6 expression in the iris and cornea, respectively. In the mouse model, the 
results revealed that pretreatment with 250 µg of suppressive ODN reduced the 
expression of IP10, iNOS, MIP1α, IL-18, MIP3 α, CXCL16, and MIP1β in 100-µg 
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LPS injected mice. The suppressive action of this class of ODN was not only on the 
mRNA levels of several Th1-type cytokines and chemokines but also on the secreted 
protein level. ELISA experiments showed that suppressive ODN pre- and post-
treatments significantly diminished IL6 secretion at 6 and 24 h; simultaneous 
administration of suppressive ODN also reduced IL6 production. Several studies 
indicated that suppressing proinflammatory cytokines, including IL6, TNFα, MCP1, 
and iNOS, prevents the development of EIU [160, 163-165]. Here, we have shown 
that either local (intraocular) or systemic (intraperitoneal) administration of 
suppressive A151 ODN can significantly reduce several proinflammatory cytokines 
and chemokines even 2 h after in vivo LPS challenge. 
 
Corticosteroids and chemotherapeutic agents are currently in use in uveitis 
therapy.[221] However, long-term treatment with these drugs may have grave side 
effects such as increased intraocular pressure [222] and cytotoxicity [223] and thus 
limit their use [159] [207, 221]. Therefore, a new therapeutic strategy is urgently 
needed [224, 225]. The mechanism of action of this novel ODN-based 
immunosuppressive drug candidate is currently unknown. Previous studies revealed 
that suppressive ODN can inhibit immune response by blocking the stimulatory 
effects of CpG motifs [79, 136]. It also has been shown by Shirota et al. [31] that 
suppressive A151 ODN can also protect mice from lethal endotoxic shock that is 
induced by LPS. It has been shown that suppressive ODN can also inhibit several 
signal transduction cascades related to the production of Th1 cytokines such asIFNγ 
and IL12 by binding and inhibiting the phosphorylation of STAT1 (signal transducer 
and activator of transcription 1) and STAT4 proteins [31, 121]. Our study has 
demonstrated that suppressive ODN can block immune responses mediated by 
endotoxin in the eye (an immune privileged site), an established animal model of 
acute ocular inflammation. Recently, Fujimoto et al. [129] reported that suppressive 
A151 ODN can inhibit ocular inflammation in two murine models, IRBP 
(interphotoreceptor retinoid-binding protein)-induced experimental autoimmune 
uveitis and adoptively transferred ocular inflammation. These forms are antigen-
driven and, compared with LPS, are significantly less aggressive forms of 
experimental uveitis models. The control of LPS-mediated EIU at both the local and 
 95 
systemic levels has not been studied by others and increases the breadth of the 
suppressive ODN-mediated therapy for the eye.  
 
Collectively, these observations support the provocative possibility that the 
evolutionary expansion of TTAGGG repeats in telomeres, in addition to known 
properties such as, protecting genomic DNA from degradation, and chromosome 
capping [226, 227] may also be linked to their ability to down-regulate 
sustained/pathologic microbe-associated  molecular pattern-induced immunity. In 
conclusion, we have provided evidence that suppressive A151 ODN is able to 
significantly reduce the ocular inflammatory responses in both rabbit and murine 
EIU models.  
 
4.2 Immunosuppressive Effects of Restasis in EIU 
 
To our knowledge, the present study demonstrates for the first time that Restasis 
suppresses the expression and protein levels of several Th1- biased proinflammatory 
cytokines and chemokines that were upregulated as a result of EIU.  Moreover, the 
topically administered drug was effective both locally and systemically. Compared to 
rabbits and mice that received LPS only, animals that were treated with Restasis 
exhibited reduced expression levels of IP10, MCP1, IL6 and IL1β in their eyes 
(Figure 3.11, Figure 3.12, Figure 3.13, Figure 3.14). This reduction in 
proinflammatory cytokine and chemokine expression could stem from the 
downregulatory effect of Restasis on TLRs message. Our results indicated that either 
pre or post- treatment with Restasis was able to downregulate the expressions of 
several TLRs such as TLR2, TLR4, TLR5, TLR6, TLR7, and TLR9 in the mouse 
eye (Figure 3.10). Therefore, the decrease in IL6 levels in Restasis treated animals 
(Figure 3.12) could be due to the downregulation of TLR4, the receptor required for 
LPS signaling. In this respect, our results are consistent with the literature where oral 
administration of cyclosporines were proven to be beneficial in the treatment of 
several systemic and ocular autoimmune diseases as well as the prevention of 
transplant rejection [210, 211]. Along with those studies data demonstrated that CsA 
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reduced the production of the proinflammatory cytokines IL1β, TNFα, IL6 and IL8 
from U937 human monocyte-like cells in vitro [172]. Recently, Chi et al., reported 
that CsA suppressed IL17 production  from Behcet`s patients` PBMC [173]. 
Moreover, several other studies report that systemic cyclosporine treatment can 
reduce the severity of uveitis and can downregulate the expression of 
proinflammatory cytokines such as IL12, IL18 and TNFα  [174-176]. Of interest, a 
recent study showed that topical treatment with 1% cyclosporine A reduced the 
severity of subepithelial corneal infiltrates [228]. 
 
The present study established that topical Restasis treatment downregulated both the 
systemic and the local proinflammatory response. The finding that topically 
administered Restasis had a systemic effect (Figure 3.12) was an unexpected one and 
can be explained by an enhanced diffusion of the drug into circulation due to the 
breached BRB. Several studies indicated that suppressing proinflammatory cytokines 
including IL6, TNFα, MCP1 and inducible nitric oxide synthase (iNOS) prevents the 
development of EIU [160, 163, 164, 229]. Current practice in treatment of uveitis 
involves systemic administration of corticosteroids and chemotherapeutic agents 
[221, 230]. However, long-term treatment with these agents may have serious side 
effects such as increased intraocular pressure [222] or cytotoxicity [223] , thereby 
limiting their use [159, 221, 222, 230].  The study on patients with adenoviral 
keratoconjunctivitis demonstrates that topically administered CsA has fewer side 
effects and offers a safe and effective alternative [228].  While our work supports this 
observation, it extends the potential of topical CsA administration to treatment of 
intraocular diseases such as uveitis. 
 
In conclusion, present work extended the breadth of the immunoregulatory potential 
of Restasis and may offer a safe alternative in the treatment of ocular inflammatory 
diseases in the clinic. Collectively, the present findings suggest that Restasis might 
constitute a relevant therapeutic alternative for the treatment of uveitis. 
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4.3 Use of CpG ODN as a Vaccine Adjuvant Against Foot And 
Mouth Disease  
 
Major problem associated with FMDV vaccine is that, there is very limited amount 
of antigen for the production of sufficient amounts of commercial vaccine doses. 
Moreover, due to inability of providing long lasting immunity and the lack of 
inducing rapid immune responses in case of a rapid virus spread, frequent re-
vaccinations are required [179, 185-188].  
 
Protection against FMDV correlates with the high levels of neutralizing antibodies in 
the serum. Viruses are neutralized via neutralizing antibodies in serum which is 
proceeded by the clearance of the opsonized virus complexes by phagocytic cells 
[182]. Although it is established that FMD infection elicits an appreciable amount of 
humoral response some studies indicated that despite antibody levels, early 
protection could also be maintained by initiating sufficient amount of innate immune 
activity [185]. In this respect DCs play the most important role, since they express a 
panel of TLRs designed to recognize pathogenic components. Upon recognition of 
pathogenic molecular patterns a number of co-stimulatory molecules, 
proinflammatory cytokines and chemokines are secreted as well as the enhancement 
of antigen presentation function of these cells. All these processes licences DCs to 
maturate and help to elicit FMDV specific adaptive immunity [185, 231, 232]. 
Therefore, aiming to induce innate immune responses is a desirable approach to 
overcome undesirable problems associated with the conventional FMDV specific 
vaccine since innate immune system induces a rapid immune response against 
invaders and alerts adaptive immunity.  
 
To date several attempts were made in the context of inducing innate immunity to 
develop more potent FMDV vaccines. For instance, Su et al., indicated that use of 
IL6 and TNFα as molecular adjuvants can enhance both innate and adaptive immune 
responses against FMDV [185]. In another study, Barnett et al., denoted that 
protection against FMDV in pigs is correlated with high serum IL12 levels [233]. 
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Ren et al., demonstrated that CpG ODN RW03 in combination with montanide ISA 
206 can enhance immune responses against a recombinant FMDV vaccine named A7 
[186]. Most recently, Guo et al., reported that use of CpG rich plasmids can enhance 
the efficacy of traditional FMD vaccine [234].  
 
In this study, we investigated the effects of 1555 PS CpG ODN as an adjuvant on 
both Ag alone or a commercially relevant form of FMD vaccine which includes 
nanoemulsion of montanide ISA 206 comlexed serotype-O-Ag. Previously, it has 
been shown that combination of CpG ODN with montanide ISA 206 enhanced 
protective efficacy of vaccine against malaria.[216] Since challenge studies in mice 
are not well established, the potency of FMDV vaccine is tested in vaccinated 
animals indirectly according to the standard protocol of OIE. The well established 
test for assessing antibodies to FMD vaccines is virus neutralization test (VNT). A 
good correlation was reported between VNT and protection [235, 236]. Ab tests 
revealed that formulations with CpG ODN induced significantly higher anti-FMDV 
Ab titers compared to non-CpG formulations (Figure 3.16 and Figure 3.18). Our 
results implied that reducing monovalent vaccine (or serotype O-Ag alone) amount 
by 6 fold and including a potent CpG ODN sequences on to these formulations was 
much effective than high Monovalent vaccine or Ag alone doses (Figure 3.16 and 
Figure 3.18). 
 
Several studies demonstrated that CpG ODN mediate a Th1 biased immune 
response. In this study, we planned to study the induction levels of IgG subtypes. As 
expected, our results showed that formulations with CpG ODNs induced a strong 
Th1 type immune response evidenced by increased IgG2a/IgG1 ratios compared to 
non-CpG ones (Please see appendix Bvi). IFNγ is one of the major Th1 type cytokine 
which plays critical roles in the improvement of CD8+ T cell responses. It has been 
reported that IFNγ induced in vaccinated cattle is correlated with the animals ability 
to control the replication of FMD virus [219]. Since mice injected with CpG ODNs 
induced such high IgG2a/IgG1 ratios, we investigated whether CpG ODN including 
formulations can also induce cell-mediated immunity. As an indicator of cellular 
immune responses serum IFNγ levels of mice have been measured by ELISA. Our 
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results revealed that 24h after injection CpG containing formulations induced 1,5 to 2 
fold more IFNγ in serum which indicates the contribution of cell-mediated immune 
response (Figure 3.22). This type of rapid immune response also shows the 
emergency vaccine character of CpG including formulations.  
 
As a hallmark of FMD vaccine’s efficacy, virus neutralizing Ab titers of the 
vaccinated mice was studied. Consistent with the Ab results, virus neutralization 
assays suggested that mice injected with CpG including formulations have more and 
persisting titers in their sera (Figure 3.19 and please see appendix Bvii).  
 
Attaining high anti-FMDV immunity and maintaining this response for longer 
periods is another critical feature of an ideal FMD vaccine. Current practice in the 
field is to protect animals from FMDV infections via frequent re-vaccinations that 
would provide protective Ab levels[187]. Our mice study results not only revealed 
that CpG inclusion in the formulations induced higher anti-FMDV total IgG and 
IgG2a responses even 5 months after booster injection (Figure 3.16 and Figure 3.18). 
but also virus neutralization studies supported that higher levels of circulating 
neutralizing Abs were maintained in their sera after 5 months (Figure 3.19 and please 
see appendix Bvii). 
 
In summary, data presented in this study demonstrated that CpG ODNs can be used 
either in nanoemulsion form together with montanide ISA 206 or even as a 
standalone mixture for enhancing both humoral and cell mediated immune responses 
in mice. In the light of these findings, studies in cloven-hoofed animals are underway 
to examine the vaccine efficacy, protection performance as well as anti-FMD-Ab 
persistence of the candidate vaccine. 
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4.4 Prophylactic Use of CpG ODNs in Broiler Chickens 
 
Mortality during the first week of life in broiler chickens is one of the most important 
problems for broiler industry. Use of antibiotics via in ovo injection or adding into 
drinking water or food is becoming unacceptable due to several safety and human 
health issues. For instance, antibiotic use can been linked to the emergence of drug 
resistant bacteria strains and also possible drug residues in the meat products. 
Therefore, animal industry is seeking for novel therapeutics or prophylactic agents 
that can be used instead of antibiotics.  
 
As detailed in Introduction section, it is known that CpG ODNs activate innate 
immune responses to protect host against a variety of pathogens. It has been shown 
in many scientific publications that CpG can protect mice against bacterial, viral and 
protozoal infections (Krieg 2006). In most of these articles it is indicated that pre-
treatment with CpG ODNs is much more effective than post-treatment in case of 
protection (Krieg 2006). Protection time with CpG ODNs varies between a few days 
to two weeks, but that can be extended to months by repeated treatments (Klinman 
1999).  
 
There are several studies indicating the role and ability of CpG ODNs to stimulate 
innate immune responses and protection against infections in chicken. It has been 
shown that CpG pre-treatment improved survival rates of chickens upon challenge 
with E.coli (Gomis 2004). In this study 2 day old birds were subcutaneously or 
intramuscularly injected with 10-50 µg of CpG ODN and challenged with E.coli with 
the same route 3 days after CpG injection. Results were encouraging because nearly 
90% of the animals in the control group were died. In contrast, CpG pre-treated 
groups had significantly higher survival rates (Gomis 2004). In addition, it has been 
reported that CpG ODNs are effective in prevention of Salmonella infections in 
chicken. He et al., demonstrated that intraperitoneal 50 µg pre-CpG injection 
protected chicken from S.enteriditis challenge (He 2005). In another study, same 
group showed that CpG injection 24h prior to oral S.enteridis challenge prevented 
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the colonization of bacteria in liver and spleen (He 2007). Furthermore, effect of 
CpG ODNs on S.typhimurium infection has been studied. Taghavi et al., reported 
that 50 µg intramuscular CpG ODN injection in newborn chickens was able to 
reduce mortality and clinical symptoms associated with S.typhimurium infection 
upon bacterial challenge. (Taghavi 2008).  
 
While there are a plethora of studies indicating the effect of CpG ODNs in viral 
infection in mice, studies demonstrating the antiviral effects in chicken are only a 
few. One of those studies was conducted against infectious bronchitis virus (IBV) 
infection. In this study, eighteen day old chicken embryos were in-ovo injected with 
CpG ODN and 24h later challenged with IBV virus. Results indicated that chickens 
injected with CpG ODN were significantly inhibited viral replication compared to 
controls (Dar 2009). With respect to results obtained in IBV study, same group 
reported that CpG ODNs were effective in avian influenza virus (AIV) infection. In 
this in-vitro study, chicken embryo fibroblasts were treated with CpG ODN and 24h 
later infected with AIV virus and viral replication was assessed by real time PCR. 
Similar with IBV study results indicated that CpG ODNs were able to inhibit viral 
replication (Dar 2009). These two independent studies suggest that CpG ODNs may 
have potential in controlling viral infections in chicken. 
 
Parasitic diseases like avian coccidiosis are also very important for poultry industry. 
It is reported that poultry industry loses 800 million dollars every year due to avian 
coccidiosis. Currently, some expensive prophylactic agents are in use in order to 
control parasitic infections but their effectiveness are limited. Therefore new 
therapeutic applications are needed. In this context, effect of CpG ODNs against 
avian coccidiosis infection was studied by Dalloul et al. They indicated that use of 
CpG ODNs enhanced resistance against parasite in a susceptible chicken strain 
(Dalloul 2004). 
 
In the light of these studies, we decided to check the effects of CpG ODNs as a 
prophylactic agent in newborn chicken in order to reduce high mortality rates and 
provide a better quality and profit for poultry industry. For this purpose, we 
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synthesized more than 50 different CpG/Non CpG ODN sequences (i.e with their 
proper CpG flip controls) and tested them in vitro on spleen cells of both mice and 
chicken for their ability to induce pro-inflammatory and inflammatory cytokine 
secretions (Figure 3.15 and G. Tincer PhD Thesis, Bilkent Univ., 2013 ). Of those 
two different types of CpG ODN sequences were selected and tested in-vivo in 1 day 
old broiler chicken. Most of the studies conducted so far with newborn chicken have 
been carried out with high doses of CpG ODNs which may not be economical to use 
in poultry industry. In our study, we evaluated minimal amount of CpG ODN 
required for protection against pathogens. As reported in detail in Results section, 
even 0.8 µg CpG ODN per animal was sufficient to reduce mortality rates (Figure 
3.23). Although mortality percent reduction upon CpG administration is only about 
2%; this reduction, when considered on industrial scale (1.2 billion chicken 
reproduction in Turkey/year), corresponds to survival of extra 24 million chicken per 
year in Turkey.  
 
Effect of such prophylactic agents on growth performance is another important 
parameter that should be taken into consideration. For this reason live body weights 
(Figure 3.24), FCR (Figure 3.25), and EPEF (Figure 3.26) values were also 
determined. Although, results obtained from these studies are not perfectly 
correlated, it is obvious that use of CpG ODNs had significant beneficial effects on 
growth performance. Collectively, our results represented that CpG ODNs can be 
used as prophylactic agents in order to prevent bacterial, viral and parasitic infections 
and also have beneficial effects on growth performance in newborn chicken. 
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Appendix A 
 
 
 
Standard Solutions, Buffers, Media 
 
Sodium Carbonate Buffer (0.1M) (ELISA) 
 1.696 grams Na2CO3 
 2,856 grams NaHCO3 
into 500 ml ddH2O. pH should be adjusted to 9.6. The buffer should be stored at +4°C. 
 
Blocking Buffer (ELISA) 
 500 ml 1x PBS 
 25 grams BSA (5%) 
 250 μl Tween20 (0,025%) 
Crystal particles of BSA should be dissolved very well, with magnetic stirrer for 
20 
30 min. The buffer should be stored at -20°C. 
 
T-cell Buffer [ELISA] 
 500 ml 1x PBS 
 25 ml FBS (5%) 
 250 μl Tween20 (0,025%) 
The buffer should be stored at -20°C. 
 
Wash Buffer [ELISA] 
 500 ml 10x PBS 
 2,5 ml Tween20   
 4,5 lt dH2O 
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PBS (Phosphate Buffered Saline) [10x] 
 80 grams NaCl 
 2 grams KCl 
 8.01 grams Na2HPO4 . 2H2O 
 2 grams KH2PO4 
into 1 lt ddH2O 
pH= 6,8. For 1xPBS’s pH should be ≈ 7.2-7.4. Should be autoclaved prior to use. 
 
HANKS BUFFER [10x] 
 74.25 grams Nacl 
 26.03 grams HEPES (sodium salt) 
 23.83 grams HEPES (free acid) 
 4 grams KCL 
 0.47 grams Na2HPO4 
 0.6 grams KH2PO4 
Into 1 lt dd H2O 
 
TAE (Tris-Acetate-EDTA) [50x] 
 242 grams Tris (C4H11NO3) 
 37.2 grams Tritiplex 3 (EDTA= C10H14N2Na2O2 . 2H2O) 
 57.1 ml Glacial acetic acid 
into 1 lt ddH2O 
Dissolves in ≈1 day. Should be autoclaved. Diluted to 1X prior to use 
 
 
High Glucose DMEM and RPMI-1640  
 2 %: 10 ml FBS (Oligo FBS = inactivated at 65°C, Regular FBS = inactivated 
at 55°C ) 
 5 % : 25 ml FBS 
 10 % : 50 ml FBS 
 5 ml Penicillin/Streptomycin (50 µg/ml final concentration from 10 mg/ml 
stock) 
 5 ml HEPES (Biological Industries),(10 mM final concentration from 1M 
stock ) 
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 5 ml Na Pyruvate, (0.11 mg/ml final concentration from 100mM, 11 mg/ml 
stock) 
 5 ml Non-Essential Amino Acids Solution, (diluted into 1x from 100x 
concentrate stock) 
 5 ml L-Glutamine, (2 mM final concentration from 200 mM, 29.2 mg/ml 
stock) 
In 500 ml media 
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Appendix B 
 
 
 
Figure B i: A) Suppressive ODN A151 treatment after 100 µg LPS challenge induced 
substantial but insignificant down regulation of MCP1 and IL18 mRNA expression levels on 
the eyes of mice. Mice were injected intraperitoneally with 100 µg LPS and 250 µg 
suppressive ODN and were killed at 18 h after injection. B) Representative agarose gel 
picture (M1 indicates mouse #1, M2 indicates mouse #2). 
A) 
           
 
B) 
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Figure B ii: Topical Restasis treatment did not reduce disease severity in 100µg LPS 
induced EIU. Animals treated 6 times with Restasis either 2h before or 2h after LPS 
challenge. Clinical EIU evaluation was performed on both eyes and scored as described in 
methods section 2.1.3. 
 
 
              
 
 
 
Figure B iii: Restasis treatment post 50 µg (high dose) LPS challenge (4 mouse/group) did 
not downregulated IL15, CXCL16, MIP1α, IL18, MIP3α and MIP1β expression levels of 
mice eyes. 
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Figure B iv: Restasis administration after LPS treatment did not downregulated IL1β and 
IL6 expressions in rabbit iris tissues (5 rabbit/group) A) IL1β and B) IL6 mRNA levels. 
Representative agarose gel images. 
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Figure B v: Non-CpG Control ODNs did not induce any cytokine production. BALB/c 
splenocytes (4X106) were stimulated with Control ODNs for 42hrs. IL6, IL12p40 and IFNγ 
production were assessed by ELISA. Data represents average ±SEM of three independent 
experiments carried out in triplicate repeats for each treatment groups. 
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Figure B vi: Graphical representation of IgG2a/IgG1 ratios of mice immunized with either 
with Ser-O Ag or Monovalent Vaccine or their CpG ODN containing counterparts for a 
period of 20 weeks. Inclusion of CpG ODN within vaccine formulations significantly 
effected IgG2a/IgG1 ratios. Serum IgG2a and IgG1 levels were determined by ELISA. 
Graphics shows the ratios of the OD readings of anti-FMDV IgG2a and IgG1 responses at 
900 titer (8 mice/group). 
 
 
 
 
 135 
Figure B.vii: FMDV neutralizing Ab Titers of mice injected either with Optimum Dose 
(OD) and Low Dose (LD) Serotype O Ag/Monovalent Vaccine or their CpG ODN 
containing counterparts at A) 4weeks B) 6 weeks C) 12 weeks D) 16 weeks post booster 
injection was assesed by Virus Neutralization Assay. Each dot represents the neutralizing Ab 
levels of one mouse (p<0.01, p<0.05) 
 
A) Virus Neutralization titers @ 4 weeks post booster injection 
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B) Virus Neutralization titers @ 6 weeks post booster injection 
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C) Virus Neutralization titers @ 12 weeks post booster injection 
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D) Virus Neutralization titers @ 16 weeks post booster injection 
 
 
 
 
Yağcı, F.C. 
 139 
Chapter 7 
7. Curriculum Vitae and Publications 
 
Yağcı, F.C. 
 140 
 
Fuat Cem Yağcı 
(MSc/PhD Candidate) 
Personal Information 
Birth Date: 01.08.1983 
Nationality: Turkish 
Address: Bilkent University, Faculty of Science,  
Department of Molecular Biology and Genetics, 
Biotherapeutic ODN Research Laboratory, 
Ankara, Turkey 
Cellular Phone: +90 533 625 34 40 
e-mail: fuatcemyagci@gmail.com 
 
 
 
ACADEMIC DEGREES 
 
2007-….. Bilkent University, Department of Molecular Biology and 
Genetics, Ankara, Turkey (Ph.D. Degree) 
 
2005-2007 Bilkent University, Department of Molecular Biology and 
Genetics, Ankara, Turkey (M.Sc. Degree) 
 
2001-2005 Halic University, Department of Molecular Biology and Genetics, 
Istanbul, Turkey (B.Sc. Degree) 
 
1998-2001 Antalya Anadolu High School, Antalya, Turkey 
 
THESIS DEFENDED 
 
2005 – 2007 Bilkent University, Department of Molecular Biology and 
Genetics, M.Sc. Degree “Suppressive Oligodeoxynucleotides as a 
TLR Antagonist: Efforts to Treat Autoimmune Diseases”. 
Supervisor: Assoc. Prof. Dr. Ihsan Gursel,  
 
PUBLICATIONS 
 
1. Yagci FC, Cokcaliskan C, Gungor B, Alkan M, Gursel M, Gursel I. “Immunization of 
mice with CpG ODN/lipidic nanoemulsion spares antigen and generates a rapid, persistent 
humoral and cell mediated immunity against FMDV.” Vaccine (In preperation), January 
2014. 
 
2. Yagci FC, Aslan O, , Tincer G, Kahraman T, Akcali CK, Bozdogan O, Gursel M, 
Gursel I. “Immunosuppressive Effect of Topical Cyclosporin A Application on the 
Endotoxin Induced Uveitis”. Clin Exp Opthalmol (In preperation), January 2014. 
 
Yağcı, F.C. 
 141 
3. Gungor B, Yagci FC, Tincer G, Bayyurt B, Alpdundar E, Yildiz S, Ozcan M, Gursel 
I, Gursel M. “Production from Plasmocytoid Dendritic Cells and Demonstrate Potent 
Vaccine Adjuvant Activity”. Science Translational Medicine (Under Review), January 2014. 
 
4. Osmanagaoglu O, Kıran F, Yagci FC, Gursel I. “Immunomodulatory function and in 
vivo properties of Pediococcus pentosaceus OZF, a promising probiotic strain.” Ann 
Microbiol DOI 10.1007/s13213-012-0590-9, December 2012. 
 
5. Tincer G, Yerlikaya S, Yagci FC, Kahraman T, Atanur OM, Erbatur O, Gursel I. 
“Immunostimulatory Activity of Polysaccharide-Poly(I:C) Nanoparticles.” Biomaterials. 
2011 Jun;32(18):4275-82, June 2011.  
 
6. Gursel I, Yagci FC, Tincer G, Kahraman T, Gursel M. “DNA Nanoparçacıklarının 
Nanotıp ve Nanobiyoteknolojideki Yeni Kullanım Alanları.” (Novel applications of DNA 
nanoparticles in nanomedicine and nanobiotechnology) Bilim ve Teknik Dergisi. (Science 
and Technology Journal), 44-47, March 2011. (Article in Turkish) 
 
7. Yagci FC, Aslan O, Gursel M, Tincer G, Ozdamar Y, Karatepe K, Akcali CK, 
Gursel I. “Mammalian Telomeric DNA Suppresses Endotoxin Induced Uveitis”. J Biol 
Chem. 10;285(37):28806-11, September 2010. 
 
RESEARCH EXPERIENCE 
 
2013- ….. Project PI: Ministery of Science and Technology 
(TEKNOGİRİSİM Project# 1232.TGSD.2013) 
 ” “Use of several TLR agonists to enhance the efficiency of Foot and 
Mouth Disease (FMD) vaccines as adjuvants” 
 
2009-2011 Research Assistant: Ministery of Science and Technology 
(SANTEZ, Project#00448.STZ.2009-2), Bilkent University, 
Department of Molecular Biology and Genetics 
 “Improving broiler chicken immune resistance by providing 
protection and reducing losses from stress and bacterial diseases 
with CpG DNA”. 
 Supervisor: Assoc. Prof. Dr. Ihsan Gursel 
 
2009 - 2010  Research Assistant: TUBITAK, SBAG-108S316 , Bilkent  
   University, Department of Molecular Biology and Genetics 
   ”Biomedical Applications of DNA Nanoparticles” 
   Supervisor: Assoc. Prof. Dr. Ihsan Gursel 
 
2006-2009 Research Assistant: TUBITAK, SBAG-106S102, Bilkent 
University, Department of Molecular Biology and Genetics 
 “Development of Liposomal CpG Oligodeoxynucleotide Carrying 
Vaccines Against Pathogens” 
 Supervisor: Assoc. Prof. Dr. Ihsan Gursel 
 
2004 Visiting Scholar: University of Pennsylvania (UPENN), 
Department of Renal Electrolyte and Hypertension,  
“Molecular Analysis of Human Anti-GBM Antibodies” 
Supervisor: Prof. Dr. Michael P. Madaio  
Yağcı, F.C. 
 142 
 
2004 – 2005 Research Assistant: Halic University, Department of Molecular 
Biology and Genetics,  
“Endhotelial Cell Protective Gene  Expression in Response to High 
Concentrarion of D-Glucose and Insulin in the presence and absence 
Bradykinin Stimulation” 
 
AWARDS AND SCHOLARSHIPS 
 
2013   Travel Award provided by European Federation of   
   Immunological Societies to participate 15 thInternational Congress  
   of Immunology, Milan, Italy. 
 
2012 Registration and Travel Awards provided by Association for  
Cancer Immunotherapy. 10th CIMT Annual Meeting.   
Mainz, Germany, 23–25 May 2012. 
 
2012   Registration and Accomodation Awards provided by Turkish  
    Society of Immunology to participate Molecular Immunology & 
    Immunogenetics Congress (MIMIC2012),  
     Antalya, Turkey, April 2012. 
 
2011   Full Scholarship provided by Turkish Society of Immunology to 
   participate 21thNational Congress of Immunology, Marmaris,  
   Turkey. 
 
2010   Travel Award provided by European Federation of Immunological  
   Societies to participate 14th International Congress of  
   Immunology, Kobe, Japan. 
 
2009 Full Scholarship provided by Turkish Neurology Society to 
participate 9th European School of NeuroImmunology, Istanbul, 
Turkey.  
 
2009-2011 Ministery of Science and Technology (SANTEZ, 
Project#00448.STZ.2009-2) Project Bursary. “Improving broiler 
chicken immune resistance by providing protection and reducing 
losses from stress and bacterial diseases with CpG DNA”. 
 
2009 - 2010 TUBITAK, SBAG-108S316 Project Bursary ”Biomedical 
Applications of DNA Nanoparticles” 
 
2006-2009 TUBITAK, SBAG-106S102 Project Bursary  “Development of 
Liposomal CpG Oligodeoxynucleotide Carrying Vaccines Against 
Pathogens”  
 
2005 - .......  PhD Programme Bursary 
Institute of Science and Engineering, Bilkent University, Ankara, 
Turkey. 
Yağcı, F.C. 
 143 
 
2005 – 2007  M.Sc. Programme Bursary 
Institute of Science and Engineering, Bilkent University, Ankara, 
Turkey. 
 
2004 “Goldie Simon” Preceptorship Award  
 LUPUS Foundation, Wyncote, PA, USA 
 
2001 - 2005 B.Sc. Programme Bursary 
   Higher Education Council, Ankara, Turkey 
 
ORAL PRESENTATIONS 
 
1. Yagci FC, Cokcaliskan C, M, Ozturk N, Gungor B, Gursel M, Gursel I. “Use of CpG 
Oligodeoxynucleotides enhances rapidity, longevity and potency of FMDV vaccines in 
mice.” Molecular Immunology & Immunogenetics Congress (MIMIC), Antalya, Turkey, 
April 2012. 
 
2. Yagci FC, Cokcaliskan C, Alkan M, Ozturk N, Bugdayci E, Gungor B, Gursel M, 
Gursel I. “Use of CpG Oligodeoxynucleotides enhances level and duration of vaccine 
potency against FMDV in mice” 17. Biomedical Science and Technology Symposium 
(BIOMED), Ankara, Turkey, November 2011. 
 
3. Yagci FC, Aslan O, Gursel M, Simsek I, Bayyurt B, Gursel I. “İmmün Baskılayıcı 
DNA’nın Otoimmün ve Otoenflammatuvar Hastalıkların Tedavisine Yönelik Uygulamaları” 
(Applications of Immunosuppressive DNA in Autoimmune and Autoinflammatory Diseases) 
21thNational Congress of Immunology, Marmaris, Turkey, April 2011.  
 
4. Gursel I, Yagci FC Tincer G, Kahraman T, Bayyurt B, Gucluler G, Erikci E, 
Karatepe K. “Nanobilimin Uygulamalı İmmünolojiye Katkıları: TLR Ulaklarının 
İmmünterapide Daha Etkin Kullanımının Geliştirilmesi”(Contribution of Nanoscience to 
Applied Immunology: Improving the use of TLR ligands in Immunotherapy) 21thNational 
Congress of Immunology, Marmaris, Turkey, April 2011.  
 
5. Yagci FC, Aslan O, Songur MS, Simsek I, Gursel I “Applications of 
Immunosuppressive Nanoparticle Forming DNA to Treat Autoimmune and 
Autoinflammatory Diseases”. Workshop on Current Trends in Molecular Nanobiosciences, 
Bilkent University, Ankara, Turkey, January 2010. 
 
6. Yagci FC, Aslan O, Songur MS, Gursel I. “Immunosuppressive DNA Nanoparticles: A 
Potential Nanodrug to Treat Endotoxin Induced Uveitis in Mice”. 5. National Nanoscience 
and Nanotechnology Conference, Anadolu University, Eskisehir, Turkey, June 2009. 
Yağcı, F.C. 
 144 
SELECTED CONGRESS COMMUNICATIONS 
 
1. Kahraman T, Yagci FC, Gursel I. “Plasma microparticles and LL37 levels regulate 
Behcet’s disease severity.” 15th International Congress of Immunology, Milan, Italy, August 
2013. (Poster Presentation) 
 
2.Yagci FC, Kiran F, Almacioglu K, Osmanagaoglu O, Gursel I. “DNA Bakteriyosin 
komplekslerinin immune düzenleyici etkileri.” (Immunomodulatory effects of DNA-
Bacteriocin Complexes) 22 th National Immunology Congress, Cesme, Izmir, April 2013 
(Poster Presentation in Turkish) 
 
3. Yagci FC, Cokcaliskan C, Alkan M, Gungor B, Gursel M, Gursel I. “CpG 
Oligodeoxynucleotides enhances both humoral and cellular immune responses against 
FMDV in mice.” .” 10th Cancer Immunotherapy Annual Meeting (CIMT),  Mainz, Germany, 
May 2012. (Poster Presentation) 
 
4. Yagci FC, Gucluler G, Kiran F, Gursel I. “Bacteriocin DNA nanocomplexes as 
immunotherapeutic carriers.” 10th Cancer Immunotherapy Annual Meeting (CIMT),  Mainz, 
Germany, May 2012. (Poster Presentation) 
 
5. Gungor B, Yagci FC, Gursel I, Gursel M. “Potentiating the immunostimulatory 
properties of CpG oligodeoxynucleotides:aiming to develop a better vaccine adjuvant.” 10th 
Cancer Immunotherapy Annual Meeting (CIMT), Mainz, Germany, May 2012. (Poster 
Presentation) 
 
6. Gungor B, Cokcaliskan C, Alkan M, Yagci FC, Gursel I, Gursel M. “CpG 
Oligodexynucleotide/Tat Peptide Complexes Enhance the Potency of Foot and Mouth 
Disease Vaccine in Mice.” Molecular Immunology & Immunogenetics Congress (MIMIC), 
Antalya, Turkey, April 2012. (Poster Presentation) 
 
7. Kiran F, Yagci FC, Almacioglu K, Osmanagaoglu O, Gursel I. ”Enhanced 
Immunostimulatory activity of bacteriocin CpG ODN nanocomplexes” 17. Biomedical 
Science and Technology Symposium (BIOMED), Ankara, Turkey, November 2011. (Poster 
Presentation) 
 
8. Gungor B, Yagci FC, Tincer G, Alpdundar E, Yildiz S, Gursel I, Gursel 
M.”Determination of Immune Stimulatory Properties of Synthetic CpG ODN/ Cationic 
Peptide Complexes”. Biomedical Science and Technology Symposium (BIOMED), Ankara, 
Turkey. November 2011. (Invited speaker, Dr. Mayda Gürsel) 
 
9. Gungor B, Yagci FC, Tincer G, Alpdundar E, Yildiz S, Gursel I, Gursel M. 
“Immunostimulatory Properties of CpG ODN Based Nanoparticles”. ”. Biomedical Science 
and Technology Symposium (BIOMED), Ankara, Turkey, November 2011. (Poster 
Presentation) 
 
10. Yagci FC, Aslan O, Songur MS, Gursel I. “Mammalian Telomeric DNA Sequences 
Downregulate Symptoms of Autoimmune and Autoinflammatory Diseases”. BRIDGE 
Symposium, Bogazici University, Istanbul, Turkey, April 2011. (Poster Presentation) 
Yağcı, F.C. 
 145 
11. Yagci FC, Aslan O, Simsek I, Gursel M, Ozdamar Y, Tincer G, Karatepe K, Gursel 
I. “Immunosupressive Oligodeoxynucleotides: A Potential Nanodrug to Treat Autoimmune 
and Autoinflammatory Diseases”. 14th International Congress of Immunology, Day 1 
Abstract Book, P21, Kobe, Japan, August 2010. (Poster Presentation) 
 
12. Yagci FC, Aslan O, Songur MS, Gursel I. “Mammalian Telomeric DNA Sequences 
Are Immunosuppressive and Downregulate Symptoms of Endotoxin Induced Uveitis in 
Mice”. 15. Biomedical Science and Technology Symposium, P125, Guzelyurt, Turkish 
Republic of Northern Cyprus, August 2009. (Poster Presentation) 
 
13. Gursel I, Tincer G, Yagci FC, Mammadov R, Kocak H, Kahraman T, Karatepe K, 
Erikci E, Akcali C, Gursel M. “Nanobiotechnological Applications of Self-Assembled 
Immunostimulatory DNA Nanoparticles”. 15th International Biomedical Science and 
Technology Symposium, Guzelyurt, Turkish Republic of Northern Cyprus, August 2009. 
(Invited speaker, Dr. Ihsan Gürsel) 
 
14. Gursel I,  Tincer G, Yagci FC, Kahraman T, Mammadov R, Erikci E, Karatepe K, 
Akcalı C, Gürsel M. “Potential Nanomedical Applications of Self Assembled 
Immunomodulatory DNA Nanoparticles”. 5th National Nanoscience and Nanotechnology 
Conference, Eskisehir, Turkey, June 2009. (Invited speaker, Dr. Ihsan Gürsel) 
 
15. Gursel I, Tincer G, Yagci FC, Mammadov R, Kocak H, Kahraman T, Karatepe K, 
Erikci E, Gursel M. “Immunotherapeutic applications of DNA nanoparticles to cancer, 
infectious and autoimmune diseases”. 13th National Biomedical Engineering 
Conference, Ankara, Turkey, May 2008 . (Invited speaker, Dr.Ihsan Gürsel) 
 
16. Gursel I, Tincer G, Yagci FC, Mammadov R, Kocak H, Kahraman T, Karatepe K, 
Erikci E, Gursel M. “Immune activation by CpG oligodeoxynucleotides”. XX. National 
Biochemistry Congress, Nevsehir, Turkey, November 2008. (Invited speaker, Dr.Ihsan 
Gürsel) 
 
17.Gursel I, Yagci FC, Tincer G, Gursel M. “DNA Nanoparticles: Novel 
Immunomodulatory Adjuvants for Immunotherapy”. World Immune Regulation Meeting-II, 
Davos, Switzerland, March 2008. (Poster Presentation) 
 
18. Yagci FC, Biterge B, Yazar V, Bahcecioglu G, Gursel I. “Nanoparticle Forming TLR 
Antagonist as Potential Nanodrugs to Treat Autoimmune Diseases”. 13. Biomedical Science 
and Technology Symposium, P90, Istanbul, Turkey, June 2007. (Poster Presentation) 
 
19. Akis N, Aydin Z, Tezil T, Yagci FC, Kahraman S, Endothelial Cell Protective Gene 
Expression. 2nd Modern Drug Discovery & Development Summit Abstract Book, 3, 
Philadelphia, USA, 2006. (Poster Presentation) 
Yağcı, F.C. 
 146 
 
PARTICIPATED CONGRESSES 
 
Certificate of Participation “Winter School on Frontiers in Nanomedicine and 
Nanobiotechnology”, Bilkent University, Ankara, Turkey, January, 2010. 
 
Certificate of Participation. “9th European School of NeuroImmunology”, Istanbul, 
Turkey, September, 2009. 
  
Certificate of Participation. “1st Congress of the Society of Innate Immunity”, Ankara, 
Turkey, June 2007. 
  
Certificate of Participation. “31st FEBS Congress, Molecules in Health and Disease”, 
İstanbul, Turkey, 24-29 June 2006. 
  
Certificate of Participation. “First Molecular Medicine Congress”. Hilton Convention 
Center, Istanbul, Turkey, April 2005. 
  
Certificate of Participation. “XVI. National Cancer Congress”. Pine Beach City, Antalya, 
Turkey, April 2005. 
  
Certificate of Participation. “9. National Biology Students Congress”, Abant Izzet Baysal 
University, Bolu, Turkey, November 2002. 
 
SOCIETY MEMBERSHIPS 
 
American Association of Immunologists- Student Member 
Turkish Society of Immunology  
Turkish Neurology Society 
Biomaterial and Tissue Engineering Society 
 
Mammalian Telomeric DNA Suppresses Endotoxin-induced
Uveitis*□S
Received for publication,March 22, 2010, and in revised form, June 16, 2010 Published, JBC Papers in Press, July 14, 2010, DOI 10.1074/jbc.M110.125948
Fuat C. Yagci‡1, Ozlem Aslan§1, Mayda Gursel¶, Gizem Tincer‡, Yasemin O¨zdamar§, Kutay Karatepe‡, K. Can Akcali‡,
and Ihsan Gursel‡2
Fromthe ‡BiotherapeuticOligonucleotide Laboratory,Department ofMolecular BiologyandGenetics, ¶Merkez Lojmanlari, Bilkent
University, 06800Ankara, Turkey, and the §Ministry ofHealth,Ulucanlar EyeResearchandEducationHospital, 06240 Ankara, Turkey
Telomeric regions of mammalian chromosomes contain sup-
pressive TTAGGG motifs that inhibit several proinflammatory
and Th1-biased immune responses. Synthetic oligodeoxynucle-
otides (ODN) expressing suppressive motifs can reproduce the
down-regulatory activity of mammalian telomeric repeats and
have proven effective in the prevention and treatment of several
autoimmune and autoinflammatory diseases. Endotoxin-in-
duced uveitis (EIU) is an established animalmodel of acute ocu-
lar inflammation induced by LPS administration. Augmented
expression of proinflammatory cytokines/chemokines such as
TNF, IL-6, andMCP1 and bactericidal nitric oxide production
mediated by LPS contribute to the development of EIU. Sup-
pressing these mediators using agents that are devoid of unde-
sirable systemic side effects may help prevent the development
of EIU. This study demonstrates the selective down-regulatory
role of suppressive ODN after (i) local or (ii) systemic treatment
in EIU-induced rabbits and mice. Our results indicate that sup-
pressive ODN down-regulate at both the transcript and protein
levels of several proinflammatory cytokines and chemokines as
well as nitric oxide and co-stimulatory surface marker mole-
cules when administrated prior to, simultaneously with, or even
after LPS challenge, thereby significantly reducing ocular
inflammation in both rabbit and mouse eyes. These findings
strongly suggest that suppressive ODN is a potent candidate for
the prevention of uveitis and could be applied as a novel DNA-
based immunoregulatory agent to control other autoimmune or
autoinflammatory diseases.
DNA and RNA are the essential components of all living
organisms. Accumulated evidence strongly suggests that these
nucleic acids havemultiple and complex effects on the immune
system and aremore than a blueprint of life (1, 2). On one hand,
due to their high unmethylated CpGmotif frequency, bacterial
DNAs are recognized as “non-self” via TLR9 (Toll-like receptor
9) and trigger an innate immune response characterized by the
proliferation and maturation of B cells, natural killer cells, and
plasmacytoid dendritic cells and the secretion of T-helper
1-type cytokines, chemokines, and/or multivalent immuno-
globulins (3–8). On the other hand, telomeric regions of mam-
malian chromosomes contain suppressive TTAGGG motifs
that can inhibit several TLR-dependent and TLR-independent
Th1-mediated immune responses. Of note, these motifs are
underrepresented in the prokaryotic genome. Synthetic single-
stranded oligodeoxynucleotides (ODN)3 containing repetitive
TTAGGG motifs mimic this effect (1, 9–11). Previous studies
revealed that deleterious inflammatory responses to a host can
be down-regulated by suppressive ODN. In vitro, suppressive
ODN inhibits the production of several proinflammatory cyto-
kines and chemokines induced by bacteria (1, 12–14). Further-
more, in vivo suppressive ODN administration reduces the fre-
quency and severity of several autoimmune and inflammatory
diseases such as arthritis, systemic lupus erythematosus, pul-
monary inflammation, toxic shock, silicosis, and experimental
autoimmune encephalomyelitis (10, 15–21).
Uveitis is an ophthalmic disorder that causes vision loss in
developed countries (22, 23) and is characterized by acute,
recurrent, or persistent ocular inflammation, the breakdown of
the blood-ocular barrier, and infiltration of leukocytes (24). The
underlying causes of uveitis can vary. For example, acute ante-
rior uveitis is often associated with (i) Behcet disease, (ii) Reiter
syndrome, and (iii) ankylosing spondylitis, as well as other sys-
temic inflammatory diseases (25).
Endotoxin-induced uveitis (EIU) is an established animal
model of acute ocular inflammation. It is triggered by the
administration of LPS, which is a component of the Gram-neg-
ative bacterial outer membrane (26). A ligand for TLR4, LPS
enhances the expression of various proinflammatory cytokines
and chemokines such as IL-6 (27, 28), TNF (29), and MCP1
(monocyte chemoattractant protein 1) (30) and the production
of nitric oxide. All of these mediators contribute to the break-
down of the blood-ocular barrier and infiltration of leukocytes,
resulting in the development of EIU (26). It has been shown that
suppressing proinflammatory cytokines, including IL-6, TNF,
MCP1, and inducible nitric-oxide synthase (iNOS), retards if
not prevents the development of EIU (31). Conventional drugs
used to control these concerted inflammatory activation are
mainly immunosuppressive in character and are associated
with undesirable systemic side effects (24). It is of the utmost
importance to develop effective, less toxic agents that selec-
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tively block proinflammatory immune activation while elimi-
nating the unwanted systemic side effects.
To date, the inhibitory effect of suppressive ODN on LPS-
mediated EIU at both the local and systemic levels has not been
studied by others. In this study, a very aggressive form of exper-
imental uveitis was initiated via endotoxin administration. We
investigated whether the suppressive ODN “A151” can inhibit
the induction and development of ocular inflammation (before
or at the time of LPS insult or even 2 h after LPS treatment) and
help to reduce the symptoms of EIU in rabbits and mice. Our
results revealed, for the first time, that A151 is capable of down-
regulating the mRNA expression and protein levels of several
potentially pathologic chemokines and cytokines at both the
local and systemic levels. Consequently, suppressive ODN
mimicking telomeric DNA offers a novel nucleic acid-based
immunotherapeutic agent to control overexuberant undesir-
able immune responses such as seen in autoimmune and auto-
inflammatory diseases.
EXPERIMENTAL PROCEDURES
Materials—All cell culture medium components were from
HyClone. Cytokine pairs for ELISAs were from Endogen.
LPS (isolated from Escherichia coli) was obtained from
Sigma. The phosphorothioate-modified suppressive ODN
A151 (24-mer, 5-(TTAGGG)4-3) and control ODN (24-
mer, 5-(TTACCC)4-3) were obtained from Alpha DNA
(Montreal, Canada). TRIdity G (AppliChem GmbH, Darms-
tadt, Germany) was used for RNA isolation. cDNAs were
synthesized using a DyNAmoTM cDNA synthesis kit
(Finnzymes, Espoo, Finland) according to the manufac-
turer’s protocol. DyNAzymeTM PCR Master Mix was used
for PCRs.
Maintenance of Animals—Adult female BALB/c mice and
adult New Zealand rabbits were used for the experiments. The
animals were kept in the animal holding facility of the Depart-
ment of Molecular Biology and Genetics at Bilkent University
under controlled conditions at 22 °C with 12-h light and 12-h
dark cycles. They were provided with unlimited access of food
and water.
Induction of Endotoxin-induced Uveitis—Specific pathogen-
free 10-week-old female BALB/c mice were injected intraperi-
toneally with 25, 50, 100, or 200 g of LPS in 200 l of PBS
and/or suppressive ODN.Mice were killed at the end of clinical
evaluation. Both eyes were enucleated and used for cytokine
expression assays. Spleens were removed and split in two;
splenocytes were incubated on tissue culture plates for 6, 12,
and 24 h; and supernatants were collected for cytokine deter-
mination by ELISA. IL-6 was measured as an indicator of EIU
response. The other half of the spleen was used to extract total
RNA for further cytokine/chemokine gene transcript expres-
sion analysis by RT-PCR. In another experiment, rabbits (three
to four animal/group,1500 g each; housed in theAnkaraHos-
pital animal facility) were separated into different treatment
groups, and EIUwas initiated via intraocular LPS injection (100
g) with or without suppressive ODN treatment. Eyes were
removed, and further analyses as described for mice were
conducted.
Clinical Evaluation and Histopathological Investigation—Ani-
mals were subjected to blind investigation by an ophthalmolo-
gist under a dissectionmicroscope 18–24 h after injection, cor-
responding to the time of maximal severity of EIU. Clinical
ocular inflammation was graded on a scale from 0 to 4 for each
animal described previously (32): no sign of inflammation 0;
discrete inflammation in iris and conjunctiva 1; dilatation of
iris and conjunctiva vessels  2; hyperemia in iris associated
with Tyndall effect in anterior chamber 3; in addition to the
signs in scale 3, synechia or fibrin is formed  4 (32). For his-
topathological investigations, enucleated eyeswere fixed in 10%
formalin for 24 h, washed with running tap water for 1 h, and
placed in 60% ethyl alcohol for an extra 3 h. Eyes were embed-
ded in paraffin, whichwas sectioned and stainedwith hematox-
ylin and eosin. Sections were examined blindly by a his-
topathologist, using score systems of severity ranging from 0 to
4. Focal non-granulomatous monocytic infiltration in the cho-
roid, the ciliary body and retina were scored as 0.5. Retinal
perivascular infiltration andmonocytic infiltration in the vitre-
ous were scored as 1. Granuloma formation in the uvea and
retina and the presence of occluded retinal vasculitis alongwith
photoreceptor folds, serous detachment, and loss of photore-
ceptor were scored as 2. In addition, the formation of Dalen-
Fuchs nodules (granuloma at the level of the retinal pigmented
epithelium) and the development of subretinal neovasculariza-
tion were scored as 3 and 4 according to the number and size of
the lesions (33).
Cytokine and IgM ELISAs and NO Assays—Immulon 2 HB
microtiter plates (Thermo Scientific) were coated with anti-
cytokine or anti-IgM antibodies (BD Pharmingen) and then
blocked with PBS and 1% BSA (1, 34). Serially diluted stand-
ards and culture supernatants or mouse sera were added to
these plates for 2 h. Cytokine was detected using biotinylated
anti-cytokine antibody followed by phosphatase-streptavi-
din (Perbio), whereas bound IgM was detected using phos-
phatase-conjugated anti-IgM antibodies (Southern Biotech-
nology Associates, Birmingham, AL) as described (1). Nitric
oxide detection by theGriessmethodwas conducted onmurine
peritoneal exudate cells (106/ml) after 12–36 h of ex vivo incu-
bation as described by the supplier (Promega).
Analysis of Cell-surface Molecule Expression by FACS—2 
106 spleen cells/ml were isolated from 24-h post-treated mice.
Cells were washed, fixed, and co-stained with one of the phy-
coerythrin-labeled anti-CD40, anti-CD86, and anti-ICAM-1
and FITC-labeled cell-specific antibodies (i.e. CD11c for den-
dritic cells, CD11b for macrophages, and B220 for B cells (BD
Pharmingen)) for 30 min at room temperature. Following
washing, they were studied using a FACSCalibur (BD Bio-
sciences) and analyzed with CellQuest Pro software.
Cytokine and Chemokine RT-PCR—Animals were injected
with LPS and/or suppressive ODN. Total RNA was extracted
from the eyes or spleens of the mice 4–6 h later (or from the
irises or corneas of the rabbits), reverse-transcribed, and ampli-
fied to obtain cDNA in a standard PCR for 30 cycles using
primers for mouse- or rabbit-specific target genes (Table 1) as
described previously (1, 34). PCR-amplified material was sepa-
rated on 1.5% agarose gels and visualized under UV light after
ethidium bromide staining.
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Statistical Analysis—Assays were performed in triplicate on
at least three to five different cell preparations. Statistical sig-
nificance between untreated (or control) and treated groups
was evaluated using Student’s t test.
RESULTS
EIU is an established animal model of acute ocular inflam-
mation. It is induced by either systemic or intravitreal
administration of LPS, the major component of Gram-neg-
ative bacteria. LPS acts through the TLR4-triggering proin-
flammatory signaling cascade. The expression of Th1 cyto-
kines and chemokines, including IL-6, IL-1, and MIP3
(macrophage inflammatory protein 3), contributes to the
development of EIU.
This study was performed with 82 mice and 26 rabbits. Initial
experiments were conducted to optimize the induction of EIU
(supplement Fig. 1). For themouse experiments, systemic admin-
istration of LPS doses between 25 and 100 g/mouse were suffi-
cient to induce uveitic eyes within 24 h as judged by clinical and
histopathological investigations (supplement Figs. 1 and 2). For
the rabbit experiments, intraocular 100-g LPS injection was
found to be optimal to induce EIU. Following local or intraperito-
neal LPS and or suppressive ODN administration, rabbit and
mouseeyeswere removed, andRNAs fromthe irises, vitreous, and
corneas of the rabbit eyes were obtained. PCR was run with the
cDNAfromeach sample, and themRNAlevels of IL-6, IL-15, IP10
(interferon--inducible protein 10), iNOS,MIP1, IL-18,MIP3,
CXCL16 (CXC chemokine ligand 16), MIP1, and IL-1 were
monitored. In addition, 24 h post-LPS and/or A151 treatment,
splenocyte suspensions were incubated ex vivo for 6–24 h,
and IgM, IL-6, IL-10, IL-12, and IFN levels from the super-
natants were determined by ELISA. FACS analyses were
conducted on spleen cells to monitor co-stimulatory/surface
marker molecule expressions.
The results indicated that in rabbits, suppressive ODN
administered before or after 100-g LPS treatment or co-in-
jected with LPS significantly down-regulated the expression of
IL-1message from the iris (Fig. 1A). In cornea, IL-6was down-
regulated when suppressive ODN was given before or simulta-
neously with LPS administration (Fig. 1B). There was no sig-
nificant inhibitory effect when A151 was given post-LPS
treatment. In all these experiments, the mRNAmessage reduc-
tion was suppressive ODN-dependent because control ODN
administration did not show any benefit for alleviation of LPS
reactogenicity.
TABLE 1
Oligonucleotide PCR primers used in mouse or rabbit experiments
m, mouse; rb, rabbit.
Primer Forward Reverse Product
bp
m-actina GTATGCCTCGGTCGTACCA CTTCTGCATCCTGTCAGCAA 450
mIP10a GCCGTCATTTTCTGCCTCAT GCTTCCCTATGGCCCTCATT 127
miNOSa CAGCTGGGCTGTACAAACCTT CATTGGAAGTGAAGCGTTTCG 95
mMIP1b ACCATGACACTCTGCAACCA AGGCATTCAGTTCCAGGTCA 238
mIL-5a AGCACAGTGGTGAAAGAGACCTT TCCAATGCATAGCTGGTGATTT 117
mIL-15a CATCCATCTCGTGCTACTTGTGTT CATCTATCCAGTTGGCCTCTGT 126
mIL-18b GATCAAAGTGCCAGTGAACC ACAAACCCTCCCCACCTAAC 384
mMCP1b AGGTCCCTGTCATGCTTCTG TCTGGACCCATTCCTTCTTG 249
mMIP3b CGTCTGCTCTTCCTTGCTTT CCTTTTCACCCAGTTCTGCT 250
mCXCL16b CCTTGTCTCTTGCGTTCTTC GGTTGGGTGTGCTCTTTGTT 384
mMIP1b CCAGCTCTGTGCAAACCTAA CTGTCTGCCTCTTTTGGTCA 250
rbGAPDHc TCACCATCTTCCAGGAGCGA CACAATGCCGAAGTGGTCGT 319
rbIL-6c GCTCCTGGTGGTGGCTAC GGGTGGCTTCTTCATTCAAA 450
rbIL-1c GCCGATGGTCCAATTACAT ACAAGACCTGCCGGAAGCT 121
a Taken from Ref. 43.
b In house-designed primers.
c Taken from Ref. 44.
FIGURE 1. Suppressive A151ODNadministration after LPS challenge sig-
nificantly down-regulates IL-1 and IL-6 expression in the iris and cor-
nea, respectively.Rabbitswere injected intraocularlywith 100gof LPS and
250 g of suppressive ODN. The average of densitometric measurements of
four animals for IL-1 mRNA from iris (A) and IL-6 mRNA from cornea (B) is
shown. Insets are the representative gel image of each group labeled from
untreated to A151 and then LPS as 1 to 6. *, p  0.05; **, p  0.01 between
LPS-treated and A151 ODN-co-administered groups.
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In the murine EIU model, mice tolerated up to 100-g LPS
intraperitoneal treatment. Doses 150 g caused animals to
succumb to endotoxin treatment. The mouse experiments
were conducted with three doses of LPS: 25, 50, and 100 g.
SuppressiveA151ODNand controlODN (2 h before and at the
time of LPS injection and 2 h after LPS treatment) were used in
the range of 100–250 g. Although in rabbits, the injection of
ODN and endotoxin was intraocular, in mice, injections were
given intraperitoneally in 200 l of PBS.
The results showed that when 250 g of suppressive ODN
was administered before LPS injection (2 h), it significantly
down-regulated the expression of IP10, iNOS, MIP3,
CXCL16, and MIP1 in the 100-g LPS-injected mouse EIU
model (Figs. 2, A and B). Other cytokines such as MIP1 and
IL-18 also showed substantial but insignificant down-regula-
tion at these doses (data not shown). To understand the sys-
temic effect of suppressive A151, IL-6 secreted from murine
splenocytes after ex vivo incubation for up to 24 h in culturewas
monitored by ELISA (Fig. 3). Our results revealed that suppres-
sive ODNwas able to reduce65% of the secreted IL-6 (430
70 and 135 55 ng/ml for LPS andA151 LPS groups, respec-
tively). Co-administration of suppressiveODNwith LPS signif-
icantly decreased cytokinemRNA levels in vivoor cytokine pro-
duction in ex vivo spleen cells (p 0.01) (Figs. 2 and 3). These
effects were attributable to the activity of suppressive motifs
because control ODN did not reduce the cytokine production
elicited by co-administered LPS (Figs. 1–3).
The (TTAGGG)4 multimers inhibited LPS-dependent up-
regulation of co-stimulatory and surface marker molecules on
antigen-presenting cells (CD40, CD86, and ICAM-1), IgM pro-
duction by B cells, and NO release from peritoneal macro-
phages (p  0.01) (Fig. 4). Furthermore, co-administration of
LPS (50g)withA151ODN (250g) inhibited65%of several
immunoregulatory and inflammatory cytokines (i.e. IL-6,
IL-10, and IL-12; p  0.001) (Fig. 4). This reduction reached
85% for IFN (176 29 and 26 15 ng/ml for LPS andA151
LPS groups, respectively).
DISCUSSION
In this study, we examined the effect of synthetic telomeric
repeat units (suppressive A151 ODN) localized at the end of
mammalian chromosomes on EIU, which is an established ani-
mal model of acute ocular inflammation in both mouse and
rabbit models. The results indicated that suppressive ODNwas
able to down-regulate the expression and protein levels of sev-
eral proinflammatory and immunoregulatory cytokines/che-
mokines at local and systemic levels when administrated (i)
prior to, (ii) simultaneously with, or (iii) even after LPS chal-
lenge (Figs. 2–4).
FIGURE 2. A, suppressive A151 ODN treatment after 100-g LPS challenge
significantly down-regulates IP10, MIP3, iNOS, MIP1, and CXCL16 expres-
sion levels in the eyes of mice. Mice were injected intraperitoneally with 100
gof LPS and250gof suppressiveODNand killed 18h after injection. *,p
0.05; **,p0.01between LPS-treated andLPSA151ODN-co-administered
groups. B, representative gel image.
FIGURE 3. Suppressive A151 ODN administration significantly sup-
presses IL-6 release from murine splenocytes.Mice were injected intrap-
eritoneally with 100 g of LPS and 250 g of suppressive or control ODN as
further indicated. Spleen cells were removed (24 h post injection) and incu-
bated 6–24 h, and supernatants were collected for cytokine ELISA. IL-6 was
measured as an indicator of EIU response. *, p 0.05, between LPS and LPS
A151 groups.
FIGURE4. Inhibitoryeffect of suppressiveODNonLPS-mediated immune
activation. The levels of CD40, CD86, and ICAM-1 expression (mean fluores-
cence intensity)were determinedby FACS 24h after in vivo injection of LPS or
LPS plus A151 (50 g of LPS and 250 g of ODN). IL-6, IL-10, IL-12, IFN, and
IgM levels in culture supernatantsweredeterminedbyELISA following36hof
ex vivo incubation. The Griess method was used to detect nitric oxide in
isolated peritoneal exudate cells supernatants 24 h post-treatment. % Sup-
pression was calculated by the following formula: (1	 ((activation by LPS
suppressive ODN) 	 (background)/(activation by LPS  control ODN) 	
(background))) 100.
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Compared with local injection of (intraocular) LPS and/or
LPS- and control ODN-treated rabbits, suppressive ODN-ad-
ministrated animals exhibited reduced levels of IL-1 and IL-6
expression in the iris and cornea, respectively. In the mouse
model, the results revealed that pretreatment with 250 g of
suppressive ODN reduced the expression of IP10, iNOS,
MIP1, IL-18, MIP3, CXCL16, and MIP1 in 100-g LPS-
injected mice. In another experiment, with different doses of
suppressive ODN and LPS, suppressive ODN also down-regu-
lated the expression of MCP1, which is an important chemo-
kine formonocyte chemoattraction (data not shown). The sup-
pressive action of this class of ODNwas not only on the mRNA
levels of several Th1-type cytokines and chemokines but also on
the secreted protein level. ELISA experiments showed that sup-
pressive ODN pre- and post-treatments significantly dimin-
ished IL-6 secretion at 6 and 24 h; simultaneous administration
of suppressive ODN also reduced IL-6 production.
Several studies indicated that suppressing proinflammatory
cytokines, including IL-6, TNF, MCP1, and iNOS, prevents
the development of EIU (26, 29, 30, 31). Here, we have shown
that either local (intraocular) or systemic (intraperitoneal)
administration of suppressive A151 ODN can significantly
reduce several proinflammatory cytokines and chemokines
even 2 h after in vivo LPS challenge.
Corticosteroids and chemotherapeutic agents are currently
in use in uveitis therapy (35). However, long-term treatment
with these drugs may have grave side effects such as increased
intraocular pressure (36) and cytotoxicity (37) and thus limit
their use (25, 33, 35). Therefore, a new therapeutic strategy is
urgently needed (38, 39). Themechanism of action of this novel
ODN-based immunosuppressive drug candidate is currently
unknown. Previous studies revealed that suppressive ODN can
inhibit immune response by blocking the stimulatory effects of
CpGmotifs (1, 15). It also has been shown by Shirota et al. (10)
that suppressive A151 ODN can also protect mice from lethal
endotoxic shock that is induced by LPS. It has been shown that
suppressive ODN can also inhibit several signal transduction
cascades related to the production of Th1 cytokines such as
IFN and IL-12 by binding and inhibiting the phosphorylation
of STAT1 (signal transducer and activator of transcription 1)
and STAT4 proteins (10, 13). Our study has demonstrated that
suppressive ODN can block immune responses mediated by
endotoxin in the eye (an immune privileged site), an established
animalmodel of acute ocular inflammation. Recently, Fujimoto
et al. (40) reported that suppressive A151 ODN can inhibit
ocular inflammation in two murine models, IRBP (interpho-
toreceptor retinoid-binding protein)-induced experimental
autoimmune uveitis and adoptively transferred ocular in-
flammation. These forms are antigen-driven and, compared
with LPS, are significantly less aggressive forms of experimental
uveitis models. The control of LPS-mediated EIU at both the
local and systemic levels has not been studied by others and
increases the breadth of the suppressive ODN-mediated ther-
apy for the eye. Collectively, these observations support the
provocative possibility that the evolutionary expansion of
TTAGGG repeats in telomeres, in addition to known proper-
ties such as, protecting genomic DNA from degradation, and
chromosome capping (41, 42)may also be linked to their ability
to down-regulate sustained/pathologic microbe-associated
molecular pattern-induced immunity. In conclusion, we have
provided evidence that suppressive A151ODN is able to signif-
icantly reduce the ocular inflammatory responses in both rabbit
and murine EIU models.
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a b s t r a c t
Immunostimulatory properties of mushroom derived polysaccharides (PS) as stand-alone agents were
tested. Next, PS were nanocomplexed with polyI:C (pIC) to yield stable nanoparticles around 200 nm in
size evidenced by atomic force microscopy and dynamic light scattering analyses. PSs were selectively
engaged by cells expressing TLR2 and initiated NFkB dependent signaling cascade leading to a Th1-
biased cytokine/chemokine secretion in addition to bactericidal nitric oxide (NO) production from
macrophages. Moreover, cells treated with nanoparticles led to synergistic IL6, production and upre-
gulation of TNFa, MIP3a, IFNg and IP10 transcript expression. In mice, PS-Ovalbumin-pIC formulation
surpassed anti-OVA IgG responses when compared to either PS-OVA or pIC-OVA mediated immunity.
Our results revealed that signal transduction initiated both by TLR2 and TLR3 via co-delivery of pIC by PS
in nanoparticle depot delivery system is an effective immunization strategy. The present work implicate
that the PS and nucleic acid based nanoparticle approach along with protein antigens can be harnessed
to prevent infectious diseases.
 2011 Elsevier Ltd. All rights reserved.
1. Introduction
Toll-like receptors (TLRs) are the most extensively studied
pathogen recognition receptors (PRRs) that recognizes speciﬁc
microbial associated molecular patterns (MAMPs) including lipo-
polysaccharides, peptidoglycans, lipoproteins, ﬂagellin, unmethy-
lated CpG motifs or viral RNA/DNA that triggers innate immune
response [1e3]. TLRs are subcategorized as endosomal or intracel-
lular receptors dependingon their site of expression. TLR3, 7/8 and 9
are specialized to sense pathogens via their nucleic acids moieties
[4]. TLR3, a member of endosome-associated TLR is activated
directly in response to dsRNA, or synthetic poly(riboinosinic:polyr-
ibocytidylic acid) (pIC) [5] and are harnessed as vaccine adjuvant,
anti-cancer or anti-allergic therapeutic agents. When these ligands
are given in vivo, they are rapidly cleared by nucleases, and could be
adsorbed by serum proteins hampering their in vivo therapeutic
applications [6]. In order to improve their immune stimulatory
potential repeated high doses are necessary, however, in many
instances this may cause undesirable side effects including septic
shock [7]. Nucleic acid backbone modiﬁcations such as phosphor-
othioate linkages are another widely accepted approach but this not
only induces undesirable side effects such as granuloma formation,
temporary splenomegaly, and lymphadenopathy but also increases
the cost of the ﬁnal product [8e11].
Several strategies were proposed as carriers for labile nucleic
acids attempting to increase their in vivo performances [12e14].
Among many, liposome encapsulation, biodegradable nano/micro
carriers and soluble macromolecules with cationic moieties were
widely studied [12e14]. We and others demonstrated that, uptake,
duration and in vivo immunostimulatory activity of oligodeox-
ynucleotides enhanced when encapsulated in sterically stabilized
cationic liposomes (SSCL) [15e17]. Although co-administration of
pIC with liposomes induced anti-viral immunity and activated
effective CD8þ T cells in vivo [18], still several obstacles prevent
these depot delivery systems enter into clinic. Of note, batch to
batch variation, limited shelf-life, difﬁculty in reproducible recon-
stitution and sterility are the major concerns from FDA stand point.
Furthermore, organic solvents used during the production of
certain formulations are of major concern [19e21].
In the present study, natural amphiphilic polysaccharides puriﬁed
from mushrooms were studied to assess their immunostimulatory
Abbreviations: AFM, Atomic Force Microscopy; BMDC, Bone marrow derived
dendritic cell; HEK, Human embryonic kidney; NOD, Nucleotide-binding oligo-
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potential. Later, a nanoparticle delivery system was formulated to
efﬁciently harbour pIC. The TLR2 mediated PS targeting and subse-
quent initiation of signal transduction cascade and ability of the
nanoparticles to inducesynergistic immuneactivationwasevaluated.
Furthermore, inan immunizationstudy inmiceco-deliveringamodel
protein antigen ovalbumin (OVA), immunogenicity of PS-OVA-pIC
nanoparticles was compared to either PS-OVA or pIC-OVA mediated
immune response.
2. Materials and methods
2.1. Materials
All cell culturemedia components were fromHyclone (USA). Cytokine, IgG ELISA
were from Endogen and Southern Biotech, respectively (USA). TLR ligands were
obtained from several vendors: peptidoglycan (PGN) (Fluka, Switzerland), pIC
(Amersham, UK). b-Glucan based polysaccharides were provided by Prof. Oktay
Erbatur (Cukurova University, Chem Dept., Adana, Turkey). A high pressure/high
temperature stainless steel reactor (Parr 4575 HT/HP) with 500 ml volumewas used
for extraction of polysaccharide at subcritical water conditions from different
mushrooms. The sugar content of the extracts was determined by HPLC (Varian
Prostar210, equipped with a RI detector) against monosaccharide standards and
protein determination by Lowry assay. Monosaccharide analyses of the PS yielded
mainly glucose, in addition to mannose and galactose. The purity was found to be
>93%. Following protease digestion to eliminate protein contamination purity
reached over 97%. Molecular weight determination was carried out by high
performance size exclusion chromatography (on a HPSEC-MALLS system). In this
study, polysaccharides were abbreviated as PS1 to PS4. Their physicochemical
characteristics were as follow: i) Ganoderma lucidum (Alata strain)-PS1 (Ave. MWt:
2.9  106 Da and pKa: 6.64), ii) G. lucidum (Balcalı strain)-PS2 (Ave. MWt:
3.8  106 Da and pKa: 6.99), iii) Shiitake-PS3 (Ave. MWt:1.6  106 Da and pKa: 6.67),
and iv) G. lucidum (Alata strain)-PS4 (Ave. MWt: 5.2  106 Da and pKa: 6.69).
Endotoxin levels for all PSs were checked by LAL assay and were found to be
undetectable (minimum detection limit of the assay was 0.01 EU/ml). PS nano-
complexes with pIC (1:1 w/w, PS:ligand ratio) were prepared overnight at 4 C.
Unbound pIC was ﬁltered (Microspin G-25 column) free nucleic acid concentration
was measured by Nanodrop from the eluent. pIC incorporationwas over 90% in all
preliminary trials.
2.2. Mice
Adult C57BL/6 and BALB/C mice (female, 6e8 weeks old) were housed in
Department of Molecular Biology and Genetics, facility and were provided with
unlimited access of food and water. All experimental procedures were approved by
the animal ethical committee of Bilkent University (Bil-AEC/Protocol#: 2006/027).
RAW 264.7 cells (ATCC) or splenocytes were culturedwith RPMI 1640 supplemented
with 5% FBS, 50 mg/ml penicillin/streptomycin, 2 mM L-glutamine, 10 mM HEPES
buffer, 0,11 mg/ml sodium pyruvate. HEK 293 or stably hTLR2 transfected cells
(Invivogen, USA), were kept in high-glucose DMEM media with 10% FBS,
2.3. Immunization
Adult female C57/BL6 mice (5/group) were injected ip with of PS, pIC (15 mg
each) or PS-pIC nanocomplex combined with 7.5 mg of OVA. One day before booster
injection (@d ¼ 13) animals were bled and next day injected with the same
formulations. On day 28 mice were bled. Sera from the primary and secondary
bleedings were studied for total IgG, IgG1, and IgG2a by ELISA.
2.4. ELISA and NO assays
Immulon 2 HB microtitre plates (Thermo Scientiﬁc, USA) were coated with anti-
cytokine or anti-IgG antibodies and then blocked with PBS-BSA 1% [17,35]. Serially
diluted standards and culture supernatants or mouse sera were added to these
plates for 2 h. Cytokine was detected using biotinylated anti-cytokine Ab (TNFa:
XT22 and IL6: 2OF3 clones) followed by phosphatase-streptavidin (Perbio Pierce,
USA) whereas bound IgG subclasses were detected using phosphatase-conjugated
anti-IgG, IgG1, and IgG2a antibodies as described elsewhere [17]. Nitric oxide
detection by Griessmethodwas conducted on RAW264.7 cells (105/ml) after 6e48 h
of incubation as described by the suppliers (Promega WI, USA).
2.5. Luciferase assay
hTLR2 expressing HEK cells were transfected using FuGENE6 with p5xlucNFkB
luciferase as described inmanufacturer’s protocol. Following overnight stimulations,
cells were further incubated for 24e36 h and were harvested and assayed for
luciferase activity (Roche, Germany). Plots were generated from relative light units.
2.6. Cytokine and chemokine RT-PCR
Total RNA was extracted from the cells that were treated either with PS or with
pIC nanocomplexes for 2e6 h. They were reverse-transcribed and ampliﬁed to
obtain cDNA in a standard PCR reaction for 30 cycles using primers for murine
speciﬁc target genes (Supplementary Table S2) as previously described [35,36]. PCR
ampliﬁed material was separated on 2% agarose gels and visualized under UV light
after ethidium bromide staining.
2.7. Atomic force microscopy (AFM) and size measurement studies of the
nanocomplexes
pIC, PS4 and their nanocomplexes were diluted in DNase/RNase free H2O and
were deposited on silicon wafer. Following complete drying images were taken by
using non-contact mode XE-100E model AFM (PSIA with XEI 1.6 software incorpo-
rated) with a 0.73e0.79 Hz scanning rate. The scanning area sizes were in 1  1 mm.
Particle size analyses of the generated nanocomplexes were measured using dynamic
light scattering method on a zetasizer (Model: Nano ZS, Malvern, UK).
2.8. Statistical analysis
Statistical signiﬁcant differences between groups were determined using
Student’s t- test analysis via SigmaSTAT software. P values < 0.05 were considered
signiﬁcant.
3. Results
3.1. TNFa and nitric oxide production by polysaccharides
Initial experiments were designed to understand the immu-
nostimulatory potential of the four PS candidates in dose-titration
(20e0.02 mg/ml) assays. A well established positive control pepti-
doglycan (PGN) was run in parallel to compare the response raised
by b-Glucan polymers. Fig. 1 shows that when RAW cells were
treated with different PSs for 24 h, a dose dependent TNFa (Fig. 1A)
and NO (Fig. 1B) production were induced especially by PS2 and
PS4. PS4 was the most active among other tested PSs at doses
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Fig. 1. Dose dependent TNFa, and NO, induction from RAW cells following 24 h post-
stimulation with different b-Glucan polymers. A) TNFa and B) NO were detected by
ELISA and Griess assay, respectively from cell supernatants. Result represents combi-
nation of at least two independent experiments (mean  SEM) of triplicate samples
treated with different stimulants (0.02e20 mg/ml). PS4 vs PS2 comparison gave
a p < 0.001 for TNFa (at all doses) and p < 0.004 for NO (at 0.02 mg/ml).
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greater or equal to 0.2 mg/ml (Fig. 1A). In the case of NO induction
PS4 was superior (at all doses) than the rest of the stimulants
including positive control PGN (Fig. 1B).
3.2. PS mediated upregulation of various cytokine/chemokine
transcripts
To examine the kinetics of PS driven immune activation RAW cells
were incubatedwith different b-Glucan stimulants. The culture ﬂuids
collected at different time intervals (6, 12, 24, 36, and 48 h after
stimulation) after 2 mg/ml PS treatments were assayed for TNFa
(Fig. 2A) and bactericidal mediator NO (Fig. 2B). As seen in Fig. 2A, as
early as 6 h post-stimulation all PS types secreted substantial amount
of TNFa. Among the testedgroups, only PS4 typecontinued to increase
TNFa level by 48 h. Similarly, nitric oxide secretionproﬁles of different
PStypesgavea time-dependent response.Again, consistentwithFig.1,
only PS2 and PS4 (Fig. 2B) displayed time-dependent NO production
frommacrophages. Also these b-Glucans’ effects on mRNA transcript
upregulation of TLRs as well as various cytokines were assessed after
4 h incubation. When TLR transcript levels of an untreated mouse
splenocyteswere compared to thatof PS treated cells’ transcript levels
PS2 and PS4 treatment highly upregulated expression of tlr1, 2, 5, 7,
and 9 genes (Supplementary Figure S1A). Moreover, compared to
untreatedvs PS treated cells,mRNAband intensities for il-15, il-18,and
TNFa signiﬁcantly increasedonlyuponPS4 treatment (Supplementary
Figure S1B). These results suggested that PS4 and then PS2 poly-
saccharides were the most potent stimulants.
3.3. Engagement of PS by TLR2
Several b-Glucan polymers were reported to trigger signaling
cascade either using cell surface expressed TLR2 (alone or engaging
TLR1 or TLR6), TLR4 or even cytosolic sensors such as NOD1 and
NOD2 [22,31]. To differentiate between these alternatives HEK cells
stably expressing hTLR2, hTLR4 or TLR2/6 genes were transfected
with p5xlucNFkB and in subsequent experiments co-transfected
with pcDNA3NOD1 or pcDNA3NOD2 or mock plasmids to check
whether these PS polymers either engages only through TLRs or
additionally interact with the cytosolic NOD sensors. In Fig. 3,
NFkB-mediated luciferase activity studies demonstrated that PS
triggers via TLR2 receptor (Fig. 3A) and furthermore regulates IL8
production (Fig. 3B). Expression of TLR6 did not improve TLR2
mediated promoter activation (data not shown). Consistent with
previous results, PS4 is the most potent inducer. Of note, other TLRs
or NODs were not contributing to this immune cascade since
subsequent experiments demonstrated that there was no further
signiﬁcant increase (either luciferase activity or IL8 production)
mediated by PS treatment of cells expressing TLR4, or NOD1 or
NOD2 (data not shown).
3.4. PS4 activity upon in vivo administration to mice
These four PSs were given to mice (2 mg/ml) and 6 h later PEC
and spleen cells were recovered and incubated in culture without
further stimulation to evaluate cytokine production or chemokine
message transcript upregulation by ELISA and RT-PCR, respectively.
Consistent with previous observations, PS4 was the most active
stimulant among the tested polysaccharides. It yielded the highest
IL6 production fromPECs after 48 h ex-vivo incubation (Fig. 4A). The
spleen cells TNFa and IP10 transcript levels were signiﬁcantly
upregulated when PS1, 2, and 3 vs PS4 band intensities were
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Fig. 2. Time dependent TNFa, and NO release by RAW cells following different PS
treatments at 2 mg/ml. A) TNFa and B) NO levels were assessed by ELISA and Griess
assay respectively. Result represents combination of at least three independent
experiments (mean  SEM) of triplicate samples treated at different time points (6 h,
12 h, 24 h, 36 h & 48 h). PS4 vs PS1, PS2 (except 12 h) or PS3 comparison gave
a p < 0.01 for TNFa (at all time points) and for NO, PS4 vs PS2 is NS, and PS4 vs PS1 or
PS3 is p < 0.001 (at all time points except 6 h).
A
0
1000
2000
3000
4000
5000
6000
e
v
i
a
N
1
S
P
2
S
P
3
S
P
4
S
P
N
G
P
S
P
L
)
y
t
i
v
i
t
c
a
e
s
a
r
e
f
i
c
u
L
(
U
L
R
B
0
50
100
150
200
250
300
350
e
v
i
a
N
1
S
P
2
S
P
3
S
P
4
S
P
N
G
P
S
P
L
)
l
m
/
g
n
(
8
L
I
Fig. 3. PS mediated promoter assay and IL8 production by hTLR2-HEK cells. A) Relative
luciferase activity after PS treatment of stable hTLR2-HEK cells. Cells were transfected
with p5xlucNFkB plasmid for 24 h and stimulated with 5 mg/ml of each PS for 12 h. B)
IL8 production following PS treatment. Stable hTLR2-HEK cells were stimulated with
5 mg/ml of each PS for 24 h. IL8 ELISA was studied from the culture supernatants. Data
represents combination of at least two independent experiments (mean  SEM) of
triplicate samples treated with different stimulants (PS1-4, PGN and LPS). PS4 vs PS1, 2,
3 and LPS gave a p < 0.001.
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compared, (Fig. 4B). Although previously PS2 activity in culture was
similar to PS4, surprisingly it failed to reproduce this trend when
administered in vivo. When in vitro and in vivo data are collectively
considered, among four tested PS candidates, PS4 consistently
displayed the highest immunostimulatory performance, and was
selected to develop PS4-pIC nanoparticles.
3.5. Physical characterization of PS4-pIC nanocomplexes
When nucleic acids are injected in vivo they are either subjected
to premature digestion by nucleases or adsorbed by serum proteins,
therefore, hampering their bioavailability. Accumulating evidence
strongly suggested that their in vivo applications are limited due to
their labile nature. Strategies to improve their stability as well as
retaining activity and facilitate their cellular internalization
without premature clearance are of great importance to pursue
these ligands into clinical use [15,17]. To establish whether PS4-pIC
complexes form stable nanoparticles their physical characteristics
by i) AFM and by ii) dynamic light scattering techniques (Zetasizer
Nano, ZS) were studied. AFMphotomicrographs revealed that PS4
appeared as individual nanoparticles around 50e70 nm in size
(Fig. 5). This was further conﬁrmed by Zetasizer and was found to
be ca. 40  20 nm (Ave  SEM) (Supplementary Figure S2). PS4
nanocomplex with pIC led to an increase in the nanoparticle size
from 40 nm to 165 nm (Supplementary Figure S2). The stability of
these nanocomplexes was also studied by dynamic light scattering
method using Zetasizer. There was no signiﬁcant change in the size
of the generated nanocomplexes over a period of two weeks indi-
cating that there was no spontaneous fusion (or disintegration) of
the individual particles when suspended either in PBS or in FBS
supplemented media (Supplementary Table S1, and data not
shown).
3.6. Synergistic immune activation by PS4-pIC nanoparticles
Next we analyzed the immunostimulatory effect of PS4 nano-
complexes harbouring one of the labile nucleic acid ligands, pIC.
Whether it improves pIC dependent immune activation to that of its
free form is of great interest. As presented in Fig. 6, PS4-pIC nano-
particles induced synergistic activation on both RAW264.7 ormouse
spleen cells upon in vitro or in vivo treatments. PS4epIC nano-
complexes led to a signiﬁcantly high IL6 production (Fig. 6 and data
not shown). It is important to note that pIC alone, when given at this
concentration could not produce any detectable IL6, however, the
nanoparticlesyielded125057ng/mlof IL6 secretion. Thisamount is
>6x fold more cytokine production to that of PS4 alone stimulation
(Fig. 6A left panel). Furthermore, macrophages stimulated by these
nanocomplexes induced very strong bactericidal mediator, NO
compared to either of the PS4 alone or pIC alone treatments
(Supplementary Figure S3). When spleen cells were incubated with
PS4-pIC nanocomplexes, the gene message levels of tnfa, il15, il18,
mip3a, and ip10 were signiﬁcantly upregulated (compared to either
PS4 alone or pIC alone treatments, Fig. 6B). The activity of these
nanocomplexes were further analyzed following ip injection of mice
(3/group) and checking IFNg transcript level from recovered spleen
cells (Fig. 6C). Consistently, PS4-pIC nanocomplex treated animals
displayed thehighest ifngmessage. These results stronglysupport the
synergistic activation mediated by the nanocomplex.
3.7. Immunization with PS4-pIC nanoparticles
To examine whether the PS4-pIC nanoparticles could act as an
effective immune adjuvant/delivery system, ovalbumin (OVA) was
loaded as the model antigen and C57BL/6 mice were immunized.
Primary and secondary bleeding sera were analyzed to detect the
levels of total IgG, IgG1 and IgG2a. As seen in Fig. 7, total IgG and
anti-OVA speciﬁc IgG subtypes were signiﬁcantly boosted by the
PS4-OVA-pIC nanoparticles when compared to dual combination
groups (i.e. pIC þ OVA or PS þ OVA). This was evident even after
primary immunization, since therewas 2e3-foldmore anti-OVA Ab
induction at 1/2000 antibody titre, (Fig. 7A). As expected, signiﬁ-
cantly higher magnitude of total IgG, IgG1 as well as IgG2a titers
were obtained after booster injection. In Fig. 7B, at titre 1/8000, all
IgG types were improved at least 2- fold and up when mice were
immunized with the nanocomplex. These data implied that
generated stable nanoparticles ensured simultaneous internaliza-
tion of the adjuvant (signal 1) and antigen (signal 2) by antigen
presenting cells (APCs), thereby led to stronger anti-OVA immunity.
4. Discussion
Natural polysaccharides extracted from mushrooms was shown
to activate host immune system leading to production of various
Th1-biased cytokines [23]. One approach to induce an improved
immune response is to ensure that these formulations achieve
simultaneous presentation of antigen and adjuvant to relevant
APCs. Developing such systems that act in synergy with the loaded
adjuvant may further improve the success of the therapy and help
host defence [14,24e26].
In this study, PS/Nucleic acid ligand nanocomplexes were
designed to solve several key problems associated with poor in vivo
performance. Polysaccharides used in this study are; i) naturally
occurring, readily available, easily extracted in bulk ii) cheap iii)
does not require sophisticated formulation technology as it is water
soluble iv) readily undergoes stable interaction with charged
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Fig. 4. In vivo immunostimulatory activity of polysaccharides. A) Six hours after i.p. PS
injection (2 mg/ml), PECs were isolated (3 mice/group). Cells (4  106/ml) were incu-
bated ex-vivo for further 24 h or 48 h, IL6 levels from supernatants were measured by
cytokine ELISA. Fold induction of IL6 production over naive cells was plotted (naive
cells induced 56  13 @ 24 h and 164  23 @ 48 h pg/ml IL6). B) mRNA levels of TNFa
and IP10 were assessed by RT-PCR from spleen cells. Densitometric measurements
(obtained from 3 independent mice) for the gel band intensities were plotted. PS4 vs
PS1, 2 and 3 gave a p < 0.001.
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macromolecules due to their amphiphilic nature v) effectively
engage by cells expressing TLR2 on their surface (i.e. natural tar-
geting), vi) the labile cargo is protected from premature degrada-
tion/elimination and ﬁnally vii) act as a co-adjuvant in vaccine
formulations along with the adjuvant to augment Ag-dependent
immune activation. Our ﬁndings strongly suggest that all these key
features are fulﬁlled by the developed formulation.
Recent studies showed that a natural b-glucan polysaccharide
isolated from Schizophyllan modiﬁed with peptides and cholesterol
formed a complex with TLR9 ligand, CpG ODNs and signiﬁcantly
elevated secretion of cytokines (IL12, IL6 and TNFa) from BMDCs,
and murine macrophages [27,28]. These compounds were proposed
to trigger several immune cells through various receptors including
complement receptor (CR3), scavenger receptors, as well as TLR4 or
TLR2/6 [29e32]. In other study,G. lucidum polysaccharides enhanced
CD14 mediated endocytosis of LPS and promoted TLR2/4 signal
transduction of cytokine expression [31].
Contrary to previous reports, our ﬁndings suggested that mush-
room derived PS polymers recognized only via TLR2 but not via TLR4
or TLR2/6. Furthermore, to date, there is no document reporting the
collaborative activation of TLR3 ligand with PS obtained from edible
mushrooms.Moreover, in thepresent studyplainPS compoundswere
used with no further modiﬁcation (i.e cholesterol or peptide). The
cytokine secretion panels (dose-dependent and time-dependent
ﬁndings) presented in Figs. 1 and 2 clearly suggested that PS4 is the
most potent stimulant. Moreover, in HEK cell system we established
that these PS types only interact with TLR2 (Fig. 3) but not with other
cell surface or cytosolic receptors (NOD1 or 2). In the literature,
receptor usage of PS is still elusive. This is probably due to the problem
associated with the extraction of PS from different sources. Similar
compounds were reported to trigger a group of immune cells
including macrophages, neutrophils, monocytes, natural killer cells
and dendritic cells through various receptors including Dectin-1 and
scavenger receptors [31,32]. We have attempted to delineate the
contribution of PS mediated activation via the scavenger receptor
CXCL16. It was found that it does not involve in PS mediated cytokine
production, since there was no up or down regulation of the cxcl16
gene transcript (Supplementary Figure S2).However, Dectin-1hasnot
been studied here, and must be checked to resolve its involvement.
We further assessed the nitric oxide production mediated by
different PS compounds. Since NO is an important regulator and
mediator of macrophage directed cytotoxicity against microbes and
tumour cells, detecting the most potent NO inducer as well as estab-
lishing thebreadthof activationpatternof PS4wasverycritical [33,34].
The results of in vitroﬁndingswere reproduced in vivo (Figs.1, 2 and4).
Among all tested PSs, consistently PS4 triggered the highest IL6
production in addition toNO secretion aswell as enhanced several key
cytokine/chemokine gene expression in PECs and splenocytes. This is
the ﬁrst example to demonstrate that a polysaccharide extracted from
mushrooms induced strong NO production from immune cells.
PS4-pIC nanoparticles supported the added effect of formulating
them as a carrier depot system. In addition to IL6 production by
Fig. 5. AFM photomicrographs of phase, 2D phase (left) and 3D topography (middle and right) images. A) PS4, B) pIC and C) PS4-pIC nanoparticles at 1000 nm2 area. Images were
recorded under contact mode.
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Fig. 6. PS-pIC nanoparticles induced higher IL6 production and strong gene upregulation of various cytokine and chemokines after in vitro and in vivo stimulations. A) RAW cell
supernatants from 36 h culture were analyzed by ELISA. Result represents combination of at least two independent experiments (mean  SEM) of triplicate samples. p < 0.002
nanocomplexes vs nucleic acid alone treated groups. B) After stimulation with PS4 (0.016 mg/ml) or PS4-pI:C (0.16 mg/ml each) for 4 h in culture, total RNA from spleen cells were
subjected to RT-PCR and cDNA were ampliﬁed against gene-speciﬁc primers. C) PS4-pIC nanoparticles (2 mg each) was injected to mice and spleen cells were recovered 18 h post-
treatment for IFNg transcript analyses (inlet; representative band intensities from a single animal). Band intensities were reported as average of 3 mice/group.
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immune cells compared to their alone treatments (Fig. 6A), data
also demonstrated that several cardinal chemokine and cytokine
mRNA messages were upregulated (Fig. 6B). The in vivo beneﬁt of
PS4-pIC nanocomplexes were documented in ex vivo study along
with model antigen immunization study. Data suggested that these
formulations could improve primary and booster immunity against
OVA antigen (Fig. 7). This is primarily due to the fact that, the
present formulation helped avoiding premature clearance and
digestion of its cargo as well as increased stability and efﬁcient
delivery of OVA þ adjuvant simultaneously to APCs, thereby
resulting more pronounced immune response.
5. Conclusions
The present work established that combination of mushroom
derived polysaccharide and pIC forms stable nanocomplexes and
triggered upregulation of inﬂammatory cytokines, and bactericidal
mediators as evidenced by dose and time-dependent kinetic
proﬁles of, IL6, IL18, TNFa and NO productions. Immune enhance-
ment of PS is dependent on TLR2 signaling, compounded by the pIC
mediated TLR3 signaling resulted stronger pro-inﬂammatory effect
of the formulation. When used in vivo as a protein vaccine carrier,
nanocomplex led to elevated IgG titers against ovalbumin antigen
in mice, compared to either PSþ OVA or pICþOVA immunizations.
In conclusion, present system can be formulated with other clini-
cally valuable bioactive agents such as siRNA, plasmids, and
different nucleic acid based TLR ligands, along with peptides or
proteins as vaccine carriers to control infectious pathogenic insults.
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Abstract Some of the important properties of probiotics are
the ability to survive during gastrointestinal transit and to
modulate the immune functions. The objectives of the
reported study were to assess in vivo gastrointestinal sur-
vival of orally administered Pediococcus pentosaceus OZF
using an animal model BALB/c mice, and to examine its
effects on the immune response. Following oral administra-
tion to mice, the ability of Pediococcus pentosaceus OZF to
pass and survive through the mouse gastrointestinal system
was investigated by analyzing the recovery of the strain in
fecal samples. Microbiological and polymerase chain reac-
tion (PCR) methods proved that the strain OZF could over-
come specific conditions in the gastrointestinal tract of mice
and reach the intestine alive after ingestion. To observe the
effect of oral administration on immune response, IL-6,
IL-12 and IFN-γ were measured by ELISA, and the strain
OZF was found to cause increases in IL-6 synthesis in
regularly fed mice. However, stimulation was carried out
with various concentrations of bacterial ssDNA and heat
killed cells of Pediococcus pentosaceus OZF. The heat
killed cells of the strain OZF were shown to produce IFN-
γ independently from IL-12. On the other hand, a signifi-
cant difference between control and experimental group was
noticed when lipopolysaccharide, a TLR4 (toll like receptor)
ligand, was used. Overall, Pediococcus pentosaceus OZF
may be a valuable probiotic strain for therapeutic uses.
Nevertheless, further studies on the mechanisms of immu-
nomodulatory effect will allow for better clarification of the
immune functions of this strain.
Keywords Probiotic . Survival . Immunomodulation . Invivo
Introduction
Lactic acid bacteria (LAB) are very important in the pro-
duction of many fermented foods (cheese, yogurt, etc.).
Applications of these organisms are now being extended to
the area of health improvement, which is known as a pro-
biotic activity. An expert committee defined the term pro-
biotic, popularized by Roy Fuller in 1989, as “living
microorganisms, which upon ingestion in certain numbers
exert health benefits to the host animal by improving its
intestinal microbial balance” (Guarner and Schaafsma
1998). Several aspects, including general, functional and
technological characteristics, have to be taken into consid-
eration in the selection process of probiotic strains. The
criteria for selecting a good probiotic strain have been listed
comprehensively by several authors (Collins et al. 1998;
Salminen et al. 1998; Deshpande et al. 2011). A successful
probiotic needs to be able to reach the distal part of the
intestine successfully in order to have a beneficial effect
(Freter 1992; Havenaar et al. 1992; Lo Curto et al. 2011).
In order to survive in and colonize the gastrointestinal tract
(GIT), ingested bacteria need to express high tolerance to
the enzymes in the oral cavity (e.g., lysozyme), as well as to
the digestion process in the stomach (e.g., exposure to low
pH) and the intestine (e.g., exposure to bile); to have the
ability for adhesion to the intestinal surfaces. However, it is
reported that many bacteria cannot tolerate these stresses
(Fujiwara et al. 2001; Suskovic et al. 2001; Iannitti and
Palmieri 2010).
In recent years, the incorporation of probiotic bacteria into
foods has received increasing scientific interest for health
promotion and disease prevention such as anti-infection prop-
erties (Isolauri et al. 1991), beneficial effects in intestinal
inflammation (Peran et al. 2005), immunomodulatory activity
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(Olivares et al. 2006), and efficacy in the prevention of allergic
diseases (Furrie 2005). Our immune system is one of the most
dynamic body components in determining our state of health
or disease. Therefore, the immunoregulatory effects of LAB
are of primary interest and nowadays there is growing interest
in research of immunobiotic LAB that have an ability to
modulate or stimulate the gastrointestinal immune system
(Nagao et al. 2000; Sheih et al. 2001; Lomax and Calder
2009). Many researchers actively studied the immunomodu-
latory function of LAB, reporting selected strains as able to
prevent or reduce allergies and to preserve the host from
various infectious diseases and cancer (Yasui et al. 1999;
Takagi et al. 2001; Shida et al. 2002; Repa et al. 2003;
Fujiwara et al. 2004; Kimoto et al. 2004). Several studies in
the literature focused on the ability of selected probiotics to
modulate in vitro cytokine production by human or murine
cells (Niers et al. 2005; Baken et al. 2006; Helwig et al. 2006;
Shida et al. 2006; Perez-Cano et al. 2010). These effects range
from stimulation to inhibition of several pro-inflammatory and
anti-inflammatory cytokines, as well as some chemokines,
and these effects are often strain-specific and each strain
appears to have its own unique immunomodulatory profile
(Niers et al. 2007). The pro-inflammatory cytokines secreted
by the epithelium, such as tumor necrosis factor (TNF)-α,
interleukin (IL)-1, IL-6, IL-8 and IL-12, are hallmarks of the
inflammatory responses in the intestine (Isolauri 1999).
Recently, a new potential probiotic strain, P. pento-
saceus OZF, has been isolated from human breast milk
(Osmanagaoglu et al. 2010). The strain OZF has been
shown to tolerate low pH, pepsin, bile acid and pancreatic
fluid under in vitro conditions, to bind human Caco-2 cells
and to exert inhibitory activity against a wide range of bacte-
ria, including some pathogens by producing pediocin AcH/
PA-1 (Osmanagaoglu et al. 2010, 2011). Since the strain was
shown to fulfill in vitro probiotic selection criteria, the study
was extended one step further, and this article presents results
of some in vivo pre-selective studies on promising probiotic P.
pentosaceus OZF, such as the survival in the GIT of mice and
its effects on the immune system modulation.
Materials and methods
In vivo survival of Pediococcus pentosaceus OZF
during passage through GIT of mice
Maintenance of animals Seven-week old female BALB/c
mice weighing 20–22 g were purchased from Gazi Univer-
sity Animal Reproduction and Animal Research Center
(GUDAM) and were housed in stainless-steel cages with a
12 h light/dark cycle under specific pathogen-free controlled
environmental conditions (temperature 22±1 °C, humidity
55±5 °C). Mice were fed with an unlimited commercial
rodent diet (Harlan, Barcelona, Spain) and water ad libitum
during the experimental protocol. The protocol was carried
out according to the guidelines of the Helsinki declaration
and was approved by the Local Ethics Committee on Ani-
mal Experiments of the Gazi University, Ankara, Turkey
(G.U.E.T., Protocol No: 07/0029).
Preparation of bacterial suspension and administration to
mice Pediococcus pentosaceus OZF was grown in tryptone-
glucose-yeast extract (TGE) broth at 37 °C for 18 h. Cells
were removed by centrifugation at 3,000 g for 10 min,
washed twice with physiological saline solution and resus-
pended in the same solution to a final concentration of 108
CFU per 200 μL. Mice in the experimental group (n=7)
received a daily dose of 108CFU of bacterial suspension,
while the control group (n=7) received 200 μL of physio-
logical saline solution by intragastric gavage. Sera, spleen
cells and peritoneal exudate cells (PECs) obtained from
mice fed 30 days with P. pentosaceus OZF were used for
detection of in vivo immunomodulatory capacity of the
strain, while feces of mice fed 5 days with OZF were used
in viability (survival ability in GIT) studies.
Recovery of Pediococcus pentosaceus OZF from feces The
mice were fed with bacterial suspension regulary for 5 days.
The survival ability of P. pentosaceus OZF through the GIT
was investigated every day for 5 days, by analyzing the
recovery of the strain in fecal samples as bacteriocin-
producing colonies. At the end of 5 days, the feeding trial
was stopped, but fecal samples were collected for 5 addition-
al days to check the colonization ability of the strain, and
subjected to the same analysis. For this aim, daily collected
fecal samples were pooled, resuspended in physiological
saline solution (100 mg mL−1) and mechanically homoge-
nized. Dilutions were plated onto Pediococci Selective Me-
dium (PSM) agar and incubated at 37 °C for 24 h before
enumeration (Simpson et al. 2006). To verify existence of P.
pentosaceus OZF in feces, bacteriocin assay and PCR-based
methods were applied before and after administration.
For bacteriocin assay, following pour plating, the plates
containing ∼50 to 100 colonies were overlaid with TSB
(Tyriptic soy broth) soft agar seeded with Listeria monocy-
togenes ATCC 7644 as an indicator. Plates were further
incubated overnight at 37 °C and examined for the presence
of an inhibition halo against L. monocytogenes ATCC 7644
(Biswas et al. 1991). The bacteriocin-producing colonies on
PSM medium were counted as CFU mL−1. Approximately
50 colonies passed through GITwere randomly picked from
plates, observed microscopically, Gram-stained and then
subjected to API kit for identification. Identification was
confirmed by 16S rDNA sequencing using specific univer-
sal primers (Edwards et al. 1989; Osborne et al. 2005) as
previously discussed (Osmanagaoglu et al. 2011). Amplified
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PCR fragments were purified by PCR purification kit (Prom-
ega, Agarose Gel DNA Extraction Kit) and sequenced by
REFGEN Biotechnology (METU Technocity, Ankara, Tur-
key). Basic local alignment search tool (BLAST) was used to
compare the sequences with the one deposited for P. pentosa-
ceus OZF (accession number 1337739, 706 bp) in National
Centre for Biotechnology Information (NCBI) (http://
www.ncbi.nlm.nih.gov.tr/BLAST).
For P. pentosaceus OZF detection from feces by using
PCR based methods, multiplex PCR was carried out first.
DNA templates for PCR reactions were prepared from bac-
teriocin producing colonies. One colony was resuspended in
50 μL of sterilized TE (10 mM Tris–HCl, 1 mM EDTA pH
7.5) buffer and boiled for 10 min. Supernatant containing
released DNA was directly used as template in PCR ampli-
fication. Target specific genes for pediococci, P. pentosa-
ceus and pediocin AcH/PA-1 were amplified by using the
method proposed by Suwanjinda et al. (2009). To determine
whether or not the original OZF strain and the strains obtained
in the feces following oral administrationwere the same strain,
the recovered strains were further typed by RAPD profile.
DNAwas extracted by using Promega DNA isolation kit, and
PCR was carried out with using different RAPD primers
[OPO-09 (5 ′ TCCCACGCAA 3 ′ ) , OPF -14 (5 ′
TGCTGCAGGT 3′), and OPA-07 (5′ GAAACGGGTG 3′)].
Immunomodulatory function of Pediococcus pentosaceus
OZF
Culture medium, cytokines, antibodies and reagents All cell
culture media components were obtained from Hyclone
(USA). Cytokine ELISA assay reagents, recombinant
mouse IL-6, IL-12 and IFN-γ, and their monoclonal and
biotinylated antibodies were obtained from Thermo, Pierce
Endogen and BD Biosiences, respectively. Streptavidin-
alkaline phosphatase (SA-AKP) and p-nitrophenyl phos-
phate disodium salt substrate (PNPP) were purchased from
Thermo. Lipopolysaccharide (LPS) and peptidoglycan
(PGN), isolated from Escherichia coli, was obtained from
Sigma. Immunsuppressive CpG oligodeoxynucleotide
(ODN) K-type; K23 (12mer) and control ODN were chem-
ically synthesized by Alpha DNA (Montreal, Canada).
Cell culture and stimulation assay BALB/c mice involved
in control and experimental groups were used after a 30 day
daily feeding period. Mice were euthanized by cervical
dislocation. Blood, spleen cells and PECs were aseptically
extracted and used for further analysis. Sera were obtained
by centrifugation (1,000 g for 5 min at room temperature,
RT) and stored at −20 °C until ELISA (Enzyme-linked
immunosorbent assay) was carried out. Unstimulated spleen
cells (4 millions of cells in 200 μL), PECs (200.000 cells in
200 μL) and serum samples of mice were used for in vivo
detection of immunomodulatory function in strain OZF. In
addition, stimulated forms were used to understand the
differentation of immunostimulatory effect between the con-
trol and experimental group. For stimulation assay, spleen
cells and PECs in 96 well plates were stimulated with three
increasing concentrations of ss DNA (0.08, 0.8 and 8 μg in
200 μL) and heat killed cells of P. pentosaceus OZF (107 to
102CFU mL−1). DNA of P. pentosaceus OZF was extracted
with Promega Wizard DNA purification kit. To avoid stim-
ulatory effects due to contamination of bacterial proteins or
LPSs, DNA preparations used in the experiments had purity
values higher than 1.8 (OD260/280). Single-stranded DNA
was prepared by heat denaturing of double-stranded DNA at
95 °C for 5 min, followed by cooling on ice. To obtain heat
killed cells, the remaining culture fluid was heated to 121 °C
for 15 min, and washed three times with PBS (phosphate
buffer saline pH 7.2). For positive controls, LPS (5 μg
mL−1), PGN (5 μgmL−1), CpG-ODN K23 (1 μM) and
CONTROL ODN (1 μM) were used. Stimulations were
performed in duplicate wells for each indicated treatment.
The cells were incubated overnight at 37 °C in a 5 % CO2
incubator and following incubation, collected superna-
tants were stored at −20 °C for further use.
Evaluation of cytokines production by ELISA Unstimulated
and stimulated serum and cells supernatants were immedi-
ately analyzed by ELISA, to measure the IL-6, IL-12 and
IFN-γ concentrations as described in Erikci et al. (2011).
The optical densities of the enzymatic reaction solutions
were read using an automatic ELISA plate reader (Molecu-
lar Devices, SoftmaxPro Software V5) at 405nm until re-
combinant standards (with the starting concentrations of
4,000 ng mL−1 for IL-6, 100 ng mL−1 for IL-12 and
1,000 ng mL−1 for IFN-γ) reached a four parameter sat-
uration. All ELISA assays were performed in duplicate for
each group.
Statistical analysis
A student’s t test was used to evaluate the statistical signifi-
cances (p<0.05) of the differences in cytokine production of
mice before and after exposure to tested bacterium. Values
of p<0.05 were considered significant.
Results and discussion
In vivo survival of Pediococcus pentosaceus OZF
during passage through GIT of mice
From a safety as well as a functional point of view, it is
essential to determine if a strain survives in the GIT. In the
present study, following oral administration to mice, the
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ability of P. pentosaceus OZF to pass and survive through
the mouse GIT was investigated by analyzing the recovery
of the strain in fecal samples as bacteriocin-producing col-
onies. Clear inhibition zones characterized as bacteriocin
production against L. monocytogenes ATCC 7644 were
observed in all colonies recovered from fecal samples after
administration with the strain OZF, and it has been sug-
gested that ingested bacteria as probiotics cannot affect the
intestinal environment unless their population reaches a
certain minimum level of between 106 and 108CFU g−1 in
intestinal content (Marteau and Rambaud 1993). According
to PSM counts, no Pediococcus was recorded in feces of
mice belonging to control groups, highlighting the lack of
this genus within the intestinal flora of mice (Data not
shown). Viable cells of P. pentosaceus OZF administered
orally to mice decreased time dependently (Fig. 1). Twelve
hours after the first administration, the strain OZF appeared
at a level of 107 CFU g−1 in feces of all mice in the treated
group and at a level of 106to 107CFU g−1 after further 24 h .
The strain OZF was detected in three of seven mice at
gradually reduced levels at 48, 72, 96 and 120 h. This
indicates that P. pentosaceus OZF administered to mice
can survive in the stomach and reach the mouse intestine
alive. However, the strain OZF was not detected in any
mouse at 144 h (24 h after the administration had ceased).
Feeding trials with the strain OZF showed that the promis-
ing probiotic strain disappears from the GIT within 1 day
after the feeding was discontinued. This indicates that the
strain could not get through to colonize in the mouse intes-
tine and although it could reach the intestine alive, is elim-
inated from the intestine. This is because the normal
intestinal microbiota provide an excellent resistance against
colonization by introduced bacteria (Wells et al. 1988). On
the other hand, pediococci were not detected in the control
group. However, other studies showed that the number of
probiotic bacteria detected 14 days after the administration
of probiotic strains was lower than on the first day after
administration (Murphy et al. 1999). This observation is
supported by results of a human study completed by Goldin
et al. (1992) where it was demonstrated that 60–80 % of
individuals consuming Lactobacillus rhamnosus GG excret-
ed the bacterium for 3–4 days, but only 33 % of the popu-
lation excreted the bacterium after 7 days. In a similar study,
the probiotic strain could be recovered (with no oral supple-
mentation) from feces up to 3 days after cessation of feed-
ing. Therefore, it appears increasingly likely that daily
administration of the preferred strain is necessary for main-
tenance of high levels of probiotics (Murphy et al. 1999).
By using bacteriocin-producing ability, the survival and
persistence of the administered strain could be monitored after
transit in the GIT of mice. Almost 50 (ten for each day of
administration) randomly selected bacteriocin-producing col-
onies were found in tetrad morphology, Gram-positive and
catalase-negative. Nevertheless, to avoid the risk of mistaking
colonies of Pediococcus spp. grown on PSM agar medium,
multiplex and RAPD PCR were used. PCR was performed on
the colonies grown on PSM agar to detect live bacterial cells
in feces (Fig. 2). Biochemical profiles of five randomly chosen
strains were obtained with API 50CH (bioMerieux) following
the manufacturer’s guidelines and identified as P. pentosa-
ceus. Besides, 16S rRNA sequence analysis allowed us to
identify the five strains as P. pentosaceus, and the obtained
sequences were found to be the same (99 % similarity) that
have already been registered for OZF strain in GenBank
database system under accession number HM051378
(706 bp). Multiplex PCR profiles of 50 randomly selected
colonies from the fecal samples of treated mice group were all
found to be identical to the pattern of administered P. pento-
saceusOZF. Amplification of template DNA obtained from P.
pentosaceus OZF before and after administration, using spe-
cific primer sets, resulted in two well-differentiated PCR
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Fig. 1 Survival and time dependent changes in the fecal populations
of P. pentosaceus OZF after oral administration to mice
Fig. 2 Molecular identification of Pediococcus pentosaceus OZF in
mouse feces by multiplex-PCR. Lane M, 100 bp DNA ladder (Gen-
eRulerTM 100 bp DNA Ladder Plus, Fermentas); Lane 1, negative
PCR control (no template DNA); Lane 2, P. pentosaceus OZF used for
oral administration to mice as positive control; Lane 3–7, multiplex-
PCR products derived from colonies on PSM agar after oral adminis-
tration of P. pentosaceus OZF at 1, 2, 3, 4 and 5 days respectively
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fragments with molecular weights of 500 and 278 bp specific
for P. pentosaceus, and a 332 bp DNA fragment for pediocin
AcH/PA-1 (Fig. 2). RAPD-PCR for the same randomly se-
lected colonies generated reproducible patterns identical to
fingerprint obtained for P. pentosaceus OZF (Fig. 3). There-
fore, the one representing each day was choosen randomly
and its band profiles are shown in Fig. 3. Multiplex PCR was
found to be an easy, fast, reliable and reproducible method,
and can be used as an alternative for verification of
bacteriocin-producing pediococci strains. RAPD-PCR was
also found as a rapid and reliable molecular technique to
generate DNA fingerprints for each strain, and to distinguish
the ingested strain from the potentially thousands of other
bacterial strains that make up the gastrointestinal ecosystem.
Immunomodulatory function of Pediococcus pentosaceus
OZF
Some LAB strains may be able to activate the immune
system cells (Christensen et al. 2002; Medina et al. 2007;
Vizoso Pinto et al. 2007, 2009). Inducing or enhancing the
cytokine production could be a major mechanism for pro-
biotic bacteria to exert immunomodulating activities (Marin
et al. 1997). This would open up a promising use of P.
pentosaceus OZF as an immunomodulator. Our study was
performed in two stages, in vivo and in vitro. The analysis
of the cytokines profiles revealed that the most remarkable
effect was an increase in the IL-6 (Fig. 4), an important
mediator both in humoral and cellular host defense. IL-6
plays an important role in host immune mechanism by
regulating immune response and acute-phase reactions
(Morita et al. 2002). In control group, IL-6 was not detected
in sera, while a statistically significant increase was detected
in mice regularly fed with bacterial suspension (89.15±
7.89 ng mL−1, p<0.001). On the other hand, no significant
difference was recorded in IL-12 production between groups
(control: 3.96±1.58 ng mL−1; experimental: 4,82±1.72 ng
mL−1). Besides, the resulting amount of IFN gamma level
was below the detection level of the method in cell super-
natants including serum (Fig. 4). The increase in the pro-
duction of IL-6, as a result of regular feeding with P.
pentosaceus OZF, may create an advantage for defense of
infections encountered in any way (Van Enckevort et al.
1999). Despite growing evidence for immunomodulatory
capability of LAB, especially human milk-derived species,
there is still little information regarding their mode of action.
Several similar studies have reported the in vitro and in vivo
cytokine response patterns of co-culturing cells of the innate
immune defense system with different probiotic LAB for
understanding their health protection mechanism. Our
results are in agreement with the results obtained by Gill
(1998); Morita et al. (2002); Kimura et al. (2006); Foligne et
al. (2010); Perez-Cano et al. (2010) and Zhu et al. (2011).
Intestinal epithelial cells from conventional mice were
reported to produce IL-6 in response to the challenge in
Fig. 3 Molecular typing of
Pediococcus pentosaceus OZF
in mouse feces by RAPD PCR.
Lane M, 100 bp DNA ladder
(GeneRulerTM 100 bp DNA
Ladder Plus, Fermentas; Marker
bp, ruler was given at Fig. 2);
Lane 1, negative PCR control
(no template DNA); Lane 2, P.
pentosaceus OZF used for oral
administration to mice as
positive control; Lane 3–7,
RAPD PCR profiles derived
from colonies on PSM agar after
oral administration of P.
pentosaceusOZF at 1, 2, 3, 4 and
5 day respectively. Primers used
are OPA-9 (a), OPF-14 (b) and
OPA-7 (c)
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Fig. 4 IL-6, IL-12 and IFN-γ production in serum samples of BALB/c
mice involved in control and experimental group after 30 days daily
feeding period (*significantly difference: p<0.001)
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vitro with certain LAB strains that had also demonstrated in
vivo immunomodulating capacity (Vinderola et al. 2005).
Two P. pentosaceus strains isolated from traditional vegetable
pickles were shown to have a high capacity to survive in the
GIT, and have in vitro immunomodulatory and allergy inhibi-
tion effects (Jonganurakkun et al. 2008). In contrast, anotherP.
pentosaceus strain, used as preservative to prevent farmer’s
lung pneumonitis, was shown to induce an inflammatory
response in mice in the study of Duchaine et al. (1996).
In order to find out whether or not P. pentosaceus OZF
exhibit in vitro immunostimulating capacity, ssDNA and
heat killed cells of the strain were used, since it is known
that cellular components of LAB such as peptidoglycans,
lipoteichoic acids, cell surface protein, exopolysaccharide
and DNA CpG motifs, as well as live bacteria and inacti-
vated bacteria, may present a capacity for immune system
stimulation (Lebeer et al. 2008; Ng et al. 2009). In both
experimental and control groups, stimulation studies were
carried out by use of both spleen cells and PECs. Following
stimulation, the release of IL-6 and IL-12 was not detected
in spleen cells. In PECs, when we look at the results from
the perspective of IL-6 production after stimulation, the
control group was found to react more than experimen-
tal group to high dosage of heat killed cells of the
strain OZF (p<0.01). However, when the concentration
of heat killed cells was decreased (104CFU mL−1 and
lower titrations), IL-6 production was found to be higher in
the experimental group than in the control group (p<0.05).
When the results of heat killed bacteria stimulation are
evaluated in terms of IL-12 and IFN gamma secretion,
no significant difference was recorded between the groups
(data not shown).
Although studies are limited in this regard, available refer-
ences reported that DNA of LAB have immunostimulatory
properties (Lammers et al. 2003; Iliev et al. 2005; Li et al.
2005; Medina et al. 2007; Ghadimi et al. 2008; Satokari et al.
2009; Menard et al. 2010). The present study showed that
ssDNA of P. pentosaceus OZF induced the secretion of IL-6
and IL-12, but this was not found to be significantly different
when compared to each group (data not shown). IFN-γ was
not detected after stimulation with ssDNA, which could be
related to the use of low dosages of ssDNA.
In conclusion, P. pentosaceus OZF strain proved to be
able to pass live through the GIT after oral administration to
mice and to stimulate an immune response. To the authors'
knowledge, this is the first article dealing with the effects of
a Pediococcus strain, isolated from human breast milk, on
cytokines activation. The comparison of the stimulant effect
of heat killed cells and ssDNA after co-culture with spleen
cells and PECs is also novel. On the other hand, further
studies are necessary to better assess the fulfill breadth of the
immunomodulatory capability of our strain in the gut envi-
ronment, and to understand its cellular or humoral immune
effect by measuring the inductive activity of IgA, IgG and
IgM in case of usage as a oral vaccine carrier.
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